

# CITATION REPORT

List of articles citing

## Transection of the oesophagus for bleeding oesophageal varices

DOI: 10.1002/bjs.1800600817

British Journal of Surgery, 1973, 60, 646-9.

**Source:** <https://exaly.com/paper-pdf/38358449/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2293	Editorial: Massive upper gastrointestinal bleeding. <b>1974</b> , 1, 403-4		2
2292	Emergency and elective operations for bleeding esophageal varices. <b>1974</b> , 54, 561-71		6
2291	Modified oesophagoscope for injecting oesophageal varices. <b>1975</b> , 2, 540-1		27
2290	Editorial: New measures for bleeding oesophageal varices. <b>1975</b> , 3, 450		
2289	Interposition grafting for portal hypertension. <b>1975</b> , 130, 733-8		14
2288	Fibreoptic endoscopy and the use of the Sengstaken tube in acute gastrointestinal haemorrhage in patients with portal hypertension and varices. <b>1976</b> , 17, 258-63		100
2287	Results of interposition "H" grafts for portal hypertension. <b>1978</b> , 187, 515-22		15
2286	Use of anaesthesia. Preoperative assessment of patients. <b>1980</b> , 280, 1507-8		1
2285	Prospective comparison of two Sengstaken tubes in the management of patients with variceal haemorrhage. <b>1980</b> , 21, 570-3		31
2284	Prospective controlled trial of injection sclerotherapy in patient with cirrhosis and recent variceal haemorrhage. <b>1980</b> , 2, 552-4		125
2283	Endoscopic sclerotherapy in acute variceal hemorrhage. <b>1981</b> , 141, 164-8		42
2282	Transhepatic embolization in patients with acute variceal hemorrhage. <b>1981</b> , 142, 731-4		9
2281	Variceal hemorrhage. <b>1981</b> , 81, 635		4
2280	Does multiple injection sclerotherapy have a role in the long-term management of oesophageal varices?. <b>1982</b> , 58, 399-402		5
2279	Strategies in the management of bleeding varices. <b>1982</b> , 12, 320-4		
2278	Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial. <b>1982</b> , 1, 124-7		238
2277	Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices. <b>1982</b> , 2, 66-8		130

2276	The liver and anaesthesia. <b>1983</b> , 30, 208-17	10
2275	Emergency endoscopic sclerotherapy for bleeding esophageal varices: a prospective study in patients not responding to balloon tamponade. <b>1983</b> , 29, 8-14	62
2274	The history injection sclerotherapy for esophageal varices. <b>1983</b> , 29, 303-7	10
2273	POSTER COMMUNICATIONS. <b>1983</b> , 80, 494P-580P	1
2272	Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. <b>1983</b> , 309, 1539-42	274
2271	Factors affecting successful endoscopic sclerotherapy for oesophageal varices. <b>1983</b> , 24, 946-9	59
2270	The management of acute variceal haemorrhage. <b>1983</b> , 53, 197-202	9
2269	Esophageal procedures to control bleeding from varices. <b>1983</b> , 63, 905-14	9
2268	Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension. <b>1984</b> , 25, 121-4	76
2267	Injection sclerotherapy for oesophageal varices: a prospective randomised trial of different treatment schedules. <b>1984</b> , 25, 129-32	110
2266	Perivenous sclerotherapy of oesophageal varices. <b>1984</b> , 3, 17-21	
2265	Sclerotherapy of esophageal varices: an endoscopic and portographic study. <b>1984</b> , 4, 877-84	21
2264	Monitoring the liver. <b>1984</b> , 31, 401-402	
2263	Reductions in portal pressure by selective beta 2-adrenoceptor blockade in patients with cirrhosis and portal hypertension. <b>1984</b> , 17, 753-7	29
2262	Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. <b>1984</b> , 3, 63-6	9
2261	Body protein metabolism and plasma amino acids in cirrhosis of the liver. The effect of varying the branched chain amino acid content of intravenous amino acid solutions. <b>1984</b> , 3, 153-62	11
2260	Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. <b>1984</b> , 199, 648-55	378
2259	Management of complications of portal hypertension. <b>1985</b> , 65, 231-62	9

2258	Long-term sclerotherapy of bleeding esophageal varices in patients with liver cirrhosis. An evaluation of mortality and rebleeding risk factors. <b>1985</b> , 20, 51-8	32
2257	[Thyroid hormones in women with liver cirrhosis]. <b>1985</b> , 63, 752-61	2
2256	A prospective, randomized controlled trial of chronic esophageal variceal sclerotherapy. <b>1985</b> , 5, 584-9	226
2255	Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial. <b>1985</b> , 5, 827-30	269
2254	The prevention of recurrent variceal haemorrhage by chronic injection sclerotherapy. <b>1985</b> , 30, 148-51	2
2253	Morbidity and mortality after peritoneovenous shunt surgery for refractory ascites. <b>1985</b> , 26, 1070-3	29
2252	Clinical course of cirrhosis in young adults and therapeutic potential of liver transplantation. <b>1985</b> , 26, 1359-63	17
2251	Pharmacology of propranolol in patients with cirrhosis and portal hypertension. <b>1985</b> , 26, 14-9	29
2250	Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy?. <b>1985</b> , 26, 1226-32	399
2249	B1 selective adrenoreceptor blockade for the long term management of variceal bleeding. A prospective randomised trial to compare oral metoprolol with injection sclerotherapy in cirrhosis. <b>1985</b> , 26, 421-5	27
2248	Total and renal sympathetic nervous system activity in alcoholic cirrhosis. <b>1985</b> , 1, 639-48	67
2247	Endoscopic Nd:YAG laser therapy for active esophageal variceal bleeding. A randomized controlled study. <b>1985</b> , 31, 4-9	35
2246	Sedation for gastroscopy: a comparative study of midazolam and Diazemuls in patients with and without cirrhosis. <b>1986</b> , 22, 643-7	16
2245	Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity. <b>1986</b> , 21, 191-6	63
2244	Repeated endoscopic sclerotherapy of oesophageal varices due to non-cirrhotic portal fibrosis using intravariceal polidocanol. <b>1986</b> , 1, 443-448	5
2243	Preponderance of serum and intra-hepatic 5 alpha-dihydrotestosterone in males with hepatocellular carcinoma despite low circulating androgen levels. <b>1986</b> , 3, 304-9	6
2242	Effect of somatostatin on oesophageal variceal pressure assessed by direct measurement. <b>1986</b> , 2, 262-6	26
2241	Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. <b>1986</b> , 1, 1409-11	117

2240	Effects of repeated injection sclerotherapy on acid gastroesophageal reflux. <b>1986</b> , 32, 81-3	20
2239	Sympathetic tone modulates portal venous pressure in alcoholic cirrhosis. <b>1986</b> , 2, 939-43	74
2238	Results of a randomized trial of end-to-side portacaval shunt and distal splenorenal shunt in alcoholic liver disease and variceal bleeding. <b>1986</b> , 91, 802-9	101
2237	Prognostic significance of serum bile acids in cirrhosis. <b>1986</b> , 6, 50-3	66
2236	Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. <b>1986</b> , 6, 79-86	152
2235	A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. <b>1986</b> , 6, 410-3	184
2234	Vasopressin and nitroglycerin in the treatment of bleeding varices: the bottom line. <b>1986</b> , 6, 523-5	42
2233	Use of propranolol to reduce the rebleeding rate during injection sclerotherapy prior to variceal obliteration. <b>1986</b> , 6, 673-5	84
2232	Prognostic value of the aminopyrine breath test in cirrhotic patients. <b>1986</b> , 6, 928-31	91
2231	Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial. <b>1986</b> , 6, 1239-43	125
2230	Endoscopic sclerotherapy for esophageal varices. <b>1986</b> , 31, 1085-121S	27
2229	Effect of branched chain amino acid infusions on body protein metabolism in cirrhosis of liver. <b>1986</b> , 27 Suppl 1, 96-102	12
2228	Somatostatin in Portal Hypertension. <b>1986</b> , 21, 256-258	2
2227	Denver peritoneovenous shunting for malignant or cirrhotic ascites. A prospective consecutive series. <b>1986</b> , 21, 1161-72	12
2226	Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. <b>1986</b> , 27, 1204-9	156
2225	Variceal bleeding: does variable delay in trial entry invalidate comparison between trials?. <b>1987</b> , 28, 653-6	7
2224	Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. <b>1987</b> , 317, 856-61	247
2223	Surgery in the patient with liver disease. <b>1987</b> , 71, 453-76	46

2222	Systemic and hepatic hemodynamics after variceal hemorrhage: effects of propranolol and placebo. <b>1987</b> , 93, 1218-24	31
2221	Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. <b>1987</b> , 23, 753-7	40
2220	Increased susceptibility to liver disease in relation to alcohol consumption in women. <b>1987</b> , 22, 1251-6	69
2219	[Sex hormones and the hypophyseal-gonadal axis in females with liver cirrhosis in postmenopause]. <b>1987</b> , 65, 411-8	4
2218	Sonographic evaluation of the portal venous system after elective endoscopic sclerotherapy of esophageal varices. <b>1987</b> , 1, 165-7	4
2217	Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. <b>1987</b> , 7, 149-54	81
2216	Prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage: prospective, randomized comparison of propranolol and sclerotherapy. <b>1987</b> , 7, 355-61	94
2215	Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. <b>1987</b> , 7, 447-51	80
2214	Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: possible role of serotonergic mechanisms in portal hypertension. <b>1987</b> , 7, 644-7	63
2213	Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. <b>1987</b> , 7, 660-4	268
2212	Prevention of recurrence of esophageal varices after endoscopic injection sclerotherapy with ethanolamine oleate. <b>1987</b> , 7, 810-5	102
2211	Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. <b>1987</b> , 7, 1278-84	89
2210	Alterations in the carbohydrate moiety of alpha-1-acid glycoprotein purified from human cirrhotic ascitic fluid. <b>1987</b> , 913, 308-12	37
2209	Preoperative evaluation: the assessment and management of surgical risk. <b>1987</b> , 2, 257-69	12
2208	Sex hormone imbalance in male alcoholic cirrhotic patients with and without hepatocellular carcinoma. <b>1988</b> , 62, 760-2	33
2207	Propranolol for prophylaxis of bleeding in cirrhotic patients with large varices: A multicenter, randomized clinical trial. <b>1988</b> , 8, 1-5	74
2206	Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. <b>1988</b> , 8, 6-9	138
2205	Prophylactic propranolol: the first big step. <b>1988</b> , 8, 167-70	13

2204	Renal sodium retention in cirrhosis: tubular site and relation to hepatic dysfunction. <b>1988</b> , 8, 831-6	60
2203	A prospective evaluation of bacteremic patients with chronic liver disease. <b>1988</b> , 8, 1099-103	63
2202	Prophylactic sclerotherapy of high-risk esophageal varices: results of a multicentric prospective controlled trial. <b>1988</b> , 8, 1495-500	80
2201	Glucagon selectively increases splanchnic blood flow in patients with well-compensated cirrhosis. <b>1988</b> , 8, 1501-5	38
2200	Prognostic value of indocyanine green and lidocaine kinetics for survival and chronic hepatic encephalopathy in cirrhotic patients following elective end-to-side portacaval shunt. <b>1988</b> , 8, 1506-10	18
2199	Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. <b>1988</b> , 8, 1620-6	69
2198	Immediate endoscopic sclerosis of bleeding esophageal varices. A prospective evaluation over five years. <b>1988</b> , 2, 18-23	24
2197	Frequency of upper gastrointestinal lesions in patients with liver cirrhosis. <b>1988</b> , 33, 1218-22	45
2196	Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. <b>1988</b> , 36, 256-85	40
2195	Initial control of bleeding from esophageal varices with the Sengstaken-Blakemore tube. Experience in 82 patients. <b>1988</b> , 155, 509-11	16
2194	Endoscopic ligation of esophageal varices. <b>1988</b> , 156, 9B-12B	20
2193	Modifications of concanavalin A patterns of alpha 1-acid glycoprotein and alpha 2-HS glycoprotein in alcoholic liver disease. <b>1988</b> , 176, 49-57	32
2192	Atrial natriuretic peptide in alcoholic cirrhosis. <b>1988</b> , 3, 601-609	1
2191	Urinary Tract Candidosis. <b>1988</b> , 332, 1000-1002	1
2190	Abnormal tissue oxygenation in patients with cirrhosis and liver failure. <b>1988</b> , 7, 98-105	94
2189	Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. <b>1988</b> , 7, 118-25	122
2188	Management of Acute Variceal Bleeding. <b>1988</b> , 332, 999-1000	
2187	Reduction in early recurrence of variceal bleeding by propranolol. <b>1988</b> , 23, 369-74	30

2186	Auxiliary partial liver transplantation for end-stage chronic liver disease. <b>1988</b> , 319, 1507-11	114
2185	Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. <b>1988</b> , 319, 983-9	1090
2184	Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension. <b>1988</b> , 29, 372-7	51
2183	Relationship among beta-adrenergic blockade, propranolol concentration, and liver function in patients with cirrhosis. <b>1988</b> , 23, 925-30	15
2182	Somatostatin does not reduce oesophageal variceal pressure in liver cirrhotics. <b>1988</b> , 29, 153-6	56
2181	Comparative haemodynamic effects of betaxolol and propranolol in patients with cirrhosis. <b>1988</b> , 23, 691-5	19
2180	Protease inhibitors in liver disease. <b>1988</b> , 23, 620-4	13
2179	Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. <b>1988</b> , 95, 749-59	89
2178	Neutrophil and eosinophil involvement of the small bowel affected by chronic alcoholism. <b>1988</b> , 29, 1656-60	10
2177	Prophylactic sclerotherapy for varices. <b>1988</b> , 297, 370-1	1
2176	Pressure of intraoesophageal varices assessed by fine needle puncture: its relation to endoscopic signs and severity of liver disease in patients with cirrhosis. <b>1989</b> , 30, 228-32	45
2175	Prophylactic endoscopic sclerotherapy of oesophageal varices in liver cirrhosis. A multicentre prospective controlled randomised trial in Vienna. <b>1989</b> , 30, 873-9	40
2174	Propranolol in the primary prevention of upper gastrointestinal tract haemorrhage in patients with cirrhosis of the liver and oesophageal varices. <b>1989</b> , 37 Suppl 2, 52-61; discussion 74-6	2
2173	Plasma leucine enkephalin is increased in liver disease. <b>1989</b> , 30, 1392-5	34
2172	Propranolol in prevention of rebleeding from oesophageal varices during the course of endoscopic sclerotherapy. <b>1989</b> , 24, 339-45	69
2171	Glucose metabolism in cirrhosis: a review with some perspectives for the future. <b>1989</b> , 5, 691-709	106
2170	Frequent endoscopic variceal sclerotherapy increases risk of complications. Prospective randomized controlled study of two treatment schedules. <b>1989</b> , 34, 1068-74	30
2169	Midazolam versus diazepam for combined esophogastroduodenoscopy and colonoscopy. <b>1989</b> , 34, 1265-71	19



2168	Esophageal tamponade in the management of acute variceal hemorrhage. <b>1989</b> , 34, 913-8	38
2167	Suivi endoscopique après sclérotisation de varices œsophagiennes. <b>1989</b> , 19, 239-249	
2166	Correlation of caffeine elimination and Child's classification in liver cirrhosis. <b>1989</b> , 67, 6-15	33
2165	Long-term prognosis of esophageal variceal cases treated with injection sclerotherapy. <b>1989</b> , 24, 469-75	4
2164	Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver. <b>1989</b> , 24, 159-63	4
2163	Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. <b>1989</b> , 71, 65-70	83
2162	Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect. <b>1989</b> , 9, 83-7	48
2161	Controlled clinical trial of injection sclerotherapy for active variceal bleeding. <b>1989</b> , 9, 274-7	185
2160	Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis. <b>1989</b> , 9, 417-22	64
2159	Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. <b>1989</b> , 9, 423-6	52
2158	Propranolol does not alter cerebral blood flow and functions in cirrhotic patients without previous hepatic encephalopathy. <b>1989</b> , 9, 439-42	14
2157	Cirrhotics with variceal hemorrhage: the importance of the time interval between admission and the start of analysis for survival and rebleeding rates. <b>1989</b> , 9, 801-7	131
2156	Low dose of nitroglycerin failed to improve splanchnic hemodynamics in patients with cirrhosis: evidence for an impaired cardiopulmonary baroreflex function. <b>1989</b> , 10, 93-7	29
2155	Blunted natriuretic response and low blood pressure after atrial natriuretic factor in early cirrhosis. <b>1989</b> , 10, 148-53	30
2154	Sucralfate for the prevention of early rebleeding following injection sclerotherapy for esophageal varices. <b>1989</b> , 10, 279-82	45
2153	Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis. <b>1989</b> , 10, 283-7	49
2152	Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma. <b>1989</b> , 10, 346-8	17
2151	Successful endoscopic obturation of gastric varices with butyl cyanoacrylate. <b>1989</b> , 10, 488-93	145

2150	Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial. <b>1989</b> , 10, 962-8	106
2149	A method to evaluate changes in prognostic status during follow-up, illustrated by an assessment of the effect of a rebleed in patients with oesophageal variceal bleeding. <b>1989</b> , 19, 181-8	8
2148	Endoscopic removal of impacted Sengstaken-Blakemore tube. <b>1989</b> , 3, 54-5	4
2147	Penetration of cefoperazone into ascites. <b>1989</b> , 37, 577-80	4
2146	Inhibition of platelet aggregation by abnormal high density lipoprotein particles in plasma from patients with hepatic cirrhosis. <b>1989</b> , 1, 693-5	58
2145	Renal function and effective beta-blockade in cirrhosis with ascites. Relationship with baseline sympathoadrenergic tone. <b>1989</b> , 8, 279-86	13
2144	Prescribing for patients with liver disease. <b>1989</b> , 3, 109-30	2
2143	Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis. <b>1989</b> , 9, 16-22	52
2142	Neuropsychological deficits and morphological MRI brain scan abnormalities in apparently healthy non-encephalopathic patients with cirrhosis. A controlled study. <b>1989</b> , 9, 319-25	64
2141	Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. <b>1989</b> , 24, 269-76	217
2140	A comparison of sclerotherapy with staple transection of the esophagus for the emergency control of bleeding from esophageal varices. <b>1989</b> , 321, 857-62	147
2139	Drug metabolism in liver disease. <b>1989</b> , 40, 439-74	73
2138	Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. <b>1989</b> , 27, 763-70	15
2137	The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. <b>1989</b> , 27, 205-13	30
2136	Reduction of portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. <b>1989</b> , 9, 246-51	26
2135	Endoscopic findings in alcoholic liver disease: does gender make a difference?. <b>1989</b> , 6, 465-8	15
2134	Prevention of stricture formation after endoscopic sclerotherapy of esophageal varices. <b>1989</b> , 35, 377-80	19
2133	Population pharmacokinetic analysis of bisoprolol. <b>1989</b> , 17, 53-63	15

2132	Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis. Survival and prognostic factors. <b>1989</b> , 24, 999-1006	61
2131	Improved results with selective distal splenorenal shunt in a highly selected patient population. A prospective study. <b>1989</b> , 210, 184-9	20
2130	A randomised controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. <b>1989</b> , 37 Suppl 2, 30-4; discussion 47	3
2129	Portal hypertension. <b>1989</b> , 73, 931-53	69
2128	Combined upper and lower gastrointestinal endoscopy: a prospective study in alcoholic and nonalcoholic cirrhosis. <b>1989</b> , 13, 790-4	12
2127	Spontaneous ruptured hepatocellular carcinoma. An appraisal of surgical treatment. <b>1989</b> , 210, 24-8	69
2126	Steatorrhoea in cirrhosis: effect of ursodeoxycholic acid administration. <b>1990</b> , 18, 289-97	7
2125	Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. <b>1990</b> , 211, 178-86	51
2124	Splenomegaly--an insensitive sign of portal hypertension. <b>1990</b> , 20, 771-4	28
2123	Influence of the degree of liver failure on portal blood flow in patients with liver cirrhosis. <b>1990</b> , 25, 395-400	26
2122	Taking the tension out of the portal system. An approach to the management of portal hypertension in the 1990s. <b>1990</b> , 175, 131-45	12
2121	Abstracts of Communications. <b>1990</b> , 49, 1A-87A	
2120	Flash visual evoked responses in the early encephalopathy of chronic liver disease. <b>1990</b> , 25, 1205-14	14
2119	Propranolol may prevent recurrence of oesophageal varices after obliteration by endoscopic sclerotherapy. <b>1990</b> , 25, 352-6	23
2118	Gastroesophageal endoscopic features in cirrhosis: Observer variability, interassociations, and relationship to hepatic dysfunction. <b>1990</b> , 98, 156-162	157
2117	Nonshunting operations for variceal hemorrhage. <b>1990</b> , 70, 425-48	19
2116	Resection of hepatocellular carcinomas. <b>1990</b> , 98, 733-738	276
2115	Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. A controlled trial. <b>1990</b> , 98, 185-90	91

2114	Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. <b>1990</b> , 98, 715-20	268
2113	Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. <b>1990</b> , 98, 1594-602	100
2112	Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. <b>1990</b> , 99, 1388-95	218
2111	Colonic disease in cirrhosis. An endoscopic evaluation in 412 patients. <b>1990</b> , 99, 195-9	98
2110	Anesthesia for liver transplantation in patients with arterial hypoxemia. <b>1990</b> , 3, 103-107	2
2109	A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. <b>1990</b> , 74, 471-9	57
2108	Cirrhosis of the liver. A risk factor for development of cholelithiasis in males. <b>1990</b> , 35, 1403-8	41
2107	Serum-ascites albumin gradients in nonalcoholic liver disease. <b>1990</b> , 35, 33-7	14
2106	Prevalence of duodenal ulcer in cirrhotic males referred for liver transplantation. Does the etiology of cirrhosis make a difference?. <b>1990</b> , 35, 321-6	37
2105	Diarrhea as a presenting symptom of hepatocellular carcinoma. <b>1990</b> , 35, 681-5	15
2104	Prevalence of endoscopic findings in 510 consecutive individuals with cirrhosis evaluated prospectively. <b>1990</b> , 35, 705-10	58
2103	Drug metabolism in liver disease. <b>1990</b> , 1, 204-212	2
2102	Gastric red spots in patients with cirrhosis: subclinical condition of gastric mucosal hemorrhage?. <b>1990</b> , 25, 685-92	18
2101	Comparison between ultrasonographic signs and the degree of portal hypertension in patients with cirrhosis. <b>1990</b> , 15, 218-22	61
2100	Effects of a small bolus dose of ANF in healthy volunteers and in patients with volume retaining disorders. <b>1990</b> , 68, 709-17	13
2099	Can hepatic failure after surgery for hepatocellular carcinoma in cirrhotic patients be prevented?. <b>1990</b> , 14, 123-7	71
2098	Anesthesia for liver transplantation in patients with arterial hypoxemia. <b>1990</b> , 3, 103-7	2
2097	Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. <b>1990</b> , 11, 7-11	103

2096	A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding. <b>1990</b> , 11, 353-9	71
2095	Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. <b>1990</b> , 11, 360-4	61
2094	Spontaneous bacterial empyema in cirrhotic patients: analysis of eleven cases. <b>1990</b> , 11, 365-70	73
2093	Energy metabolism in patients with acute and chronic liver disease. <b>1990</b> , 11, 387-93	122
2092	A randomized trial of terlipressin plus nitroglycerin vs. balloon tamponade in the control of acute variceal hemorrhage. <b>1990</b> , 11, 678-81	77
2091	Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. <b>1990</b> , 11, 874-8	136
2090	Abnormal pressor response to vasopressin in patients with cirrhosis: evidence for impaired buffering mechanisms. <b>1990</b> , 12, 7-12	34
2089	Predictive value of whole blood chemiluminescence in patients with alcoholic hepatitis. <b>1990</b> , 12, 264-72	10
2088	The auditory P300 event-related potential: an objective marker of the encephalopathy of chronic liver disease. <b>1990</b> , 12, 688-94	60
2087	Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. <b>1990</b> , 12, 1413-9	101
2086	Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. <b>1990</b> , 65, 926-30	51
2085	Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. <b>1990</b> , 25, 622-30	113
2084	Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. <b>1990</b> , 31, 1298-302	144
2083	Prognostic scores in oesophageal or gastric variceal bleeding. <b>1990</b> , 25, 501-12	7
2082	Factors of prognostic importance in primary biliary cirrhosis. <b>1990</b> , 25, 119-26	63
2081	Relation between zinc status and hepatic functional reserve in patients with liver disease. <b>1990</b> , 31, 694-7	42
2080	Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. <b>1990</b> , 31, 204-7	62
2079	Alterations of glucose metabolism in chronic liver disease. <b>1990</b> , 8, 29-36	44

2078	Use of prognostic models for assessment of value of liver transplantation in primary biliary cirrhosis. <b>1990</b> , 335, 493-7	59
2077	A comparative evaluation of sclerosants for esophageal varices: a prospective randomized controlled study. <b>1990</b> , 36, 127-30	27
2076	Assessment of hepatic function. Comparison of caffeine clearance in serum and saliva during the day and at night. <b>1990</b> , 10, 129-37	42
2075	Submaximal oxygen consumption in liver cirrhosis. Evidence of severe functional aerobic impairment. <b>1990</b> , 10, 163-7	75
2074	Systemic and portal haemodynamic changes following triglycyllysine vasopressin plus nitroglycerin administration in patients with hepatitis B-related cirrhosis. <b>1990</b> , 10, 370-4	29
2073	The effect of non-protein liquid meals on the hepatic venous pressure gradient in patients with cirrhosis. <b>1990</b> , 11, 221-5	49
2072	Endoscopic and histologic appearance of the gastric mucosa in patients with portal hypertension. <b>1990</b> , 36, 575-9	50
2071	Patient characteristics in SUPPORT: disease specific clinical data. <b>1990</b> , 43 Suppl, 41S-45S	5
2070	Study population in SUPPORT: patients (as defined by disease categories and mortality projections), surrogates, and physicians. <b>1990</b> , 43 Suppl, 11S-28S	52
2069	Endoscopic classification of gastric varices. <b>1990</b> , 36, 276-80	142
2068	Natural history of hepatocellular carcinoma in Spain. Five year's experience in 249 cases. <b>1990</b> , 10, 311-7	111
2067	Endoscopic variceal ligation in patients who have failed endoscopic sclerotherapy. <b>1990</b> , 36, 572-4	45
2066	Surgical procedures for bleeding esophagogastric varices when sclerotherapy fails: a prospective study. <b>1990</b> , 160, 43-7	20
2065	Hormonal and metabolic changes during exercise in cirrhotic patients. <b>1990</b> , 39, 18-24	29
2064	Comparative efficacy of emergency endoscopic sclerotherapy for active variceal bleeding due to cirrhosis of the liver, non-cirrhotic portal fibrosis and extrahepatic portal venous obstruction. <b>1990</b> , 5, 432-7	12
2063	Assessment of liver function: principles and practice. <b>1990</b> , 5, 468-82	40
2062	Hepatic function and liver resection. <b>1990</b> , 5, 296-309	72
2061	Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure. <b>1990</b> , 29, 9-18	16

2060	Haemodynamic and pharmacokinetic study of intravenous fenoldopam in patients with hepatic cirrhosis. <b>1990</b> , 29, 19-25	8
2059	The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. <b>1990</b> , 29, 289-97	138
2058	Survival after transhepatic embolization of gastro-oesophageal varices. <b>1991</b> , 44, 178-80	1
2057	Decrease in plasma tryptophan after a tryptophan-free amino acid solution. A comparison between cirrhotic and control subjects. <b>1991</b> , 48, 409-18	12
2056	Efficacy of endoscopic sclerotherapy on long-term management of oesophageal varices: a comparative study of results in patients with cirrhosis of the liver, non-cirrhotic portal fibrosis (NCPF) and extrahepatic portal venous obstruction (EHO). <b>1991</b> , 6, 471-5	24
2055	Comparative effects of 5% ethanolamine oleate versus 5% sodium morrhuate for sclerotherapy of oesophageal varices. <b>1991</b> , 6, 476-80	9
2054	A randomized controlled study of low-dose and high-dose terlipressin in the control of acute oesophageal variceal haemorrhage. <b>1991</b> , 6, 481-4	8
2053	Duplex Doppler ultrasound of the ligamentum teres and portal vein: a clinically useful adjunct in the evaluation of patients with known or suspected chronic liver disease or portal hypertension. <b>1991</b> , 6, 61-5	9
2052	Snake skin pattern gastropathy in cirrhotic patients. <b>1991</b> , 6, 145-9	28
2051	Reduction of transmural oesophageal variceal pressure by metoclopramide. <b>1991</b> , 12, 362-6	27
2050	Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy. <b>1991</b> , 12, 283-9	61
2049	Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. <b>1991</b> , 337, 1431-4	222
2048	Clearance of atrial natriuretic peptide in patients with cirrhosis. Role of liver failure. <b>1991</b> , 13, 351-7	9
2047	Outcome of injection sclerotherapy using absolute alcohol in patients with cirrhosis, non-cirrhotic portal fibrosis, and extrahepatic portal venous obstruction. <b>1991</b> , 37, 460-4	12
2046	Endoscopic sclerotherapy in the management of gastric variceal haemorrhage. <b>1991</b> , 13, 274-8	75
2045	Regional sympathetic activity, severity of liver disease and hemodynamics in patients with cirrhosis. <b>1991</b> , 13, 161-8	28
2044	A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. <b>1991</b> , 12, 236-40	44
2043	Chronic viral hepatitis. From clinical trials to the therapeutic decision in the individual patient. <b>1991</b> , 13 Suppl 1, S27-30	

2042	Regional cerebral blood flow and cognitive function in patients with chronic liver disease. <b>1991</b> , 337, 1250-3	122
2041	Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis. <b>1991</b> , 14, 317-21	52
2040	Development of Gastroesophageal Varices and Risk of Variceal Bleeding in Patients With Cirrhosis. <b>1991</b> , 3, 485-490	7
2039	Peri-operative mortality in hepatic resection. <b>1991</b> , 61, 201-6	28
2038	Correlations between plasma levels of fibrin(ogen) derivatives as quantified by different assays based on monoclonal antibodies. <b>1991</b> , 61, 441-52	3
2037	Jejunal immunoglobulin secretion in alcoholic patients with and without cirrhosis. <b>1991</b> , 12, 145-9	10
2036	Endoscopic injection sclerotherapy versus conservative treatment for patients with unresectable hepatocellular carcinoma and bleeding esophageal varices. <b>1991</b> , 37, 161-4	27
2035	Caffeine Metabolism. <b>1991</b> , 513-539	3
2034	Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. <b>1991</b> , 214, 114-7	429
2033	Portasystemic shunting versus liver transplantation for the Budd-Chiari syndrome. <b>1991</b> , 214, 581-9	81
2032	Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. <b>1991</b> , 100, 1737-42	224
2031	Medical and surgical treatment of acute bleeding from esophageal varices in patients with cirrhosis. <b>1991</b> , 26, 897-908	2
2030	Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. <b>1991</b> , 100, 520-8	386
2029	Assessment of the Risk of Bleeding From Esophageal Varices by Continuous Monitoring of Portal Pressure. <b>1991</b> , 100, 1403-1410	75
2028	Prophylactic sclerotherapy in high-risk cirrhotics selected by endoscopic criteria. A multicenter randomized controlled trial. <b>1991</b> , 101, 1087-93	52
2027	A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. <b>1991</b> , 101, 1382-90	97
2026	A prospective controlled study of the risk of bacteremia in emergency sclerotherapy of esophageal varices. <b>1991</b> , 101, 1642-8	65
2025	Spontaneous bacterial peritonitis in patients with hepatitis B-related cirrhosis and hepatocellular carcinoma. <b>1991</b> , 101, 1656-62	20



2024	Prevalence of spontaneous hepatofugal portal flow in liver cirrhosis. Clinical and endoscopic correlation in 228 patients. <b>1991</b> , 100, 160-7	165
2023	Value of preoperative physiologic assessment in outcome of patients undergoing major surgical procedures. <b>1991</b> , 71, 1141-50	11
2022	Prediction of Variceal Hemorrhage in Cirrhosis: A Prospective Follow-up Study. <b>1991</b> , 100, 1332-1337	104
2021	Scfthofpapie prophylactique des varices Eophagiennes ^ haut risque de saignement etude prospective et randomisè, avec longue pfiode de surveillance. <b>1991</b> , 21, 463-472	1
2020	Portal hypertensive colopathy. A new entity. <b>1991</b> , 36, 1774-81	89
2019	Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. <b>1991</b> , 36, 1197-203	72
2018	Low serum levels of alpha-interferon, gamma-interferon, and interleukin-2 in alcoholic cirrhosis. <b>1991</b> , 36, 1209-12	25
2017	Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage. <b>1991</b> , 36, 299-302	22
2016	Increased plasma cathepsin D concentration in hepatic carcinoma and cirrhosis but not in breast cancer. <b>1991</b> , 24, 491-6	26
2015	Plasma noradrenaline in cirrhosis: a study of kinetics and temporal relationship to ascites formation. <b>1991</b> , 21, 238-43	16
2014	Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: A systemic, splanchnic and renal hemodynamic study. <b>1991</b> , 13, 111-116	24
2013	Prophylactic sclerotherapy for esophageal varices: Long-term results of a single-center trial. <b>1991</b> , 13, 117-123	50
2012	Hemodynamic study during transdermal application of nitroglycerin tape in patients with cirrhosis. <b>1991</b> , 13, 124-128	24
2011	Hyposensitivity to vasopressin in patients with hepatitis BÈrelated cirrhosis during acute variceal hemorrhage. <b>1991</b> , 13, 407-412	24
2010	Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: Results of a western comparative study in 60 patients. <b>1991</b> , 13, 427-433	131
2009	Hepatic amino-nitrogen clearance to urea-nitrogen in control subjects and in patients with cirrhosis: A simplified method. <b>1991</b> , 13, 460-466	29
2008	Plasma catecholamines in patients with presinusoidal portal hypertension: Comparison with cirrhotic patients and nonportal hypertensive subjects. <b>1991</b> , 13, 913-916	18
2007	Hepatitis B virus infection in patients with idiopathic liver disease. <b>1991</b> , 13, 1044-1051	68

2006	Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients. <b>1991</b> , 14, 91-8	46
2005	Effect of insulin and plasma amino acid concentration on leucine metabolism in cirrhosis. <b>1991</b> , 14, 432-441	37
2004	Are patients with primary biliary cirrhosis hypermetabolic? a comparison between patients before and after liver transplantation and controls. <b>1991</b> , 14, 464-472	20
2003	Sexual function and testosterone levels in men with nonalcoholic liver disease. <b>1991</b> , 14, 479-482	26
2002	Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis. <b>1991</b> , 14, 483-487	26
2001	Bone loss after liver transplantation. <b>1991</b> , 14, 613-619	167
2000	Effect of propranolol on portosystemic collateral circulation in patients with cirrhosis. <b>1991</b> , 14, 824-9	38
1999	Colchicine clearance is impaired in alcoholic cirrhosis. <b>1991</b> , 14, 1013-1015	22
1998	Predictors of one-year pretransplant survival in patients with cirrhosis. <b>1991</b> , 14, 1029-1034	96
1997	Relationships between plasma atrial natriuretic peptide concentrations and hemodynamics and hematocrit in patients with cirrhosis. <b>1991</b> , 14, 1035-1039	5
1996	Surgical treatment of severe postshunt hepatic encephalopathy. <b>1991</b> , 15, 109-113; discussion 113-4	9
1995	Results of endoscopic variceal sclerotherapy: influence of etiology of portal hypertension and hepatic functional status. <b>1991</b> , 26 Suppl 3, 32-5	2
1994	Functional hepatic imaging with receptor-binding radiopharmaceutical: clinical potential as a measure of functioning hepatocyte mass. <b>1991</b> , 26, 734-41	40
1993	Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy subjects and in disease states. <b>1991</b> , 40, 101-6	5
1992	Portal hypertension--25 years of progress. <b>1991</b> , Suppl, S18-24	6
1991	Congestive gastropathy and Helicobacter pylori: an endoscopic and morphometric study. <b>1991</b> , 32, 351-4	53
1990	Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. <b>1991</b> , 325, 829-35	234
1989	Hepatocellular carcinoma in Italian patients with cirrhosis. <b>1991</b> , 325, 675-80	674

1988	Plasma beta endorphin in cirrhosis and renal failure. <b>1991</b> , 32, 306-8	12
1987	Amenorrhoea in women with non-alcoholic chronic liver disease. <b>1991</b> , 32, 202-6	44
1986	Non-invasive diagnosis of portal vein occlusion by radionuclide angiography. <b>1992</b> , 33, 1671-4	5
1985	Bleeding varices in the elderly. <b>1992</b> , 33, 1009-10	4
1984	Pugh's grading in the classification of liver decompensation. <b>1992</b> , 33, 1583	13
1983	Metabolic clearance of a fat emulsion containing medium-chain triglycerides in cirrhotic patients. <b>1992</b> , 16, 279-83	16
1982	Plasma concentrations of endogenous heparinoids in portal hypertension. <b>1992</b> , 33, 1549-52	28
1981	A prospective trial of endoscopic sclerotherapy v oesophageal transection and gastric devascularisation in the long term management of bleeding oesophageal varices. <b>1992</b> , 33, 1553-8	15
1980	Factors related to early mortality in cirrhotic patients bleeding from varices and treated by urgent sclerotherapy. <b>1992</b> , 33, 1381-5	36
1979	Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. <b>1992</b> , 33, 836-42	71
1978	Activation of the classical complement pathway in spontaneous bacterial peritonitis. <b>1992</b> , 33, 307-11	6
1977	Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. <b>1992</b> , 326, 1527-32	586
1976	Chronic Hepatitis and Cirrhosis. <b>1992</b> , 281-415	
1975	Mechanism of insulin resistance associated with liver cirrhosis. <b>1992</b> , 102, 2033-41	105
1974	Portal hypertensive gastropathy in patients with cirrhosis. <b>1992</b> , 102, 2060-5	89
1973	Hemodynamic, neurohumoral, and metabolic responses to amino acid infusion in patients with cirrhosis. <b>1992</b> , 103, 601-8	8
1972	Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. <b>1992</b> , 103, 229-34	70
1971	Serum levels of cytokines in chronic liver diseases. <b>1992</b> , 103, 264-74	623

1970	Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. <b>1992</b> , 102, 973-9	156
1969	Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis and ascites. <b>1992</b> , 102, 1309-1318	35
1968	Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. <b>1992</b> , 103, 641-6	88
1967	Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. <b>1992</b> , 103, 1875-82	102
1966	Selection for and outcome of liver transplantation in alcoholic liver disease. <b>1992</b> , 102, 1736-41	135
1965	Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. <b>1992</b> , 102, 248-54	45
1964	Breast cancer-associated antigen CA 15.3 in liver cirrhosis. <b>1992</b> , 31, 741-4	5
1963	Local deterioration of the cutaneous venoarterial reflex of the hand in cirrhosis. <b>1992</b> , 27, 326-32	8
1962	Decreased in vitro production of tumor necrosis factor in primary biliary cirrhosis patients. <b>1992</b> , 27, 124-8	20
1961	Relationship of insulin resistance to protein-energy malnutrition in patients with alcoholic liver cirrhosis: effect of short-term nutritional support. <b>1992</b> , 16, 971-8	4
1960	Relationship of portal pressure, anorectal varices and hemorrhoids in cirrhotic patients. <b>1992</b> , 15, 170-3	42
1959	Long-term follow-up study of adult patients with non-cirrhotic obstruction of the portal system: comparison with cirrhotic patients. <b>1992</b> , 15, 299-303	40
1958	Hemodynamic and sympathetic responses to human atrial natriuretic peptide infusion in patients with cirrhosis. <b>1992</b> , 14, 347-56	19
1957	Alteration of erythrocyte glutathione, cysteine and glutathione synthetase in alcoholic and non-alcoholic cirrhosis. <b>1992</b> , 52, 207-13	24
1956	Mechanisms and consequences of portal hypertension. <b>1992</b> , 44 Suppl 2, 1-13; discussion 70-2	15
1955	Effects of vaso-active agents on hepatic function and blood gases in patients with cirrhosis: a study of vasopressin and nitroglycerin. <b>1992</b> , 7, 148-53	7
1954	Hypercholesterolaemia in patients with hepatocellular carcinoma. <b>1992</b> , 7, 491-6	19
1953	Surgical resection and survival in Western patients with hepatocellular carcinoma. <b>1992</b> , 15, 350-5	24

1952	Bacterial peritonitis and sclerotherapy for variceal hemorrhage. <b>1992</b> , 38, 200	3
1951	Selenium in chronic liver disease. <b>1992</b> , 14, 176-82	78
1950	Ascites dynamics in cirrhosis. Proposal and validation of a methylene blue dilution test. <b>1992</b> , 16, 369-75	11
1949	Value of measurement of mean portal flow velocity by Doppler flowmetry in the diagnosis of portal hypertension. <b>1992</b> , 16, 298-303	132
1948	Metabolic responses to lipid infusions in patients with liver cirrhosis. <b>1992</b> , 11, 193-206	33
1947	Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. <b>1992</b> , 11, 303-8	13
1946	Hepatocellular carcinoma. Prognostic factors and survival analysis in 135 Italian patients. <b>1992</b> , 16, 66-72	21
1945	Bacteriuria in patients with cirrhosis. <b>1992</b> , 16, 73-6	26
1944	Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis b-related cirrhosis. <b>1992</b> , 15, 54-8	13
1943	Natural history of autonomic neuropathy in chronic liver disease. <b>1992</b> , 339, 1462-4	150
1942	Thermogenic response to intravenous nutrition in patients with cirrhosis. <b>1992</b> , 16, 145-52	9
1941	Theophylline metabolism in patients with hepatosplenic mansoniasis and cirrhosis. <b>1992</b> , 15, 35-9	6
1940	Peripheral and cardiovascular autonomic impairment in chronic liver disease: prevalence and relation to hepatic function. <b>1992</b> , 16, 177-83	77
1939	Injection sclerotherapy preceded by esophageal tamponade versus immediate sclerotherapy in arresting active variceal bleeding: a prospective randomized trial. <b>1992</b> , 38, 421-4	41
1938	Disseminated intravascular coagulation in liver cirrhosis. <b>1992</b> , 15, 330-5	38
1937	A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. <b>1992</b> , 16, 320-5	91
1936	The validity of bioelectrical impedance analysis in estimating total body water in patients with cirrhosis. <b>1992</b> , 16, 59-65	35
1935	Increased procoagulant activity in peripheral blood mononuclear cells from patients with liver cirrhosis. <b>1992</b> , 68, 103-8	10

1934	Bed-rest-induced hypernatremia in cirrhotic patients without ascites: does it contribute to maintain 'compensation'?. <b>1992</b> , 16, 190-6	51
1933	The thermogenic and metabolic effects of food in liver cirrhosis: consequences on the storage of nutrients and the hormonal counterregulatory response. <b>1992</b> , 41, 476-82	24
1932	Pharmacokinetics of glafenine and glafenic acid in patients with cirrhosis, compared to healthy volunteers. <b>1992</b> , 6, 197-203	5
1931	Pharmacokinetics of lomefloxacin in patients with cirrhosis. <b>1992</b> , 92, 41S-44S	8
1930	Spontaneous Dialytic Ultrafiltration with Intraperitoneal Reinfusion of the Concentrate versus Large Paracentesis in Cirrhotic Patients with Intractable Ascites: A Randomized Study. <b>1992</b> , 15, 432-435	11
1929	Spontaneous Dialytic Ultrafiltration with Intraperitoneal Reinfusion of the Concentrate in 15 Cirrhotic Patients with Intractable Ascites. <b>1992</b> , 15, 168-171	1
1928	Evaluation of the Behavior of Carcinoembryonic Antigen in Cirrhotic Patients. <b>1992</b> , 7, 244-248	6
1927	A Pugh score of 8 adequately selects patients with parenchymal cirrhosis for liver transplantation. <b>1992</b> , 5, S175-S178	2
1926	Surgical Measures for Active Variceal Bleeding. <b>1992</b> , 2, 77-93	1
1925	Endoscopic Diagnosis and Classification of Varices. <b>1992</b> , 2, 17-30	4
1924	Pattern and concentration of free and acetylated polyamines in urine of cirrhotic patients. <b>1992</b> , 7, 52-58	5
1923	Protein-calorie malnutrition in liver cirrhosis. <b>1992</b> , 70, 478-86	195
1922	Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions. <b>1992</b> , 31 Suppl, S38-44	11
1921	Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors. <b>1992</b> , 31 Suppl, S82-5	34
1920	Esophageal strictures following endoscopic variceal sclerotherapy. Antecedents, clinical profile, and management. <b>1992</b> , 37, 347-52	19
1919	Balloon tamponade and vasoactive drugs in the control of acute variceal haemorrhage. <b>1992</b> , 6, 451-63	4
1918	The role of portosystemic shunting in the management of portal hypertension. <b>1992</b> , 6, 497-515	9
1917	Pharmacokinetics of famotidine in patients with cirrhosis and ascites. <b>1992</b> , 43, 559-62	7

1916	Upper gastro-intestinal tract bleeding in cirrhotic children candidates for liver transplantation. <b>1992</b> , 151, 326-8	38
1915	Pre- and post-transplant assessment of liver function in paediatric liver transplantation. <b>1992</b> , 151 Suppl 1, S39-43	14
1914	Portal hypertension and bleeding esophageal varices. <b>1992</b> , 6, 553-61	5
1913	Glucagon-independent renal hyperaemia and hyperfiltration after an oral protein load in Child A liver cirrhosis. <b>1992</b> , 22, 31-7	6
1912	Preoperative assessment of hepatic function. <b>1992</b> , 6, 781-793	
1911	Anaesthetic management of patients with alcoholic liver disease. <b>1992</b> , 6, 847-861	1
1910	Sclerotherapy vs. esophageal transection vs. distal splenorenal shunt for the clinical management of esophageal varices in patients with child class A and B liver function: a prospective randomized trial. <b>1992</b> , 15, 63-8	31
1909	Endoscopic injection sclerotherapy for 1,000 patients with esophageal varices: a nine-year prospective study. <b>1992</b> , 15, 69-75	73
1908	Treatment of hepatocellular carcinoma associated with advanced cirrhosis by transcatheter arterial chemoembolization using autologous blood clot: a preliminary report. <b>1992</b> , 15, 252-7	20
1907	Esophageal staple transection as a salvage procedure after failure of acute injection sclerotherapy. <b>1992</b> , 15, 403-6	21
1906	Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. <b>1992</b> , 15, 672-6	79
1905	Energy expenditure and substrate oxidation in patients with cirrhosis: the impact of cause, clinical staging and nutritional state. <b>1992</b> , 15, 782-94	243
1904	Total effective vascular compliance in patients with cirrhosis: a study of the response to acute blood volume expansion. <b>1992</b> , 15, 809-15	46
1903	Polymorphism of alcohol dehydrogenase, alcohol and aldehyde dehydrogenase activities: implication in alcoholic cirrhosis in white patients. The French Group for Research on Alcohol and Liver. <b>1992</b> , 15, 1017-22	59
1902	Bleeding from staple line erosion after esophageal transection: effect of omeprazole. <b>1992</b> , 15, 1031-5	6
1901	Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. <b>1992</b> , 15, 1054-9	63
1900	A prospective randomized trial comparing repeated endoscopic sclerotherapy and propranolol in decompensated (Child class B and C) cirrhotic patients. <b>1992</b> , 16, 89-94	44
1899	Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. <b>1992</b> , 16, 132-7	342

1898	Defective methionine metabolism in cirrhosis: relation to severity of liver disease. <b>1992</b> , 16, 149-55	53
1897	Hormonal status of postmenopausal women with alcohol-induced cirrhosis: further findings and a review of the literature. <b>1992</b> , 16, 312-9	42
1896	The hemodynamic status of preascitic cirrhosis: an evaluation under steady-state conditions and after postural change. <b>1992</b> , 16, 341-6	77
1895	Increased tissue-type plasminogen activator activity in orthotopic but not heterotopic liver transplantation: the role of the anhepatic period. <b>1992</b> , 16, 404-8	23
1894	Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomized trial. <b>1992</b> , 16, 912-9	38
1893	Aflatoxin B1 DNA adducts in smeared tumor tissue from patients with hepatocellular carcinoma. <b>1992</b> , 16, 1150-1155	39
1892	Pallidal hyperintensity on magnetic resonance imaging in cirrhotic patients: clinical correlations. <b>1992</b> , 16, 1382-8	125
1891	Antipyrine metabolism in patients with liver metastases from colorectal cancer. <b>1992</b> , 70, 1477-82	5
1890	Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. <b>1993</b> , 72, 1557-63	87
1889	Hyperfibrinolysis Resulting from Clotting Activation in Patients with Different Degrees of Cirrhosis. <b>1993</b> , 17, 78-83	79
1888	Quantitative assessment of hepatocellular function through in vivo radioreceptor imaging with technetium 99m galactosyl human serum albumin. <b>1993</b> , 17, 814-819	56
1887	Abnormalities in proximal small bowel motility in patients with cirrhosis. <b>1993</b> , 17, 828-832	91
1886	Unresponsiveness of hepatic nitrogen metabolism to glucagon infusion in patients with cirrhosis: Dependence on liver cell failure. <b>1993</b> , 18, 28-35	16
1885	Reduced gastric mucosal blood flow in patients with portal-hypertensive gastropathy. <b>1993</b> , 18, 36-40	67
1884	Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: A multicenter randomized trial. <b>1993</b> , 18, 61-65	63
1883	Prior esophageal variceal bleeding does not adversely affect survival after orthotopic liver transplantation. <b>1993</b> , 18, 66-72	4
1882	Albumin synthesis rates in cirrhosis: Correlation with child-turcotte classification. <b>1993</b> , 18, 292-297	59
1881	Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: Long-term hemodynamic and renal effects. <b>1993</b> , 18, 477-484	46



1880	Changes of serum 7S fragment of type IV collagen and N-terminal propeptide of type III procollagen after transcatheter arterial embolization as a model of acute liver injury. <b>1993</b> , 18, 809-15	9
1879	Multiple-dose pharmacokinetics of rifloxacin in patients with cirrhosis. <b>1993</b> , 18, 847-52	5
1878	Positron-emission tomographic localization of abnormalities of brain metabolism in patients with minimal hepatic encephalopathy. <b>1993</b> , 18, 1061-1068	100
1877	Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, double-blind study. <b>1993</b> , 18, 1102-1107	62
1876	Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection. <b>1993</b> , 18, 1121-1126	246
1875	Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease. <b>1993</b> , 18, 1132-1138	65
1874	Preoperative evaluation of a patient for hepatic surgery. <b>1993</b> , 3, 49-51	15
1873	Surgical risk in alcoholic cirrhotic postmenopausal women: prognostic value of levels of hormones. <b>1993</b> , 3, 52-4	4
1872	Prognostic indicators in patients with cirrhosis and hepatocellular carcinoma undergoing surgical resection. <b>1993</b> , 3, 67-9	6
1871	Renal sodium handling and neurohumoral systems in patients with cirrhosis in sitting posture: effects of spironolactone and water immersion. <b>1993</b> , 71, 894-7	1
1870	Study of serum procollagen type III peptide in patients with hepatic cirrhosis from a clinical point of view. <b>1993</b> , 71, 416-8	2
1869	Influence of insulin on glucose metabolism and lipolysis in adipose tissue in situ in patients with liver cirrhosis. <b>1993</b> , 23, 837-44	9
1868	Effect of transferrin concentration on bacterial growth in human ascitic fluid from cirrhotic and neoplastic patients. <b>1993</b> , 23, 699-705	12
1867	Reduced portosystemic hemodynamic responsiveness after orthostasis in patients with cirrhosis. <b>1993</b> , 38, 1251-8	12
1866	Hepatic [14C]aminopyrine demethylation capacity after portocaval shunting. Comparative study in patients with and without arterialization of portal vein. <b>1993</b> , 38, 2177-82	16
1865	Surgical treatment of complications of portal hypertension. <b>1993</b> , 25, 163-165	
1864	Der transjuguläre intrahepatische portosystemische Shunt. <b>1993</b> , 25, 165-168	
1863	Orthotopic liver transplantation in the presence of partial or total portal vein thrombosis: problems in diagnosis and management. <b>1993</b> , 17, 669-74	60

1862	Critical appraisal of the angiographic portacaval shunt (TIPS). <b>1993</b> , 165, 566-71	114
1861	Endoscopic evaluation of the therapeutic effect of sclerotherapy for esophageal varices. <b>1993</b> , 39, 37-42	13
1860	Endoscopic ligation of esophageal varices compared with injection sclerotherapy: a prospective randomized trial. <b>1993</b> , 39, 123-6	87
1859	The effects of indomethacin and naproxen on zidovudine pharmacokinetics. <b>1993</b> , 36, 82-5	12
1858	Changes of sex hormone levels in patients with hepatitis B virus-related postnecrotic cirrhosis: relationship to the severity of portal hypertension. <b>1993</b> , 18, 101-5	10
1857	Diurnal pattern of variceal bleeding in cirrhotic patients. <b>1993</b> , 19, 15-22	34
1856	Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. <b>1993</b> , 19, 43-50	4
1855	Hepatic hemodynamic features in patients with esophageal or gastric varices. <b>1993</b> , 19, 85-9	40
1854	Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. <b>1993</b> , 19, 140-7	65
1853	Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study. <b>1993</b> , 17, 308-14	102
1852	Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. <b>1993</b> , 18, 185-95	126
1851	Infectious sequelae after endoscopic sclerotherapy of oesophageal varices: role of antibiotic prophylaxis. <b>1993</b> , 18, 290-4	52
1850	A prospective study of bacterial infections in patients with cirrhosis. <b>1993</b> , 18, 353-8	380
1849	Effects of vasopressin and nicardipine on hemodynamics and liver function in patients with cirrhosis: comparison with vasopressin alone. <b>1993</b> , 19, 345-52	5
1848	Autonomic and peripheral neuropathy in primary biliary cirrhosis. <b>1993</b> , 19, 401-7	30
1847	Energy expenditure and substrate metabolism after oral fructose in patients with cirrhosis. <b>1993</b> , 19, 241-51	10
1846	A prospective randomized study to evaluate propranolol in patients undergoing long-term endoscopic sclerotherapy. <b>1993</b> , 19, 291-300	27
1845	Changes of hepatic and systemic haemodynamics following somatostatin administration in patients with hepatitis B-related cirrhosis. <b>1993</b> , 8, 15-20	8

1844	Hypothalamic-pituitary adrenal function in end-stage non-alcoholic liver disease. <b>1993</b> , 8, 247-53	48
1843	Does propranolol maintain post-sclerotherapy variceal obliteration? A prospective randomized study. <b>1993</b> , 8, 358-62	13
1842	Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients. <b>1993</b> , 37, 1587-92	59
1841	Clinical pharmacokinetics of newer antibacterial agents in liver disease. <b>1993</b> , 24, 46-58	30
1840	Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. <b>1993</b> , 25, 154-63	27
1839	To treat or not to treat? The judicious use of interferon-alpha-2a for the treatment of chronic hepatitis B. <b>1993</b> , 17 Suppl 3, S42-6	18
1838	Metabolic effects of beta-adrenergic receptor blockade in advanced alcoholic cirrhosis. <b>1993</b> , 17, 74-80	7
1837	The lowly nasogastric tube: still appropriate after all these years (at times). <b>1993</b> , 11, 84-9	21
1836	Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. <b>1993</b> , 17, 56-61	71
1835	The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. <b>1993</b> , 17, 227-35	32
1834	The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites. <b>1993</b> , 47, 345-52	18
1833	Pulmonary complications of orthotopic liver transplantation. <b>1993</b> , 68, 427-34	59
1832	Excretion of caffeine and its primary degradation products into bile. <b>1993</b> , 17, 67-73	28
1831	Prevalence of hyperfibrinolysis in patients with liver cirrhosis. <b>1993</b> , 7, 59-62	17
1830	Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. <b>1993</b> , 342, 895-8	95
1829	Incidence of altered glucose tolerance in liver cirrhosis. <b>1993</b> , 22, 37-44	43
1828	The Influence of Endoscopic Injection Sclerotherapy on Organs Surrounding the Esophagus. <b>1993</b> , 5, 23-32	1
1827	Effect of Endoscopic Injection Sclerotherapy on Acute Bleeding from Esophageal Varices in Cirrhotic Patients with Advanced Hepatocellular Carcinoma. <b>1993</b> , 5, 151-155	

1826	Efficacy of Prophylactic Endoscopic Variceal Sclerotherapy in Patients with Hepatocellular Carcinoma. <b>1993</b> , 5, 350-358	1
1825	Serum concentrations of laminin in cirrhosis of the liver. <b>1993</b> , 34, 974-6	13
1824	Ethanol challenge in non-alcoholic patients with schistosomiasis. <b>1993</b> , 46, 250-3	30
1823	Congestive jejunopathy in portal hypertension. <b>1993</b> , 34, 694-7	57
1822	Successful use of a transjugular intrahepatic portosystemic stent shunt to control severe refractory oesophageal variceal haemorrhage in a poor risk patient. <b>1993</b> , 69, 945-7	
1821	Early detection of protein depletion in alcoholic cirrhosis: role of body composition analysis. <b>1993</b> , 105, 1839-45	112
1820	Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. <b>1993</b> , 104, 1492-7	169
1819	Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. <b>1993</b> , 105, 229-36	661
1818	Manometry of esophageal varices: comparison of an endoscopic balloon technique with needle puncture. <b>1993</b> , 105, 1159-66	44
1817	Renal sodium retention during upright posture in preascitic cirrhosis. <b>1993</b> , 105, 188-93	82
1816	Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. <b>1993</b> , 105, 1167-72	65
1815	Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. <b>1993</b> , 104, 1133-8	199
1814	Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis. <b>1993</b> , 217, 314-20	46
1813	Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. <b>1993</b> , 105, 148-56	56
1812	Hepatocellular carcinoma in liver cirrhosis. A prospective study. <b>1993</b> , 28, 540-4	33
1811	Sclerotherapy versus beta blockade: unanticipated anomalies of experimental design. <b>1993</b> , 105, 1575-7	4
1810	Malignant lymphoproliferative disorders in liver cirrhosis. <b>1993</b> , 4, 245-50	15
1809	Liver transplantation without the use of blood products. <b>1994</b> , 129, 528-32; discussion 532-3	47

1808	Combined (short-term plus longterm) sclerotherapy v short-term only sclerotherapy: a randomised prospective trial. <b>1994</b> , 35, 687-91	6
1807	Resistance of erythrocytes to lipid peroxidation in alcoholic patients. <b>1994</b> , 35, 1753-6	6
1806	Oral isosorbide-5-mononitrate reduces the rebleeding rate during the course of injection sclerotherapy for esophageal varices. <b>1994</b> , 29, 363-70	11
1805	Glucose intolerance in liver cirrhosis: role of hepatic and non-hepatic influences. <b>1994</b> , 32, 749-58	20
1804	Changes in debrisoquine hydroxylation capacity following liver surgery. <b>1994</b> , 13, 537-41	2
1803	Portal venous flow and follow-up in patients with liver disease and healthy subjects. Assessment with duplex Doppler. <b>1994</b> , 29, 172-7	18
1802	Gram-negative bacillary cellulitis in patients with hepatic cirrhosis. <b>1994</b> , 13, 19-24	52
1801	Hyperintense lesions of the globus pallidus on MRI in children with chronic liver disease. <b>1994</b> , 153, 802-6	4
1800	Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma. <b>1994</b> , 29, 745-50	7
1799	Impaired gastric mucosal energy metabolism in congestive gastropathy in cirrhotic patients. <b>1994</b> , 29, 245-9	5
1798	Endoscopic injection sclerotherapy for esophageal varices in the elderly. <b>1994</b> , 18, 764-8	1
1797	Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. <b>1994</b> , 72, 653-9	30
1796	Markers of potential esophageal variceal rebleeding in cirrhotic patients undergoing endoscopic injection sclerotherapy. <b>1994</b> , 1, 168-171	
1795	Lipiodolization for unresectable hepatocellular carcinoma: an analysis of 205 patients using univariate and multivariate analysis. <b>1994</b> , 56, 54-8	20
1794	Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. <b>1994</b> , 74, 16-24	162
1793	Prospective flow cytometric DNA analysis of hepatocellular carcinoma specimens collected by ultrasound-guided fine needle aspiration. <b>1994</b> , 74, 599-605	23
1792	Early and late changes in fasting and absorptive plasma amino acids and ammonia after distal splenorenal shunt in cirrhosis. <b>1994</b> , 19, 329-338	2
1791	Diuretics vs. paracentesis followed by diuretics in cirrhosis: effect on ascites opsonic activity and immunoglobulin and complement concentrations. <b>1994</b> , 19, 346-53	5

1790	Polymorphism of alcohol and aldehyde dehydrogenase genes and alcoholic cirrhosis in chinese patients. <b>1994</b> , 19, 360-366	142
1789	Influence of paraesophageal venous collaterals on efficacy of endoscopic sclerotherapy for esophageal varices. <b>1994</b> , 19, 602-8	44
1788	Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. <b>1994</b> , 19, 628-34	65
1787	Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: A multivariate analysis of prognostic factors. <b>1994</b> , 19, 1115-1123	155
1786	Tissue inhibitor of metalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis. <b>1994</b> , 19, 1418-1423	51
1785	Classification of chronic hepatitis: Diagnosis, grading and staging. <b>1994</b> , 19, 1513-1520	2149
1784	Prognostic significance of diabetes in patients with cirrhosis. <b>1994</b> , 20, 119-125	146
1783	Skeletal muscle glycogen content in patients with cirrhosis. <b>1994</b> , 20, 135-141	18
1782	Monoethylglycinexylidide test: A prognostic indicator of survival in cirrhosis. <b>1994</b> , 20, 383-387	49
1781	Phase II study of transarterial embolization in european patients with hepatocellular carcinoma: Need for controlled trials. <b>1994</b> , 20, 643-650	77
1780	Blood and plasma 5-hydroxytryptamine levels in patients with cirrhosis. <b>1994</b> , 20, 800-3	33
1779	Cysteinyl leukotrienes in the urine of patients with liver diseases. <b>1994</b> , 20, 804-12	32
1778	Evaluation of hepatocellular function by way of receptor-mediated uptake of a technetium-99m-labeled asialoglycoprotein analog. <b>1994</b> , 20, 917-23	33
1777	Cerebral Phosphorus-31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy. <b>1994</b> , 20, 1173-1178	48
1776	Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: A multicenter italian study. <b>1994</b> , 20, 1225-1230	112
1775	Portal and gastric mucosal hemodynamics in cirrhotic patients with portal-hypertensive gastropathy. <b>1994</b> , 20, 1432-6	68
1774	Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. <b>1994</b> , 20, 1502-8	53
1773	Multi-variate stepwise discriminant analysis research affecting portal hypertension's grade factors of liver function. <b>1994</b> , 14, 56-60	

1772	Delayed gastric emptying in patients with liver cirrhosis. <b>1994</b> , 39, 983-7	57
1771	Effects of propranolol on gastric mucosal perfusion and serum gastrin level in cirrhotic patients with portal hypertensive gastropathy. <b>1994</b> , 39, 2433-8	16
1770	Wedged hepatic venous pressure reflects portal venous pressure during vasoactive drug administration in nonalcoholic cirrhosis. <b>1994</b> , 39, 2439-44	14
1769	Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy. <b>1994</b> , 9, 347-59	87
1768	Serum IgE levels in liver cirrhosis. Contrasting results in alcoholic and non-alcoholic patients. <b>1994</b> , 24, 540-8	29
1767	Zinc and magnesium in liver cirrhosis. <b>1994</b> , 24, 149-55	25
1766	Evaluation of indocyanine green retention and aminopyrine breath tests in patients with malignant biliary obstruction. <b>1994</b> , 64, 759-62	10
1765	Life quality of patients undergoing liver transplantation. <b>1994</b> , 7 Suppl 1, S675-8	3
1764	An improved assay for urinary LTE4. <b>1994</b> , 47, 281-92	12
1763	The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. <b>1994</b> , 330, 165-71	612
1762	Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. <b>1994</b> , 34, 1199-207	27
1761	Orthotopic liver transplantation for preoperative early-stage hepatocellular carcinoma. <b>1994</b> , 69, 509-14	13
1760	Morbidity and mortality in cirrhotic patients undergoing major cardiac, thoracic or vascular surgery. <b>1994</b> , 8, 72	
1759	The role of transjugular intrahepatic portosystemic shunts in the management of patients with end-stage liver disease. <b>1994</b> , 168, 592-597	18
1758	Dynamics of cognitive brain dysfunction in patients with cirrhotic liver disease: an event-related P300 potential perspective. <b>1994</b> , 91, 33-41	19
1757	Relationship between lipoprotein(a) levels in serum and some indices of protein synthesis in liver cirrhosis. <b>1994</b> , 224, 125-9	12
1756	Lipid metabolism and substrate oxidation during intravenous fructose administration in cirrhosis. <b>1994</b> , 43, 1171-81	4
1755	Failure of glucagon to stimulate hepatic glycogenolysis in well-nourished patients with mild cirrhosis. <b>1994</b> , 43, 85-9	32

1754	Intravascular clotting activation and systemic hyperfibrinolysis in patients with severe liver cirrhosis: The role of ascites. <b>1994</b> , 8, 353-358	3
1753	Terlipressin or vasopressin plus transdermal nitroglycerin in a treatment strategy for digestive bleeding in cirrhosis. A randomized clinical trial. Liver Study Group of V. Cervello Hospital. <b>1994</b> , 20, 206-12	61
1752	Ascites apheresis, concentration and reinfusion for the treatment of massive or refractory ascites in cirrhosis. <b>1994</b> , 20, 289-95	15
1751	Splanchnic and peripheral glucose metabolism in cirrhosis. <b>1994</b> , 20, 760-7	12
1750	Lipid metabolism and insulin resistance in cirrhosis. <b>1994</b> , 20, 782-91	7
1749	Incidence of gallstones in a population of patients with cirrhosis. <b>1994</b> , 20, 797-801	48
1748	Indirect evidence to suggest that prolactin induces salt retention in cirrhosis. <b>1994</b> , 21, 347-52	3
1747	Effects of octreotide on postprandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis. <b>1994</b> , 21, 424-9	20
1746	Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. C.A.L.C. Group. Coagulation Abnormalities in Cirrhosis Study Group. <b>1994</b> , 20, 531-6	68
1745	Hand skin temperature changes in patients with chronic liver disease. <b>1994</b> , 21, 927-33	5
1744	Blunted postprandial reaction of portal venous flow in chronic liver disease, assessed with duplex Doppler: significance for prognosis. <b>1994</b> , 21, 966-73	15
1743	Endoscopic injection sclerotherapy vs. endoscopic variceal ligation in arresting acute variceal bleeding for patients with advanced hepatocellular carcinoma. <b>1994</b> , 21, 1048-52	22
1742	Prevalence of lupus anticoagulant in patients with cirrhosis: relationship with beta-2-glycoprotein I plasma levels. <b>1994</b> , 21, 1086-91	27
1741	Renal sodium handling in cirrhosis with ascites: mechanisms of impaired natriuretic response to reclining. <b>1994</b> , 21, 1116-22	7
1740	Portal pressure after prophylactic sclerotherapy in patients with high-risk varices. <b>1994</b> , 21, 515-20	16
1739	Ventilation-perfusion relationships and central haemodynamics in patients with cirrhosis. Effects of a somatostatin analogue. <b>1994</b> , 21, 52-7	31
1738	Prevention of rebleeding from oesophageal varices: two-year follow up of a prospective controlled trial of propranolol in addition to sclerotherapy. <b>1994</b> , 21, 81-7	23
1737	A comparison of skinfold anthropometry and bioelectrical impedance analysis for measuring percentage body fat in patients with cirrhosis. <b>1994</b> , 21, 878-83	27



1736	Relationships between the severity of cirrhosis and haemodynamic values in patients with cirrhosis. <b>1994, 9, 148-53</b>	27
1735	Long-term prognosis and prognostic factors of liver cirrhosis in the 1980s. <b>1994, 9, 154-61</b>	17
1734	Effects of an infusion of branched-chain amino acids on neurophysiological and psychometric testings in cirrhotic patients with mild hepatic encephalopathy. <b>1994, 9, 366-72</b>	17
1733	Analyses of proliferating cell nuclear antigen-positive cells in hepatocellular carcinoma: comparisons with clinical findings. <b>1994, 9, 425-32</b>	5
1732	Prolonged bleeding time in cirrhotic patients: relationship to peripheral vasodilation and severity of cirrhosis. <b>1994, 9, 437-41</b>	3
1731	Total paracentesis in non-alcoholic cirrhotics with massive ascites: mid-term effects on systemic and hepatic haemodynamics and renal function. <b>1994, 9, 592-6</b>	8
1730	Pathomorphological study of HCV antibody-positive liver cirrhosis. <b>1994, 9, 624-30</b>	21
1729	Oesophageal perforation following endoscopic variceal ligation and balloon tamponade. <b>1994, 9, 659-62</b>	8
1728	Decreased variation of electrocardiographic R-R interval in patients with liver cirrhosis. <b>1994, 9, 232-5</b>	7
1727	Cruveilhier-Baumgarten syndrome: an efficient spontaneous portosystemic collateral preventing oesophageal varices bleeding. <b>1994, 9, 236-41</b>	8
1726	Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. <b>1994, 37, 7-12</b>	18
1725	The effect of liver disease and food on plasma MEGX concentrations. <b>1994, 37, 298-301</b>	9
1724	Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. <b>1994, 37, 375-81</b>	10
1723	Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. <b>1994, 37, 421-6</b>	19
1722	Arterial oxygen desaturation during non-sedated diagnostic upper gastrointestinal endoscopy in patients with cirrhosis. <b>1994, 40, 281-4</b>	10
1721	McCormack's endoscopic signs for diagnosing portal hypertension: comparison with gastroesophageal varices. <b>1994, 40, 470-3</b>	10
1720	Design of the abdominal aortic Aneurysm Detection and Management Study. ADAM VA Cooperative Study Group. <b>1994, 20, 296-303</b>	83
1719	Insulin action on glucose transport in isolated skeletal muscle from patients with liver cirrhosis. <b>1994, 29, 71-6</b>	4

1718	One-month regular oral nutrition in alcoholic cirrhotic patients. Changes of nutritional status, hepatic function and serum lipid pattern. <b>1994</b> , 72, 937-46	24
1717	Body composition in nonalcoholic cirrhosis: the effect of disease etiology and severity on nutritional compartments. <b>1994</b> , 106, 1611-7	79
1716	Plasma arginine vasopressin response to oral, gastric, and intravenous water load in patients with cirrhosis. <b>1994</b> , 106, 678-85	4
1715	nm23-H1 expression and disease recurrence after surgical resection of small hepatocellular carcinoma. <b>1994</b> , 107, 486-91	26
1714	Evaluation of nutritional status by using anthropometry in adults with alcoholic and nonalcoholic liver disease. <b>1994</b> , 60, 269-73	44
1713	A study of endotoxaemia in patients with primary biliary cirrhosis. <b>1994</b> , 22, 95-9	18
1712	Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation. <b>1994</b> , 220, 109-20	249
1711	Early death or retransplantation in adults after orthotopic liver transplantation. Can outcome be predicted?. <b>1994</b> , 57, 1028-36	74
1710	Long-term oral refeeding of patients with cirrhosis of the liver. <b>1995</b> , 74, 557-67	68
1709	Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease. <b>1995</b> , 43, 265-75	60
1708	Hypothalamic-pituitary-testicular function in end-stage non-alcoholic liver disease before and after liver transplantation. <b>1995</b> , 43, 331-7	64
1707	Liposoluble vitamins and naturally occurring carotenoids in porphyria cutanea tarda. <b>1995</b> , 25, 510-4	16
1706	Anesthesia for the patient with liver disease. <b>1995</b> , 14, 193-203	1
1705	Lack of plasma complement activation in severe acute alcoholic hepatitis. <b>1995</b> , 19, 1537-40	8
1704	Utility of carbohydrate-deficient transferrin as a marker of relapse in alcoholic patients. <b>1995</b> , 19, 611-6	43
1703	A non-invasive method for evaluating cirrhotic portal hypertension by administration of <sup>99m</sup> Tc-MIBI per rectum. <b>1995</b> , 10, 169-73	3
1702	Carbohydrate-deficient transferrin in alcoholics with liver disease. <b>1995</b> , 10, 174-8	12
1701	Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. <b>1995</b> , 10, 198-204	40

1700	Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. <b>1995</b> , 10, 256-60	14
1699	Haemodynamic effects of a combination of propranolol and clonidine in patients with post-hepatitic cirrhosis. <b>1995</b> , 10, 281-6	4
1698	Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. <b>1995</b> , 76, 2202-10	60
1697	Relationship between portal blood flow measured by image-directed Doppler ultrasonography and hepatic blood flow measured by indocyanine green constant infusion in patients with cirrhosis. <b>1995</b> , 23, 297-303	16
1696	The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. <b>1995</b> , 1, 249-55	81
1695	Pharmacokinetics of promazine in patients with hepatic cirrhosis--correlation with a novel galactose single point method. <b>1995</b> , 84, 111-4	8
1694	Glycine conjugation of para-aminobenzoic acid (PABA): a quantitative test of liver function. <b>1995</b> , 28, 531-40	27
1693	Serum hepatocyte growth factor levels in liver diseases: Clinical implications. <b>1995</b> , 21, 106-112	187
1692	Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. <b>1995</b> , 21, 120-128	159
1691	Spontaneous bacterial peritonitis in cirrhotic patients treated using paracentesis or diuretics: results of a randomized study. <b>1995</b> , 21, 340-4	11
1690	Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: Biochemical basis of spectral appearances. <b>1995</b> , 21, 417-427	81
1689	Interobserver and interequipment variability of echo-Doppler examination of the portal vein: effect of a cooperative training program. <b>1995</b> , 21, 428-33	132
1688	31P magnetic resonance spectroscopy of the liver: Correlation with standardized serum, clinical, and histological changes in diffuse liver disease. <b>1995</b> , 21, 443-449	31
1687	Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease. <b>1995</b> , 21, 680-688	98
1686	Insulin secretion and plasma levels of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 [7-36 amide] after oral glucose in cirrhosis. <b>1995</b> , 21, 933-941	17
1685	Neopterin and soluble tumor necrosis factor receptor type I in alcohol-induced cirrhosis. <b>1995</b> , 21, 976-8	38
1684	Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: A prospective randomized trial. <b>1995</b> , 21, 1517-1522	138
1683	Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. <b>1995</b> , 22, 96-100	20

1682	Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: comparison with therapeutic paracentesis. <b>1995</b> , 22, 124-31	39
1681	High plasma levels of atrial natriuretic peptide in preascitic cirrhosis: Indirect evidence of reduced natriuretic effectiveness of the peptide. <b>1995</b> , 22, 132-137	12
1680	A prospective, randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices. <b>1995</b> , 22, 466-471	193
1679	Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. <b>1995</b> , 22, 1132-1135	28
1678	An investigation of whether polymorphisms of cytochrome P4502E1 are genetic markers of susceptibility to alcoholic end-stage organ damage in a chinese population. <b>1995</b> , 22, 1409-1414	35
1677	Randomized control trial of lipo-prostaglandin E1 in patients with acute liver injury induced by lipiodol-targeted chemotherapy. <b>1995</b> , 57, 582-9	3
1676	Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. <b>1995</b> , 58, 390-8	20
1675	Peripheral blood CD3 and CD4 T-lymphocyte reduction correlates with severity of liver cirrhosis. <b>1995</b> , 25, 153-6	40
1674	Clinical significance of the trimethadione tolerance test in chronic hepatitis: a useful indicator of hepatic drug metabolizing capacity. <b>1995</b> , 30, 478-84	14
1673	Patent ductus venosus associated with a hyperintense globus pallidum on T1-weighted magnetic resonance imaging and pulmonary hypertension. <b>1995</b> , 154, 526-9	20
1672	Evaluation of portal circulation through the superior mesenteric vein with an enteric capsule of [123I]iodoamphetamine. <b>1995</b> , 30, 55-60	1
1671	Increased serum IgE in alcohol abusers. <b>1995</b> , 25, 756-64	41
1670	Transjugular intrahepatic porto-systemic shunt (TIPS): Indications and follow up. <b>1995</b> , 2, 29-36	1
1669	MR imaging of the basal ganglia in chronic liver disease: correlation of T1-weighted and magnetisation transfer contrast measurements with liver dysfunction and neuropsychiatric status. <b>1995</b> , 10, 175-88	74
1668	Prognosis and life expectancy in chronic liver disease. <b>1995</b> , 40, 1805-15	94
1667	Regional distribution of transforming growth factor-alpha and epidermal growth factor in normal and portal hypertensive gastric mucosa in humans. <b>1995</b> , 40, 263-7	11
1666	Gallbladder emptying, plasma levels of estradiol and progesterone, and cholecystokinin secretion in liver cirrhosis. <b>1995</b> , 40, 428-34	23
1665	Pallidal lesions in patients with liver cirrhosis: clinical and MRI evaluation. <b>1995</b> , 10, 219-31	94

1664	Clinical evaluation of liver disease. <b>1995</b> , 9, 639-59	10
1663	Liver function tests. <b>1995</b> , 9, 661-77	7
1662	Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. <b>1995</b> , 40, 1252-6	121
1661	Interferon alfa for chronic active hepatitis B. <b>1995</b> , 162, 8-11	20
1660	Complications of Chronic Liver Disease. <b>1995</b> , 11, 431-463	9
1659	New approaches to endoscopic therapy for hemostasis of upper GI bleed. <b>1995</b> , 212, 90-5	
1658	Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). <b>1995</b> , 39, 2732-7	32
1657	Sclerotherapy with or without octreotide for acute variceal bleeding. <b>1995</b> , 333, 555-60	228
1656	The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. <b>1995</b> , 332, 1192-7	358
1655	Assessment of Relative Contributions of Fibrinolysis and Fibrinogenolysis to the Abnormalities of Plasma Fibrinogen/Fibrin-Related D and E Antigens and Their Ratio in Liver Cirrhosis. <b>1995</b> , 1, 183-187	
1654	Cirrhosis of the human liver: an in vitro <sup>31</sup> P nuclear magnetic resonance study. <b>1995</b> , 1272, 113-8	29
1653	Increased prostacyclin content in gastric mucosa of cirrhotic patients with portal hypertensive gastropathy. <b>1995</b> , 53, 41-5	22
1652	Brain magnetic resonance imaging in non-alcoholic cirrhosis. <b>1995</b> , 21, 84-8	7
1651	Lipoprotein (a) and fibrinolytic system in liver cirrhosis. Coagulation Abnormalities in Liver Cirrhosis (CALC) Study Group. <b>1995</b> , 49, 364-8	4
1650	Short-term changes in energy metabolism after 1 month of a regular oral diet in severely malnourished cirrhotic patients. <b>1995</b> , 44, 765-70	23
1649	Effects of beta-blockade on hepatic conversion of amino acid nitrogen and on urea synthesis in cirrhosis. <b>1995</b> , 44, 899-905	
1648	Cleavage of high molecular weight kininogen in ascites and plasma of patients with cirrhosis. <b>1995</b> , 78, 277-82	7
1647	Measuring plasma fibrinogen levels in patients with liver cirrhosis. The occurrence of proteolytic fibrin(ogen) degradation products and their influence on several fibrinogen assays. <b>1995</b> , 78, 353-62	22

1646	Hemostasis activation in patients with liver cirrhosis. <b>1995</b> , 77, 271-8	35
1645	Clinical evaluation of a monoclonal antibody to serum KM01 for the diagnosis of hepatocellular carcinoma. <b>1995</b> , 236, 71-9	2
1644	Abnormalities of the Bereitschaftspotential and MRI pallidal signal in non-encephalopathic cirrhotic patients. <b>1995</b> , 94, 425-31	6
1643	Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. <b>1995</b> , 49, 873-81	86
1642	Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. <b>1995</b> , 169, 28-34; discussion 34-5	278
1641	A critical appraisal of the small-diameter portacaval H-graft. <b>1995</b> , 170, 10-4	8
1640	Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. <b>1995</b> , 108, 138-44	199
1639	Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. <b>1995</b> , 108, 1828-34	233
1638	Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. <b>1995</b> , 108, 1143-51	274
1637	Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: relationships with portal hemodynamics. <b>1995</b> , 108, 1152-8	119
1636	Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. <b>1995</b> , 109, 531-9	104
1635	Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. <b>1995</b> , 109, 917-22	160
1634	In vivo hepatic 31P magnetic resonance spectroscopy in chronic alcohol abusers. <b>1995</b> , 108, 776-88	31
1633	The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis. <b>1995</b> , 39, 445-8	10
1632	Plasma endothelin levels in patients with cirrhosis and their relationships to the severity of cirrhosis and renal function. <b>1995</b> , 23, 681-8	50
1631	Weakness of mucosal barrier in portal hypertensive gastropathy of alcoholic cirrhosis. Effects of propranolol and enprostil. <b>1995</b> , 23, 689-96	24
1630	Elevated levels of serum carbohydrate deficient transferrin are not specific for alcohol abuse in patients with liver disease. <b>1995</b> , 23, 706-11	24
1629	Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. <b>1995</b> , 22, 410-5	80

1628	Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. <b>1995</b> , 22, 616-22	27
1627	Hemodynamic and renal effects of ascites apheresis, concentration and reinfusion in advanced cirrhosis. <b>1995</b> , 22, 10-6	21
1626	Hyperdynamic circulation of advanced cirrhosis: a re-appraisal based on posture-induced changes in hemodynamics. <b>1995</b> , 22, 309-18	77
1625	Characterization of mechanisms causing hypoalbuminemia in rats with long-term bile duct ligation. <b>1995</b> , 23, 79-86	19
1624	Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis. <b>1995</b> , 23, 129-34	57
1623	Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. <b>1995</b> , 22, 165-72	284
1622	Aminopyrine breath test improves long-term prognostic evaluation in patients with alcoholic cirrhosis in Child classes A and B. <b>1995</b> , 22, 179-83	18
1621	Sulphoxidation and sulphation capacity in patients with primary biliary cirrhosis. <b>1995</b> , 22, 551-60	37
1620	The effects of chronic administration of indomethacin and misoprostol on renal function in cirrhotic patients with and without ascites. <b>1995</b> , 30, 1194-9	15
1619	Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. <b>1995</b> , 29, 370-91	158
1618	Endoscopic variceal ligation versus conservative treatment for patients with hepatocellular carcinoma and bleeding esophageal varices. <b>1995</b> , 42, 535-9	11
1617	Changes in portal hypertensive gastropathy after endoscopic variceal sclerotherapy or ligation: an endoscopic observation. <b>1995</b> , 42, 139-44	39
1616	Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. <b>1995</b> , 346, 1051-5	778
1615	Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. <b>1995</b> , 346, 865-8	284
1614	Survival after a first episode of spontaneous bacterial peritonitis. Prognosis of potential candidates for orthotopic liver transplantation. <b>1995</b> , 10, 47-50	42
1613	CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. <b>1995</b> , 39, 71-6	54
1612	Comparison of Surgical Treatment of Ulcerative Colitis Associated With Primary Sclerosing Cholangitis: Ileal Pouch-Anal Anastomosis Versus Brooke Ileostomy. <b>1996</b> , 71, 748-756	41
1611	Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. <b>1996</b> , 71, 543-51	200

1610	Management of portal hypertension and its complications. <b>1996</b> , 80, 1021-34	9
1609	Is the role of transjugular intrahepatic portosystemic shunts limited in the management of patients with end-stage liver disease?. <b>1996</b> , 172, 536-9; discussion 539-40	15
1608	Medium aperture meso-caval shunts reliably prevent recurrent variceal hemorrhages. <b>1996</b> , 171, 490-4	4
1607	Effect of verapamil on portal and splanchnic hemodynamics in patients with advanced posthepatic cirrhosis using duplex Doppler ultrasound. <b>1996</b> , 23, 97-101	7
1606	Nutritional assessment in chronic liver disease patients: A comparison between skeletal muscle function and standard nutritional parameters. <b>1996</b> , 16, 545-553	1
1605	Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomised, placebo-controlled multicentre trial. <b>1996</b> , 98, 29-34	19
1604	Carnitine metabolism in chronic liver disease. <b>1996</b> , 59, 1579-99	24
1603	Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP). <b>1996</b> , 348, 1677-81	110
1602	Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. <b>1996</b> , 24, 293-300	88
1601	Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems. <b>1996</b> , 24, 161-8	54
1600	In vivo hepatic magnetic resonance spectroscopy: clinical or research tool?. <b>1996</b> , 25, 414-24	11
1599	Non-steroidal anti-inflammatory drugs and variceal bleeding: a case-control study. <b>1996</b> , 24, 570-3	17
1598	Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. <b>1996</b> , 24, 574-80	32
1597	Serum levels of interleukin-8 in alcoholic liver disease: relationship with disease stage, biochemical parameters and survival. <b>1996</b> , 24, 377-84	102
1596	Effect of octreotide on total effective vascular compliance in patients with posthepatic cirrhosis. <b>1996</b> , 24, 81-7	14
1595	Transamination of methionine after loading in patients with cirrhosis. <b>1996</b> , 24, 95-100	8
1594	Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. AISF Group for the Study of Liver Transplantation. Associazione Italiana per lo Studio del Fegato. <b>1996</b> , 25, 474-80	43
1593	Effect of vasopressin on esophageal varices blood flow in patients with cirrhosis: comparisons with the effects on portal vein and superior mesenteric artery blood flow. <b>1996</b> , 25, 491-7	22



1592	Transdermal nitroglycerin in cirrhosis. A 24-hour echo-Doppler study of splanchnic hemodynamics. <b>1996</b> , 25, 498-503	9
1591	Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. <b>1996</b> , 25, 684-8	76
1590	Pyridinoline collagen cross-links in patients with chronic viral hepatitis and cirrhosis. <b>1996</b> , 24, 692-8	17
1589	Systemic haemodynamic changes in patients with cystic fibrosis with and without chronic liver disease. <b>1996</b> , 25, 900-8	3
1588	Glucose intolerance in thalassemia major is related to insulin resistance and hepatic dysfunction. <b>1996</b> , 45, 652-7	28
1587	Primary liver transplantation without transfusion of red blood cells. <b>1996</b> , 120, 698-704; discussion 704-5	42
1586	Comparison of a modified Sugiura procedure with portal systemic shunt for prevention of recurrent variceal bleeding in cirrhosis. <b>1996</b> , 119, 214-21	15
1585	Combined endoscopic clipping and injection sclerotherapy for esophageal varices. <b>1996</b> , 43, 140-3	12
1584	Hypoxemia during diagnostic laparoscopy: a prospective study. <b>1996</b> , 44, 124-8	15
1583	Effect of alcohol abuse and glutathione administration on the circulating levels of glutathione and on antipyrine metabolism in patients with alcoholic liver cirrhosis. <b>1996</b> , 56, 441-7	22
1582	The assessment of body composition in patients with cirrhosis. <b>1996</b> , 23, 213-25	25
1581	Pharmacokinetics of Meloxicam in Patients with Hepatic Cirrhosis in Comparison with Healthy Volunteers. <b>1996</b> , 11, 97-107	4
1580	A Reassessment of the Optimal Sampling Time for the MEGX Liver Function Test. <b>1996</b> , 12, 181-187	3
1579	Pharmacokinetics of ondansetron in patients with hepatic insufficiency. <b>1996</b> , 36, 206-15	30
1578	Complications of endoscopic biliary sphincterotomy. <b>1996</b> , 335, 909-18	1998
1577	Pharmacokinetics of trapidil in patients with chronic liver disease. <b>1996</b> , 36, 897-902	3
1576	Chapter 3b Cancer cells and metastasis. <b>1996</b> , 197-210	
1575	Malnutrition in alcoholic and virus-related cirrhosis. <b>1996</b> , 63, 602-9	202

1574	Helicobacter pylori infection in congestive gastropathy. <b>1996</b> , 1, 168-71	12
1573	Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. <b>1996</b> , 41, 2332-9	61
1572	MR imaging and spectroscopy of the basal ganglia in chronic liver disease: correlation of T1-weighted contrast measurements with abnormalities in proton and phosphorus-31 MR spectra. <b>1996</b> , 11, 249-68	40
1571	Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. <b>1996</b> , 41, 552-6	120
1570	Effect of liver cirrhosis and age on the glutathione concentration in the plasma, erythrocytes, and gastric mucosa of man. <b>1996</b> , 20, 483-8	46
1569	Metabolic, endocrine, haemodynamic and pulmonary responses to different types of exercise in individuals with normal or reduced liver function. <b>1996</b> , 74, 246-57	11
1568	Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective beta-blocker. <b>1996</b> , 41, 1722-6	17
1567	Gastric mucus generation in cirrhotic patients with portal hypertension. Effects of tetraprenylacetone. <b>1996</b> , 41, 1727-32	17
1566	Outcome prediction for patients with cirrhosis of the liver in a medical ICU: a comparison of the APACHE scores and liver-specific scoringsystems. <b>1996</b> , 22, 559-63	75
1565	Portal hypertension and bleeding esophagogastric varices. <b>1996</b> , 10, 415-26	2
1564	Influence of clinicopathological variables on CYP protein expression in human liver. <b>1996</b> , 11, 33-9	25
1563	Echo-Doppler measurements of portal vein and superior mesenteric artery blood flow in humans: inter- and intra-observer short-term reproducibility. <b>1996</b> , 11, 40-6	42
1562	Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension. <b>1996</b> , 11, 59-64	48
1561	Sequential changes in serum levels of individual bile acids in patients with chronic cholestatic liver disease. <b>1996</b> , 11, 208-15	19
1560	Vasopressin plus oxygen vs vasopressin alone in cirrhotic patients with portal-hypertensive gastropathy: effects on gastric mucosal haemodynamics and oxygenation. <b>1996</b> , 11, 216-22	13
1559	Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis?. <b>1996</b> , 11, 417-21	107
1558	Hyperglucagonaemia in cirrhotic patients and its relationship to the severity of cirrhosis and haemodynamic values. <b>1996</b> , 11, 422-8	10
1557	Complications of percutaneous transhepatic catheterization of the portal venous system in patients with portal hypertension. <b>1996</b> , 11, 630-4	18

1556	Plasma interleukin-8 levels in patients with post-hepatic cirrhosis: relationship to severity of liver disease, portal hypertension and hyperdynamic circulation. <b>1996</b> , 11, 635-40	8
1555	Circadian occurrence of variceal bleeding in patients with liver cirrhosis. <b>1996</b> , 11, 1115-20	13
1554	Interferon-alpha 2b improves short-term survival in patients transplanted for chronic liver failure caused by hepatitis B. <b>1996</b> , 3, 333-40	9
1553	The relationship between cytokine concentrations and hemostatic abnormalities in patients with liver cirrhosis of postviral or cryptogenic origin. <b>1996</b> , 10, 249-254	2
1552	Serum and ascitic levels of soluble intercellular adhesion molecule-1 in patients with alcoholic liver cirrhosis: relation to biochemical markers of disease activity and alcohol intake. <b>1996</b> , 20, 929-33	3
1551	Protein-energy status and <sup>15</sup> N-glycine kinetic study of child a cirrhotic patients fed low- to high-protein energy diets. <b>1996</b> , 12, 519-23	9
1550	Energy metabolism in portal hypertension in children. <b>1996</b> , 12, 469-74	15
1549	Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: Studies under flow conditions. <b>1996</b> , 24, 1137-1142	40
1548	The lidocaine monoethylglycinexylidide test of liver function. <b>1996</b> , 2, 242-5	4
1547	Glucose and potassium metabolic responses to insulin during liver transplantation. <b>1996</b> , 2, 443-54	19
1546	Clinical and pathologic features of hepatocellular carcinoma in young and older Italian patients. <b>1996</b> , 77, 2223-32	44
1545	Efficacy of a surveillance program for early detection of hepatocellular carcinoma. <b>1996</b> , 78, 977-85	144
1544	Advances in hepatic resection and results for hepatocellular carcinoma. <b>1996</b> , 12, 183-8	8
1543	T-cell activation, expression of adhesion molecules and response to ethanol in alcoholic cirrhosis. <b>1996</b> , 50, 179-83	30
1542	Ultrasound-guided percutaneous ethanol injection: first choice for treatment of hepatocellular carcinoma in the elderly. <b>1996</b> , 22 Suppl 1, 295-303	1
1541	The effect of liver disease on urine caffeine metabolite ratios. <b>1996</b> , 59, 624-35	23
1540	Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. <b>1996</b> , 39, 319-24	59
1539	Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models. <b>1996</b> , 39, 141-6	34

1538	Portal hypertensive colopathy in patients with cirrhosis. <b>1996</b> , 31, 490-4	46
1537	New approaches to endoscopic therapy for a haemostasis upper GI bleed. <b>1996</b> , 218, 116-23	6
1536	Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis. <b>1996</b> , 34, 555-60	10
1535	Hyperfibrinolysis in hepatosplenic schistosomiasis. <b>1996</b> , 49, 990-3	11
1534	Portal duplex sonography in liver cirrhosis. A useful supplement to endoscopic evaluation of bleeding risk of esophageal varices?. <b>1996</b> , 31, 495-9	6
1533	Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. <b>1996</b> , 31, 500-5	82
1532	Gallstones in cirrhotics revisited by a laparoscopic view. <b>1997</b> , 7, 213-20	36
1531	Percutaneous management of hepatocellular carcinoma: Patient selection for percutaneous alcohol injection alone or combined with arterial chemoembolization. <b>1997</b> , 6, 65-70	1
1530	Oxygen Metabolism During Liver Transplantation. <b>1997</b> , 85, 746-752	6
1529	Relationship between portal pressure, esophageal varices, and variceal bleeding on the basis of the stage and cause of cirrhosis. <b>1997</b> , 32, 731-5	24
1528	Increased serum concentration of IgA2 subclass and IgA2/IgA1 ratio: specific markers of chronic alcoholic abuse?. <b>1997</b> , 35, 275-9	3
1527	The liver: new functional, prognostic and diagnostic tests. <b>1997</b> , 34 ( Pt 2), 121-41	7
1526	Percutaneous ethanol injection in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rates. <b>1997</b> , 32, 1168-73	165
1525	Effect of long-term refeeding on protein metabolism in patients with cirrhosis of the liver. <b>1997</b> , 77, 197-212	51
1524	Oxygen metabolism during liver transplantation: the effect of dichloroacetate. <b>1997</b> , 85, 746-52	5
1523	Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. <b>1997</b> , 76, 968-74	107
1522	Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. <b>1997</b> , 76, 244-50	42
1521	Endogenous nitric oxide in exhaled air from patients with liver cirrhosis. <b>1997</b> , 32, 591-7	20

1520	The clinical pharmacokinetics of zolmitriptan. <b>1997</b> , 17 Suppl 18, 15-20	49
1519	Reporting standards for transjugular intrahepatic portosystemic shunts. Technology Assessment Committee of the SCVIR. <b>1997</b> , 8, 289-97	38
1518	Glutathione kinetics in normal man and in patients with liver cirrhosis. <b>1997</b> , 26, 606-13	39
1517	IV Cefuroxime Plus Oral Clarithromycin or IV Erythromycin for the Treatment of Community-Acquired Pneumonia in Hospitalised Patients. <b>1997</b> , 14, 23-34	2
1516	L-[1-(13)C] Phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease. <b>1997</b> , 173, 270-3; discussion 273-4	44
1515	Preoperative predictors of blood transfusion in liver resection for tumor. <b>1997</b> , 173, 275-9	44
1514	Arterial oxygen desaturation during emergent nonsedated upper gastrointestinal endoscopy in the emergency department. <b>1997</b> , 15, 644-7	27
1513	Cortico-spinal pathways and inhibitory mechanisms in hepatic encephalopathy. <b>1997</b> , 105, 72-8	25
1512	Liver transplantation in Ohio. <b>1997</b> , 122, 842-8; discussion 848-9	9
1511	Value of the measurement of portal flow velocity in the differential diagnosis of asymptomatic splenomegaly. <b>1997</b> , 52, 220-3	4
1510	Effect of ondansetron hydrochloride on nausea and vomiting after transcatheter arterial embolization in patients with hepatocellular carcinoma. <b>1997</b> , 58, 10-15	
1509	Impaired nonoxidative glucose metabolism in patients with liver cirrhosis: effects of two insulin doses. <b>1997</b> , 46, 840-3	13
1508	Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. <b>1997</b> , 349, 1043-9	216
1507	Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: comparison between acute and chronic effects. <b>1997</b> , 26, 305-11	25
1506	Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. <b>1997</b> , 26, 312-24	74
1505	The pharmacokinetics of octreotide in cirrhosis and in healthy man. <b>1997</b> , 26, 1018-25	24
1504	Significance of tumor vascularity as a predictor of long-term prognosis in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection therapy. <b>1997</b> , 26, 1055-62	31
1503	Urinary assays for desmosine and hydroxylsypyrindoline in the detection of cirrhosis. <b>1997</b> , 27, 993-1002	18

1502	CYP2E1 activity in patients with alcoholic liver disease. <b>1997</b> , 27, 1009-14	39
1501	Daily profile of plasma endothelin-1 and -3 in pre-ascitic cirrhosis: relationships with the arterial pressure and renal function. <b>1997</b> , 26, 808-15	21
1500	Cerebral autoregulation in patients with cirrhosis and ascites. A transcranial Doppler study. <b>1997</b> , 27, 114-20	33
1499	Growth hormone-stimulated insulin-like growth factor (IGF) I and IGF-binding protein-3 in liver cirrhosis. <b>1997</b> , 27, 796-802	52
1498	Splanchnic and extrasplanchnic arterial hemodynamics in patients with cirrhosis. <b>1997</b> , 27, 817-23	47
1497	Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. <b>1997</b> , 27, 862-70	75
1496	Increased peripheral mononuclear cells expression of adhesion molecules in alcoholic cirrhosis: its relation to immune activation. <b>1997</b> , 27, 477-83	23
1495	Effect of posture-induced blood volume expansion on systemic and regional hemodynamics in patients with cirrhosis. <b>1997</b> , 27, 484-91	25
1494	Hypoxemia in patients with cirrhosis: relationship with liver failure and hemodynamic alterations. <b>1997</b> , 27, 492-5	65
1493	Effect of liver cirrhosis on the systemic availability of naltrexone in humans. <b>1997</b> , 27, 505-11	29
1492	Prognostic evaluation of patients with parenchymal cirrhosis. Proposal of a new simple score. <b>1997</b> , 26, 642-9	39
1491	Portal-hypertensive gastropathy develops less in patients with cirrhosis and fundal varices. <b>1997</b> , 26, 1235-41	40
1490	Autonomic dysfunction in patients with non-alcoholic chronic liver disease. <b>1997</b> , 26, 1242-8	58
1489	Seroprevalence and epidemiology of Helicobacter pylori infection in patients with cirrhosis. <b>1997</b> , 26, 1249-54	37
1488	Diversity of antinuclear antibody responses in hepatocellular carcinoma. <b>1997</b> , 26, 1255-65	36
1487	Prognostic models in chronic liver disease: validity, usefulness and future role. <b>1997</b> , 26, 1414-24	34
1486	Drug elimination in chronic liver diseases. <b>1997</b> , 26 Suppl 2, 63-72	18
1485	Gastrointestinal bleeding in cirrhotic patients with hepatocellular carcinoma undergoing intrahepatic artery chemotherapy. <b>1997</b> , 46, 430-4	7

1484	Efficacy of prophylactic sclerotherapy in patients with hepatocellular carcinoma and varices negative for the red color sign. <b>1997</b> , 45, 498-502	10
1483	Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment. <b>1997</b> , 41, 2793-6	15
1482	Fibronectin in the ascitic fluid of cirrhotic patients: correlation with biochemical risk factors for the development of spontaneous bacterial peritonitis. <b>1997</b> , 30, 843-7	4
1481	Assessment of monoethylglycinexylidide as measure of liver function for patients with chronic viral hepatitis. <b>1997</b> , 43, 1952-1957	10
1480	Plasma concentrations of cyclic 3', 5'-guanosine monophosphate in patients with cirrhosis: relationship with atrial natriuretic peptide and haemodynamics. <b>1997</b> , 12, 233-6	13
1479	Gall-bladder wall thickening in patients with liver cirrhosis. <b>1997</b> , 12, 445-9	22
1478	Prolonged bleeding time: a new clinical manifestation of hepatocellular carcinoma?. <b>1997</b> , 12, 563-8	2
1477	Abnormality in fatty acid composition of gastric mucosal phospholipids in patients with liver cirrhosis and its correction with a polyunsaturated fatty acid-enriched soft oil capsule. <b>1997</b> , 12, 644-52	8
1476	Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. <b>1997</b> , 38, 445-51	50
1475	Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. <b>1997</b> , 75, 1460-6	37
1474	Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. <b>1997</b> , 13, 185-90	50
1473	Influence of liver failure, ascites, and energy expenditure on the response to oral nutrition in alcoholic liver cirrhosis. <b>1997</b> , 13, 613-21	54
1472	Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. <b>1997</b> , 11, 243-56	162
1471	Microbial colonization of closed-system suction catheters used in liver transplant patients. <b>1997</b> , 13, 72-6	23
1470	Plasma iPGE2 and i6-keto PGF1 alpha in the course of liver cirrhosis. <b>1997</b> , 53, 11-20	15
1469	Helicobacter pylori infection among patients with alcoholic and nonalcoholic cirrhosis. <b>1997</b> , 2, 149-51	14
1468	Early feeding or enteral nutrition in patients with cirrhosis after bleeding from esophageal varices? A randomized controlled study. <b>1997</b> , 42, 536-41	81
1467	Plasma concentration of endothelin-1 does not reflect renal vasoconstriction as estimated by duplex ultrasonography in cirrhosis. <b>1997</b> , 42, 542-5	6

1466	Reinfusion of concentrated ascitic fluid versus total paracentesis. A randomized prospective trial. <b>1997</b> , 42, 1708-14	24
1465	Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis. <b>1997</b> , 42, 529-35	13
1464	Lactate blood levels in the perioperative period of orthotopic liver transplantation. <b>1997</b> , 27, 123-8	45
1463	Endoscopic follow-up study of development of gastric antral vascular ectasia associated with liver cirrhosis. <b>1997</b> , 32, 587-92	12
1462	Red cell survival in patients with nonalcoholic liver cirrhosis before and after distal splenoportal shunt. <b>1997</b> , 32, 318-23	
1461	Influence of extravariceal collateral channel pattern on recurrence of esophageal varices after sclerotherapy. <b>1997</b> , 32, 715-9	20
1460	Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose. <b>1997</b> , 32, 777-82	37
1459	Measurement of the expiratory ammonia concentration and its clinical significance. <b>1997</b> , 12, 161-169	22
1458	Transjugular intrahepatic portosystemic shunting (TIPS) with balloon-expandable and self-expanding stents: technical and clinical aspects after 3 1/2 years' experience. <b>1997</b> , 20, 29-37	20
1457	Splenomegaly and hypersplenism in cirrhotic patients before and after orthotopic liver transplantation. <b>1997</b> , 6, 43-47	1
1456	Appréciation de l'état nutritionnel dans la cirrhose : comparaison de l'anthropométrie, de l'impédancemétrie mono-fréquence et bi-fréquence. <b>1997</b> , 11, 81-89	2
1455	Intra- and extrahepatic arterial resistances in chronic hepatitis and liver cirrhosis. <b>1997</b> , 23, 675-82	49
1454	Clinical application of hepatic venous hemodynamics by Doppler ultrasonography in chronic liver disease. <b>1997</b> , 23, 829-35	12
1453	Phase shift of the hepatic vein flow velocity waveform in chronic liver disease: experimental and clinical studies. <b>1997</b> , 23, 821-8	7
1452	The pharmacokinetics of a single dose of artemisinin in subjects with liver cirrhosis. Bach Mai-Amsterdam Research Group on Artemisinin. <b>1997</b> , 2, 957-62	7
1451	Carnitine metabolism in patients with chronic liver disease. <b>1997</b> , 25, 148-153	24
1450	MR imaging of the liver: effect of portal hypertension on hepatic parenchymal enhancement using a gadolinium chelate. <b>1997</b> , 7, 142-6	6
1449	Prognostic significance of surgical margin in hepatocellular carcinoma resection: an analysis of 165 Childs' A patients. <b>1997</b> , 66, 122-6	73



1448	Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. <b>1997</b> , 79, 1501-8	52
1447	Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in France. <b>1997</b> , 74, 614-9	26
1446	Pharmacokinetics of valsartan in patients with liver disease. <b>1997</b> , 62, 272-8	80
1445	Effects of liver disease on the disposition of the opioid antagonist nalmefene. <b>1997</b> , 61, 15-23	17
1444	Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. <b>1998</b> , 64, 8-17	86
1443	Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation. <b>1998</b> , 63, 296-302	20
1442	Portal hemodynamics by duplex Doppler sonography in different grades of cirrhosis. <b>1998</b> , 43, 354-7	37
1441	Prognostic value of generation of growth hormone-stimulated insulin-like growth factor-I (IGF-I) and its binding protein-3 in patients with compensated and decompensated liver cirrhosis. <b>1998</b> , 43, 1317-21	14
1440	Analysis of impaired exercise capacity in patients with cirrhosis. <b>1998</b> , 43, 1701-7	51
1439	Effects of octreotide on lower esophageal sphincter in patients with cirrhosis and portal hypertension. <b>1998</b> , 43, 1566-71	6
1438	Effect of hepatic insufficiency on pharmacokinetics and drug dosing. <b>1998</b> , 20, 183-92	55
1437	Helicobacter pylori infection and peptic ulcer disease in cirrhosis. <b>1998</b> , 43, 1219-25	36
1436	The basal ganglia and portal-systemic encephalopathy. <b>1998</b> , 13, 261-72	37
1435	Cerebral magnetic resonance imaging in patients with chronic liver disease. <b>1998</b> , 13, 273-90	33
1434	The carbohydrate-deficient transferrin test in hospital practice. <b>1998</b> , 17, 105-9	2
1433	Transjugular intrahepatic portosystemic shunt (TIPS) for variceal bleeding in portal hypertension: comparison of emergency and elective interventions. <b>1998</b> , 43, 2463-9	35
1432	Complement system is not activated in primary biliary cirrhosis. <b>1998</b> , 87, 297-303	7
1431	Transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of refractory ascites. <b>1998</b> , 28, 620-6	17

1430	Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients. <b>1998</b> , 13, 460-6	11
1429	Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis. <b>1998</b> , 13, 907-13	40
1428	Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?. <b>1998</b> , 77, 1145-8	8
1427	Portal hypertension. <b>1998</b> , 35, 383-452	20
1426	Effects of systemic prostaglandin E1 on splanchnic and peripheral haemodynamics in control subjects and in patients with cirrhosis. <b>1998</b> , 55, 209-18	4
1425	Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. <b>1998</b> , 27, 28-34	304
1424	Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. <b>1998</b> , 27, 67-72	196
1423	Daily energy and substrate metabolism in patients with cirrhosis. <b>1998</b> , 27, 346-50	79
1422	Somatosensory evoked potentials in subclinical portosystemic encephalopathy: a comparison with psychometric tests. <b>1998</b> , 27, 357-61	42
1421	Cerebral blood flow and metabolism in patients with chronic liver disease undergoing orthotopic liver transplantation. <b>1998</b> , 27, 369-76	44
1420	Splenic impedance indices: a useful method to monitor patients after liver transplantation?. <b>1998</b> , 27, 674-8	16
1419	Plasma selenium in patients with cirrhosis. <b>1998</b> , 27, 794-8	82
1418	Effects of systemic prostaglandin E1 on hepatic amino acid-nitrogen metabolism in patients with cirrhosis. <b>1998</b> , 27, 815-21	8
1417	Decreased muscle strength in patients with alcoholic liver cirrhosis in relation to nutritional status, alcohol abstinence, liver function, and neuropathy. <b>1998</b> , 27, 1200-6	73
1416	Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. <b>1998</b> , 27, 1572-7	302
1415	Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. <b>1998</b> , 27, 1578-83	403
1414	Increased cerebrovascular resistance in cirrhotic patients with ascites. <b>1998</b> , 28, 39-44	110
1413	Subclinical hepatic encephalopathy impairs daily functioning. <b>1998</b> , 28, 45-9	401

1412	The additive effect of sclerotherapy to patients receiving repeated endoscopic variceal ligation: a prospective, randomized trial. <b>1998</b> , 28, 391-5	66
1411	Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. <b>1998</b> , 28, 683-8	49
1410	Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. <b>1998</b> , 28, 695-9	179
1409	A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. <b>1998</b> , 28, 751-5	1116
1408	Doppler study of mesenteric, hepatic, and portal circulation in alcoholic cirrhosis: relationship between quantitative Doppler measurements and the severity of portal hypertension and hepatic failure. <b>1998</b> , 28, 932-6	105
1407	Hepatic artery resistance in alcoholic liver disease. <b>1998</b> , 28, 1182-6	47
1406	Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. <b>1998</b> , 28, 1187-90	205
1405	Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia. <b>1998</b> , 28, 1199-205	25
1404	Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. <b>1998</b> , 28, 1206-14	57
1403	Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. <b>1998</b> , 28, 1215-25	110
1402	Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites. <b>1998</b> , 28, 1235-40	49
1401	Cryosurgery as a treatment for advanced stage hepatocellular carcinoma: results, complications, and alcohol ablation. <b>1998</b> , 82, 1268-78	54
1400	Hepatocellular carcinoma in Asian Americans. <b>1998</b> , 83, 1723-1729	2
1399	The fucosylation index of $\alpha$ -fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. <b>1998</b> , 83, 2076-2082	79
1398	Serum $\alpha$ -fucosidase activity and early detection of hepatocellular carcinoma. <b>1998</b> , 83, 2468-2474	58
1397	Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients. <b>1998</b> , 79, 601-5	90
1396	Hemodynamic changes in hepatic artery after glucose ingestion in healthy subjects and patients with cirrhosis. <b>1998</b> , 26, 137-42	8
1395	Health-related quality of life after liver transplantation. <b>1998</b> , 4, 215-21	58

- 1394 Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. **1998**, 4, 416-23 50
- 1393 Pharmacokinetics of milnacipran in liver impairment. **1998**, 23, 273-9 28
- 1392 Risk factors for loss of lean body mass after liver transplantation. **1998**, 49, 663-4 11
- 1391 Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors. **1998**, 5, 255-64 24
- 1390 The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients. **1998**, 12, 657-65 7
- 1389 A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group. **1998**, 12, 965-71 29
- 1388 Endogenous dopaminergic activity in Child-Pugh A cirrhosis: potential role in renal sodium handling and in the maintenance of clinical compensation. **1998**, 28, 131-7 8
- 1387 Diabetes mellitus after liver transplantation: a possible relation with the nutritional status. **1998**, 41, 203-5
- 1386 [Liver transplantation in the adult: who and when to transplant?]. **1998**, 19, 892-903
- 1385 Hepatocellular carcinoma in children: clinical review and comparison with adult cases. **1998**, 33, 1350-4 83
- 1384 Psychological distress in patients with chronic, nonalcoholic, uncomplicated liver disease. **1998**, 44, 547-54 16
- 1383 Delayed hepatic resection for ruptured hepatocellular carcinoma. **1998**, 124, 33-37 24
- 1382 Staged hepatectomy after emergency transcatheter arterial embolization for ruptured hepatocellular carcinoma. **1998**, 124, 526-535 46
- 1381 Erythrocyte membrane lipids and serum selenium in post-viral and alcoholic cirrhosis. **1998**, 270, 139-50 23
- 1380 Renal dysfunction in liver cirrhosis: renal duplex Doppler US vs. scintigraphy for early identification. **1998**, 53, 44-8 9
- 1379 Vegetative infection of transjugular intrahepatic portosystemic shunts. **1998**, 115, 110-5 81
- 1378 Transjugular intrahepatic portosystemic shunt for bleeding angiodysplasia-like lesions in portal-hypertensive colopathy. **1998**, 115, 167-72 20
- 1377 Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. **1998**, 114, 305-10 191

1376	Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. <b>1998</b> , 29, 250-6	47
1375	Characteristics of hepatocellular carcinoma in Italy. <b>1998</b> , 29, 944-52	134
1374	Spontaneous pulsatility and pharmacokinetics of growth hormone in liver cirrhotic patients. <b>1998</b> , 29, 559-64	17
1373	Regional cerebral blood flow changes in patients with cirrhosis assessed with 99mTc-HM-PAO single-photon emission computed tomography: effect of liver transplantation. <b>1998</b> , 29, 78-84	32
1372	Nutritional and prognostic significance of serum hypothyroxinemia in hospitalized patients with liver cirrhosis. <b>1998</b> , 28, 115-21	27
1371	Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. <b>1998</b> , 29, 736-42	71
1370	Sequential variceal pressure measurement by endoscopic needle puncture during maintenance sclerotherapy: the correlation between variceal pressure and variceal rebleeding. <b>1998</b> , 29, 772-8	16
1369	Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. <b>1998</b> , 28, 615-21	246
1368	The postprandial portal flow is related to the severity of portal hypertension and liver cirrhosis. <b>1998</b> , 28, 631-8	47
1367	Upright posture decreases esophageal varices flow velocity in patients with cirrhosis. <b>1998</b> , 28, 447-53	8
1366	Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol. <b>1998</b> , 28, 847-55	17
1365	Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: predicting outcomes with natural history models. <b>1998</b> , 73, 575-88	42
1364	TREATMENT OF ALCOHOLIC HEPATITIS. <b>1998</b> , 2, 799-819	6
1363	Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients. <b>1998</b> , 33, 441-7	7
1362	Effects of branched-chain-enriched amino acid solution on insulin and glucagon secretion and blood glucose level in liver cirrhosis. <b>1998</b> , 33, 853-9	11
1361	Electrogastrographic study of the effect of transcatheter arterial chemoembolization on gastric myoelectric activity. <b>1998</b> , 33, 1164-9	4
1360	AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. <b>1998</b> , 93, 44-8	353
1359	Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. <b>1998</b> , 33, 1213-8	44

1358	Increased nitric oxide production in the liver in the perioperative period of partial hepatectomy with Pringle's maneuver. <b>1998</b> , 28, 212-20	31
1357	Effects of Aging and Liver Disease upon the Pharmacokinetics of Nipradilol. <b>1998</b> , 16, 251-7	1
1356	Thickened gastric mucosal capillary wall: a histological marker for portal hypertension. <b>1998</b> , 30, 10-3	16
1355	Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy. <b>1998</b> , 42, 861-7	42
1354	Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. <b>1998</b> , 93, 2022-36	181
1353	Effect of hepatic impairment on the pharmacokinetics of zolmitriptan. <b>1998</b> , 38, 694-701	9
1352	Outcome of hepatitis C patients with and without hepatocellular carcinoma undergoing liver transplant. <b>1998</b> , 93, 2148-53	16
1351	Dark adaptation in early primary biliary cirrhosis. <b>1998</b> , 12 ( Pt 3a), 419-26	6
1350	Increased plasma levels of substance P and disturbed water excretion in patients with liver cirrhosis. <b>1998</b> , 33, 860-6	11
1349	Beneficial hemodynamic effects of dipyridamole on portal circulation in cirrhosis. <b>1998</b> , 93, 429-33	2
1348	Epidemiology of peptic ulcer disease in cirrhotic patients: role of Helicobacter pylori infection. <b>1998</b> , 93, 2501-7	33
1347	Urgent transjugular intrahepatic portosystemic shunt for control of acute variceal bleeding. <b>1998</b> , 93, 75-9	50
1346	Small bowel motility in primary biliary cirrhosis. <b>1998</b> , 93, 2436-40	15
1345	The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. <b>1998</b> , 93, 962-6	91
1344	Superior mesenteric artery impedance in chronic liver diseases: relationship with disease severity and portal circulation. <b>1998</b> , 93, 1925-30	30
1343	Effect of meal induced splanchnic arterial vasodilatation on renal arterial haemodynamics in normal subjects and patients with cirrhosis. <b>1998</b> , 43, 843-8	20
1342	Intrasplenic venous flow patterns demonstrated by Doppler ultrasound in patients with portal hypertension. <b>1998</b> , 71, 384-7	5
1341	Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction. <b>1998</b> , 38, 517-24	15

1340	Response to symptom-limited exercise in patients with the hepatopulmonary syndrome. <b>1998</b> , 114, 736-41	25
1339	Urinary Excretion of Free and Acetylated Polyamines in Hepatocellular Carcinoma. <b>1998</b> , 13, 92-97	5
1338	Chylothorax in cirrhosis of the liver: analysis of its frequency and clinical characteristics. <b>1998</b> , 114, 154-9	79
1337	Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients. <b>1998</b> , 42, 1783-7	22
1336	Immunohistochemical detection of 4-hydroxy-2-nonenal-modified-protein adducts in human alcoholic liver diseases. <b>1998</b> , 22, 145S-149S	25
1335	Hepatic pyruvate dehydrogenase activity in humans: effect of cirrhosis, transplantation, and dichloroacetate. <b>1998</b> , 274, G569-77	6
1334	Pituitary glycoprotein hormone $\alpha$ -subunit secretion by cirrhotic patients. <b>1999</b> , 32, 73-7	1
1333	Alcohol-induced generation of lipid peroxidation products in humans. <b>1999</b> , 104, 805-13	187
1332	Pharmacokinetics of dirithromycin in patients with mild or moderate cirrhosis. <b>1999</b> , 43, 1556-9	7
1331	Effect of liver disease and transplantation on urea synthesis in humans: relationship to acid-base status. <b>1999</b> , 276, G1145-52	17
1330	The Timing and Role of Nontransplant Surgery in Management of Variceal Bleeding. <b>1999</b> , 9, 331-345	1
1329	Relation between severity of liver disease and renal oxygen consumption in patients with cirrhosis. <b>1999</b> , 45, 117-21	13
1328	Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. <b>1999</b> , 44, 264-9	70
1327	Anti-inflammatory drugs and variceal bleeding: a case-control study. <b>1999</b> , 44, 270-3	80
1326	Renal distal tubular handling of sodium in central fluid volume homeostasis in preascitic cirrhosis. <b>1999</b> , 45, 750-5	20
1325	Balloon-occluded retrograde transvenous obliteration of high risk gastric fundal varices. <b>1999</b> , 94, 643-9	94
1324	Effects of octreotide on central hemodynamics and systemic oxygen use in patients with viral cirrhosis. <b>1999</b> , 94, 1012-7	3
1323	Prognostic usefulness of ultrasonographic signs of portal hypertension in patients with child-pugh stage A liver cirrhosis. <b>1999</b> , 94, 3595-600	5

1322	Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. <b>1999</b> , 94, 2475-81	2
1321	Immunogenicity of hepatitis A vaccine in decompensated liver disease. <b>1999</b> , 94, 1601-4	70
1320	Autonomic nervous system tone measured by baroreflex sensitivity is depressed in patients with end-stage liver disease. <b>1999</b> , 94, 986-9	26
1319	Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients. <b>1999</b> , 94, 2214-8	15
1318	Role of substance P in the pathogenesis of spider angiomas in patients with nonalcoholic liver cirrhosis. <b>1999</b> , 94, 502-7	15
1317	Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. <b>1999</b> , 94, 1361-5	29
1316	Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. <b>1999</b> , 94, 2193-7	58
1315	Hyperammonia and cerebral herniation: is an abnormality of ammonia metabolism responsible?. <b>1999</b> , 94, 3646-9	2
1314	État nutritionnel des patients avec maladies du foie : épidémiologie et pronostic. <b>1999</b> , 13, 232-240	1
1313	Pain and health related quality of life after heart, kidney, and liver transplantation. <b>1999</b> , 13, 453-60	47
1312	The monoethylglycinexylidide test for grading of liver cirrhosis. <b>1999</b> , 13, 67-75	14
1311	Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis. <b>1999</b> , 13, 1451-8	10
1310	[13C]-Galactose breath test: correlation with liver fibrosis in chronic hepatitis C. <b>1999</b> , 29, 624-9	25
1309	Prediction of oesophagogastric varices in patients with liver cirrhosis. <b>1999</b> , 14, 785-90	57
1308	Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. <b>1999</b> , 14, 811-6	22
1307	Mixed cryoglobulinaemia associated with hepatitis C virus infection: a predictor factor for treatment with interferon?. <b>1999</b> , 14, 1108-11	11
1306	Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study. <b>1999</b> , 29, 300-7	21
1305	Effect of mesocaval interposition shunting and repeated sclerotherapy on blood levels of gastrointestinal regulatory peptides, amino acids, and lysosomal enzymes--a prospective randomised trial. <b>1999</b> , 19, 3-11	2



1304	Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. <b>1999</b> , 19, 381-8	20
1303	Cerebral proton and phosphorus-31 magnetic resonance spectroscopy in patients with subclinical hepatic encephalopathy. <b>1999</b> , 19, 389-98	42
1302	Ethanol Consumption, Amino Acid and Glutathione Blood Levels in Patients With and Without Chronic Liver Disease. <b>1999</b> , 23, 1780-1784	29
1301	Increase of serum des-gamma-carboxy prothrombin in alcoholic liver disease without hepatocellular carcinoma. <b>1999</b> , 23, 675-705	19
1300	Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. <b>1999</b> , 90, 162-70	39
1299	Gastroduodenal Vascular Ectasia in Patients with Liver Cirrhosis. <b>1999</b> , 11, 241-245	7
1298	Assessment of liver function by the MEGX test in patients with schistosomiasis and cirrhosis. <b>1999</b> , 32, 207-12	2
1297	Effect of eating on plasma radical-trapping antioxidant activity (TRAP) in patients with cirrhosis. <b>1999</b> , 32, 447-53	2
1296	Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy. <b>1999</b> , 14, 239-51	22
1295	Locoregional treatments for hepatocellular carcinoma. <b>1999</b> , 13, 611-22	13
1294	Rapid estimation of creatinine clearances in patients with liver dysfunction. <b>1999</b> , 44, 1222-7	4
1293	Progressive liver functional impairment is associated with an increase in AST/ALT ratio. <b>1999</b> , 44, 1249-53	147
1292	Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. <b>1999</b> , 44, 372-6	37
1291	Diagnosis of hepatopulmonary syndrome with contrast transesophageal echocardiography: advantages over contrast transthoracic echocardiography. <b>1999</b> , 44, 1243-8	45
1290	Serum pancreatic enzyme concentrations in chronic viral liver diseases. <b>1999</b> , 44, 350-5	22
1289	Relationship of portal pressure and colorectal vasculopathy in patients with cirrhosis. <b>1999</b> , 44, 149-54	9
1288	Prostaglandin E1 infusion and functional hepatic flow in control subjects and in patients with cirrhosis. <b>1999</b> , 44, 377-84	7
1287	Essential fatty acid deficiencies in patients with chronic liver disease are not reversed by short-term intravenous lipid supplementation. <b>1999</b> , 44, 1342-8	15

1286	TIPS allowing for an endoscopic mucosal resection of early gastric cancer in a cirrhotic patient with severe hypertensive gastropathy: report of a case. <b>1999</b> , 29, 902-5	10
1285	Pulse analysis of patients with severe liver problems. Studying pulse spectrums to determine the effects on other organs. <b>1999</b> , 18, 73-5	48
1284	Low plasma levels of docosahexaenoic acid in patients with liver cirrhosis and its correction with a polyunsaturated fatty acid-enriched soft oil capsule. <b>1999</b> , 15, 284-8	15
1283	Mesohepatectomy for centrally located hepatocellular carcinoma: an appraisal of a rare procedure. <b>1999</b> , 188, 508-15	52
1282	Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. <b>1999</b> , 29, 62-7	864
1281	Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. <b>1999</b> , 29, 334-9	172
1280	Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. <b>1999</b> , 29, 632-9	94
1279	Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography. <b>1999</b> , 29, 1085-90	68
1278	Macronutrient preference, dietary intake, and substrate oxidation among stable cirrhotic patients. <b>1999</b> , 29, 1380-6	35
1277	The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. <b>1999</b> , 29, 1643-8	104
1276	Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. <b>1999</b> , 29, 1655-61	570
1275	Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: a clinical and electrophysiologic study. <b>1999</b> , 29, 1698-703	78
1274	The risk of surgery in patients with liver disease. <b>1999</b> , 29, 1617-23	207
1273	Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. <b>1999</b> , 30, 84-9	191
1272	Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. <b>1999</b> , 30, 265-70	40
1271	Resting energy expenditure should be measured in patients with cirrhosis, not predicted. <b>1999</b> , 30, 655-64	72
1270	Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. <b>1999</b> , 30, 1387-92	65
1269	Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. <b>1999</b> , 30, 1434-40	1594

1268	Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. <b>1999</b> , 85, 2132-2137	177
1267	Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. <b>1999</b> , 86, 793-8	36
1266	Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan. <b>1999</b> , 86, 799-804	39
1265	Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection. <b>1999</b> , 86, 1682-90	58
1264	Hepatic arterial resistance after mixed-meal ingestion in healthy subjects and patients with chronic liver disease. <b>1999</b> , 27, 239-48	11
1263	Evaluating response to nutritional therapy using the branched-chain amino acid/tyrosine ratio in patients with chronic liver disease. <b>1999</b> , 13, 31-4	37
1262	Surgery in the patient with liver disease. <b>1999</b> , 74, 593-9	79
1261	Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. <b>1999</b> , 45, 295-300	412
1260	Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and fasting state. <b>1999</b> , 34, 297-302	25
1259	The rebleeding course and long-term outcome of esophageal variceal hemorrhage after ligation: comparison with sclerotherapy. <b>1999</b> , 34, 1071-6	35
1258	Spider angiomas in patients with liver cirrhosis: role of alcoholism and impaired liver function. <b>1999</b> , 34, 520-3	26
1257	Upper gastrointestinal bleeding: an ammoniagenic and catabolic event due to the total absence of isoleucine in the haemoglobin molecule. <b>1999</b> , 52, 515-9	32
1256	Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. <b>1999</b> , 353, 1579-83	206
1255	Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. <b>1999</b> , 30, 125-30	119
1254	Prophylactic banding ligation of high-risk esophageal varices in patients with cirrhosis: a prospective, randomized trial. <b>1999</b> , 31, 451-6	71
1253	Prevalence and risk factors of bacteriuria in cirrhotic patients: a prospective case-control multicenter study in 244 patients. <b>1999</b> , 31, 464-8	24
1252	Hepatocyte proliferative activity in human liver cirrhosis. <b>1999</b> , 30, 461-71	36
1251	Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. <b>1999</b> , 30, 472-8	200

1250	Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. <b>1999</b> , 30, 479-84	55
1249	Hepatic arterial pulsatility index in cirrhosis: correlation with portal pressure. <b>1999</b> , 30, 876-81	61
1248	Prognostic significance of hepatic encephalopathy in patients with cirrhosis. <b>1999</b> , 30, 890-5	389
1247	Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. <b>1999</b> , 31, 84-90	45
1246	A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. <b>1999</b> , 31, 133-41	371
1245	Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. <b>1999</b> , 30, 632-8	38
1244	Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein. <b>1999</b> , 30, 660-8	53
1243	Effect of transcatheter arterial chemoembolization on kidney hemodynamics and function in patients with cirrhosis and hepatocellular carcinoma. <b>1999</b> , 31, 340-6	3
1242	S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. <b>1999</b> , 30, 1081-9	369
1241	Discrimination of liver cirrhosis from chronic hepatitis by measuring the ratio of Aleuria aurantia lectin-reactive serum cholinesterase to immunoreactive protein. <b>1999</b> , 281, 37-46	17
1240	A psychometric normative database for pre-liver transplantation evaluations. The Florida cohort 1991-1996. <b>1999</b> , 40, 479-85	47
1239	The role of portosystemic shunting in children in the transplant era. <b>1999</b> , 34, 117-22; discussion 122-3	20
1238	Hepatic arterial flow volume and reserve in patients with cirrhosis: use of intra-arterial Doppler and adenosine infusion. <b>1999</b> , 116, 906-14	79
1237	Prevalence of paraesophageal varices and gastric varices in patients achieving variceal obliteration by banding ligation and by injection sclerotherapy. <b>1999</b> , 49, 428-36	83
1236	Left gastric vein hemodynamics and variceal recurrence in patients undergoing prophylactic endoscopic ligation of high-risk esophageal varices. <b>1999</b> , 50, 768-74	17
1235	Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis. <b>1999</b> , 49, 690-4	74
1234	Sclerotherapy plus ligation versus ligation for the treatment of esophageal varices: a prospective randomized study. <b>1999</b> , 50, 7-12	54
1233	Prospective assessment of the risk of bacteremia in cirrhotic patients undergoing lower intestinal endoscopy. <b>1999</b> , 49, 214-7	36

1232	Endosonographic, endoscopic, and histologic evaluation of alterations in the rectal venous system in patients with portal hypertension. <b>1999</b> , 49, 218-27	45
1231	Development and application of endoloops for the treatment of bleeding esophageal varices. <b>1999</b> , 50, 677-84	14
1230	Effects of liver disease on pharmacokinetics. An update. <b>1999</b> , 37, 399-431	168
1229	Does quantitative serologic testing for Helicobacter pylori predict peptic ulcer disease in cirrhosis?. <b>1999</b> , 50, 381-6	5
1228	The critically ill patient after hepatobiliary surgery. <b>1999</b> , 3, 139-144	6
1227	Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites <sup>22</sup> Part of this work was performed while holding a Fellowship in Hepatology from Schering Canada.. <b>1999</b> , 106, 315-322	50
1226	Glucocorticosteroids for alcoholic hepatitis. <b>1999</b> ,	5
1225	Hypermetabolism in clinically stable patients with liver cirrhosis. <b>1999</b> , 69, 1194-201	183
1224	Nutritional support in alcoholic cirrhotic patients improves host defenses. <b>1999</b> , 18, 434-41	44
1223	Patterns of energy intake in patients with cirrhosis and healthy volunteers. <b>1999</b> , 82, 41-8	7
1222	Hepatitis C: a challenge for the generalist. <b>2000</b> , 35, 97-8, 101-4, 107-8 passim	2
1221	Laparoscopic Cholecystectomy in Cirrhosis: Contraindication or Privileged Indication?. <b>2000</b> , 10, 360-363	24
1220	A Revised Natural History Model for Primary Sclerosing Cholangitis. <b>2000</b> , 75, 688-694	203
1219	Anterior approach for major right hepatic resection for large hepatocellular carcinoma. <b>2000</b> , 232, 25-31	155
1218	Blood loss in orthotopic liver transplantation: a retrospective analysis of transfusion requirements and the effects of autotransfusion of cell saver blood in 164 consecutive patients. <b>2000</b> , 11 Suppl 1, S87-93	55
1217	Assessment of hepatic blood flow by PET with <sup>15</sup> O water: correlation between per-rectal portal scintigraphy with <sup>99</sup> Tc(m)-pertechnetate and scintigraphy with <sup>99</sup> Tc(m)-GSA. <b>2000</b> , 21, 533-8	6
1216	Prognostic factors for long-term actual patient survival after orthotopic liver transplantation in children. <b>2000</b> , 70, 1448-53	22
1215	A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. <b>2000</b> , 88, 50-7	139

1214	Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. <b>2000</b> , 88, 1016-24	93
1213	How should patients with hepatocellular carcinoma be staged?. <b>2000</b> , 89, 2266-2273	144
1212	Pseudothrombosis in the portal venous system: a potential pitfall with gadolinium-enhanced dynamic gradient-recalled echo imaging of the liver. <b>2000</b> , 12, 763-8	7
1211	Primary liver tumors. <b>2000</b> , 19, 135-44	50
1210	Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. <b>2000</b> , 31, 7-11	273
1209	Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. <b>2000</b> , 31, 54-8	192
1208	Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. <b>2000</b> , 31, 207-10	363
1207	Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. <b>2000</b> , 31, 230-4	119
1206	Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. <b>2000</b> , 31, 324-9	104
1205	Liver transplantation. American Association for the Study of Liver Diseases. <b>2000</b> , 6, 122-35	83
1204	Endoscopic Evaluation of Rectal Mucosal Reddening in Patients with Liver Cirrhosis. <b>2000</b> , 12, 229-232	
1203	The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. <b>2000</b> , 49 Suppl 1, 21S-26S	24
1202	The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. <b>2000</b> , 49, 417-21	32
1201	Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. <b>2000</b> , 50, 108-15	52
1200	Dysphagia after prophylactic endoscopic injection sclerotherapy for oesophageal varices: not fatal but a distressing complication. <b>2000</b> , 15, 320-3	7
1199	Renovascular resistance assessed by color Doppler ultrasonography in patients with chronic liver diseases. <b>2000</b> , 15, 1424-9	19
1198	Effect of cisapride on portal haemodynamics in patients with liver cirrhosis using duplex Doppler ultrasonography. <b>2000</b> , 12, 95-101	
1197	Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients. <b>2000</b> , 22, 147-57	72

1196	Spin-echo echo-planar MR imaging of hepatocellular carcinoma arising from chronic liver damage: comparison with turbo spin-echo imaging. <b>2000</b> , 24, 43-8	2
1195	Factors affecting survival after living-related liver transplantation. <b>2000</b> , 13, S136-S139	6
1194	Diastolic Function Impairment in Alcoholics. <b>2000</b> , 24, 1830-1835	47
1193	Perioperative safety and prognosis in hepatocellular carcinoma patients with impaired liver function. <b>2000</b> , 190, 574-9	33
1192	Effectiveness of gastric devascularization and splenectomy for patients with gastric varices. <b>2000</b> , 191, 498-503	51
1191	Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis. <b>2000</b> , 191, 657-60	76
1190	The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. <b>2000</b> , 20, 318-29	293
1189	Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment. <b>2000</b> , 20, 87S-94S	17
1188	Effects of collateral vessel occlusion on oral glucose tolerance test in liver cirrhosis. <b>2000</b> , 45, 581-6	10
1187	Evaluation of gallbladder motility in patients with liver cirrhosis: relationship to gallstone formation. <b>2000</b> , 45, 1109-14	26
1186	Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. <b>2000</b> , 45, 1392-9	38
1185	The clinical significance of lymph node metastases in patients undergoing surgery for hepatocellular carcinoma. <b>2000</b> , 30, 892-5	54
1184	Plasma endothelin-1 levels in liver cirrhosis. <b>2000</b> , 30, 169-72	11
1183	Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. <b>2000</b> , 31, 840-5	481
1182	A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. <b>2000</b> , 31, 864-71	2011
1181	Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. <b>2000</b> , 32, 461-5	219
1180	Increased hepatic iron and cirrhosis: no evidence for an adverse effect on patient outcome following liver transplantation. <b>2000</b> , 32, 1200-7	35
1179	Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. <b>2000</b> , 32, 1208-15	143

1178	Impact of liver transplantation on health-related quality of life. <b>2000</b> , 6, 779-83	76
1177	Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. <b>2000</b> , 6, 715-20	28
1176	Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates. <b>2000</b> , 6, 489-94	42
1175	Confirmation of the role of the Mayo Risk Score as a predictor of resource utilization after orthotopic liver transplantation for primary biliary cirrhosis. <b>2000</b> , 6, 749-52	9
1174	Correlation of high levels of hyaluronan and cytokines (IL-1beta, IL-6, and TGF-beta) in ascitic fluid of cirrhotic patients. <b>2000</b> , 45, 2229-32	7
1173	Current Views on Hepatitis C Virus Infection. <b>2000</b> , 2, 55-60	1
1172	Intracellular pH measurements of the whole head and the basal ganglia in chronic liver disease: a phosphorus-31 MR spectroscopy study. <b>2000</b> , 15, 223-40	22
1171	Facteurs prédictifs de hémorragie par rupture de varices œsophagiennes. <b>2000</b> , 30, 531-535	2
1170	Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. <b>2000</b> , 14, 121-6	86
1169	Correlation of Serum Concentrations of Cystatin C and Creatinine to Inulin Clearance in Liver Cirrhosis. <b>2000</b> , 46, 712-715	112
1168	[Nutritional consequences of metabolic impairment of macronutrients in chronic liver disease]. <b>2000</b> , 37, 52-7	13
1167	Cholestasis is the Main Determinant of Abnormal CA 199 Levels in Patients with Liver Cirrhosis. <b>2000</b> , 15, 226-230	24
1166	Validation of the Modified Tnm-Izumi Classification for Hepatocellular Carcinoma. <b>2000</b> , 86, 8-11	10
1165	Lipolysis and lipid oxidation in cirrhosis and after liver transplantation. <b>2000</b> , 278, G967-73	8
1164	Pulmonary hypertension associated with liver cirrhosis: an echocardiographic study. <b>2000</b> , 51, 1013-20	25
1163	The prognostic significance of subclinical hepatic encephalopathy. <b>2000</b> , 95, 2029-34	176
1162	Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. <b>2000</b> , 95, 2915-20	82
1161	Cholestatic liver diseases and health-related quality of life. <b>2000</b> , 95, 497-502	121



1160	An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. <b>2000</b> , 95, 3579-83	29
1159	Natural history of cirrhotic patients with small esophageal varices: a prospective study. <b>2000</b> , 95, 503-8	72
1158	Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. <b>2000</b> , 95, 199-203	50
1157	Delayed liquid gastric emptying in patients with hepatocellular carcinoma. <b>2000</b> , 95, 3230-7	9
1156	Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. <b>2000</b> , 95, 2015-22	82
1155	Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. <b>2000</b> , 95, 2328-32	90
1154	Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study. <b>2000</b> , 95, 1051-5	12
1153	Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction. <b>2000</b> , 95, 484-9	66
1152	Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model. <b>2000</b> , 95, 2921-7	27
1151	Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. <b>2000</b> , 95, 218-22	87
1150	Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma. <b>2000</b> , 73, 1091-7	53
1149	Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alcoholic cirrhosis. <b>2000</b> , 40, 250-7	11
1148	The Liver and Vascular Surgery. <b>2000</b> , 4, 275-288	1
1147	Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. <b>2000</b> , 217, 119-26	431
1146	UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. <b>2000</b> , 46 Suppl 3-4, III1-III15	94
1145	Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. <b>2000</b> , 215, 123-8	84
1144	Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. <b>2000</b> , 44, 821-6	61
1143	Transforming growth factor-beta1 as a surrogate marker of hepatic dysfunction in chronic liver diseases. <b>2000</b> , 38, 1129-31	10

1142	Antiphospholipid antibodies in alcoholic liver disease are influenced by histological damage but not by alcohol consumption. <b>2000</b> , 9, 451-5	6
1141	Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. <b>2000</b> , 46, 546-52	39
1140	Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis. <b>2000</b> , 12, 677-81	50
1139	Variceal band ligation and variceal band ligation plus sclerotherapy in the prevention of recurrent variceal bleeding in cirrhotic patients: a randomized, prospective and controlled trial. <b>2000</b> , 51, 157-63	29
1138	Nutritional assessment in alcoholic patients. Its relationship with alcoholic intake, feeding habits, organic complications and social problems. <b>2000</b> , 59, 295-304	47
1137	Nutritional effects of oral zinc supplementation in cirrhosis. <b>2000</b> , 20, 1079-1089	23
1136	Factors affecting survival and long-term outcome in the cirrhotic patient undergoing hepatic resection for hepatocellular carcinoma. <b>2000</b> , 26, 387-92	26
1135	Synthesis of glutathione in response to methionine load in control subjects and in patients with cirrhosis. <b>2000</b> , 49, 1434-9	22
1134	Plasma granulocyte elastase levels and its relation to D-dimer in liver cirrhosis. <b>2000</b> , 14, 300-304	
1133	Liver function and encephalopathy after partial vs direct side-to-side portacaval shunt: a prospective randomized clinical trial. <b>2000</b> , 127, 614-21	15
1132	A6. Appetite and nutritional intake in patients with chronic liver disease. <b>2000</b> , 13, 363-371	1
1131	A revised natural history model for primary sclerosing cholangitis. <b>2000</b> , 75, 688-94	221
1130	Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. <b>2000</b> , 342, 1301-8	11655
1129	Bacterial infection in cirrhotic patients and its relationship with alcohol. <b>2000</b> , 95, 1290-3	73
1128	Modification of cardiac function in cirrhotic patients with and without ascites. <b>2000</b> , 95, 3200-5	109
1127	Is the increase in serum cystathionine levels in patients with liver cirrhosis a consequence of impaired homocysteine transsulfuration at the level of gamma-cystathionase?. <b>2000</b> , 35, 866-72	51
1126	Chinese alcoholic patients with esophageal cancer are genetically different from alcoholics with acute pancreatitis and liver cirrhosis. <b>2000</b> , 95, 2958-64	75
1125	The natural history of portal hypertensive gastropathy: influence of variceal eradication. <b>2000</b> , 95, 2888-93	83

1124 Cirrosis hepática. **2000**, 8, 485-492

1123 Liver transplantation. Selection, listing criteria, and preoperative management. **2000**, 4, 513-32

9

1122 The current status of liver transplantation for primary hepatic malignancy. **2000**, 4, 591-605

21

1121 Incidencia e historia natural del carcinoma hepatocelular en los pacientes con infección crónica por el virus de la hepatitis C. **2000**, 200, 360-366

1120 Regulation of hepatic blood flow in patients with liver cirrhosis and after liver transplantation. **2000**, 6, 251-260

6

1119 Left ventricular volumes in liver cirrhosis. **2000**, 32, 392-7

11

1118 Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. **2000**, 32, 605-10

116

1117 Can dietary intake influence plasma levels of amino acids in liver cirrhosis?. **2000**, 32, 611-6

6

1116 Endoscopic treatment of bleeding gastric varices by N-butyl-2-cyanoacrylate (Histoacryl) injection: long-term efficacy and safety. **2000**, 52, 160-7

288

1115 Mucosal abnormalities of the colon in patients with portal hypertension: an endoscopic study. **2000**, 52, 511-6

48

1114 Pharmacokinetics of Reboxetine in Volunteers with Hepatic Impairment. **2000**, 19, 473-477

6

1113 Recurrence of esophageal varices following endoscopic treatment and its impact on rebleeding: comparison of sclerotherapy and ligation. **2000**, 32, 202-8

64

1112 Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. **2000**, 33, 907-14

273

1111 Serum leptin levels in post-hepatitis liver cirrhosis. **2000**, 33, 38-42

41

1110 Gene expression of TNF-receptors in peripheral blood mononuclear cells of patients with alcoholic cirrhosis. **2000**, 32, 51-7

27

1109 Screening of subclinical hepatic encephalopathy. **2000**, 32, 748-53

142

1108 Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. **2000**, 33, 301-7

166

1107 Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when?. **2000**, 33, 329-32

18

1106	High plasma cardiac natriuretic peptides associated with enhanced cyclic guanosine monophosphate production in preascitic cirrhosis. <b>2000</b> , 32, 426-33	11
1105	Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. <b>2000</b> , 32, 447-52	81
1104	The liver: a large endocrine gland. <b>2000</b> , 32, 505-7	16
1103	Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. <b>2000</b> , 32, 19-24	884
1102	Factors associated with poor health-related quality of life of patients with cirrhosis. <b>2001</b> , 120, 170-8	362
1101	Liver transplantation: current status and novel approaches to liver replacement. <b>2001</b> , 120, 749-62	182
1100	Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. <b>2001</b> , 121, 389-95	108
1099	A new "sandwich" method of combined endoscopic variceal ligation and sclerotherapy versus ligation alone in the treatment of esophageal variceal bleeding: a randomized trial. <b>2001</b> , 53, 572-8	34
1098	Adjuvant sclerotherapy after ligation for the treatment of esophageal varices: a prospective, randomized long-term study. <b>2001</b> , 53, 566-71	29
1097	The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial. <b>2001</b> , 53, 579-84	58
1096	Feasibility and potential benefit of maintenance endoscopic variceal ligation in patients with unresectable hepatocellular carcinoma and acute esophageal variceal hemorrhage: a controlled trial. <b>2001</b> , 54, 18-23	26
1095	Helicobacter pylori is not a risk factor for hepatic encephalopathy. <b>2001</b> , 33, 414-9	15
1094	Postprandial middle cerebral arterial vasoconstriction in cirrhotic patients. A placebo, controlled evaluation. <b>2001</b> , 34, 373-7	11
1093	Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. <b>2001</b> , 34, 570-5	538
1092	Daily variation of azygos and portal blood flow and the effect of propranolol administration once an evening in cirrhotics. <b>2001</b> , 34, 26-31	10
1091	Hepatopulmonary syndrome in candidates for liver transplantation. <b>2001</b> , 34, 651-7	161
1090	Amino acid challenge in patients with cirrhosis: a model for the assessment of treatments for hepatic encephalopathy. <b>2001</b> , 34, 658-64	39
1089	Increase of serum estradiol in cirrhotic men treated by transjugular intrahepatic portosystemic stent shunt. <b>2001</b> , 34, 818-24	18

1088	Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. <b>2001</b> , 34, 903-10	187
1087	Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. <b>2001</b> , 35, 421-30	355 <sup>8</sup>
1086	The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome. <b>2001</b> , 35, 338-43	74
1085	Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis. <b>2001</b> , 35, 733-8	52
1084	Excitatory and inhibitory mechanisms in Wilson's disease: investigation with magnetic motor cortex stimulation. <b>2001</b> , 192, 35-40	10
1083	Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. <b>2001</b> , 176, 667-73	254
1082	Malignant portal venous obstructions treated by stent placement: significant factors affecting patency. <b>2001</b> , 12, 1407-15	59
1081	Management of medically refractory ascites. <b>2001</b> , 181, 256-64	17
1080	Plasma endothelin-1 level as a marker reflecting the severity of portal hypertension in biliary atresia. <b>2001</b> , 36, 1609-12	15
1079	Hepatocellular carcinoma: multimodality management. <b>2001</b> , 130, 554-9; discussion 559-60	18
1078	Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. <b>2001</b> , 53, 308-12	175
1077	Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. <b>2001</b> , 23, 1180-92	23
1076	Effect of liver disease on dose optimization. <b>2001</b> , 1220, 247-258	2
1075	Serum and ascitic fluid nitrate levels in patients with cirrhosis. <b>2001</b> , 306, 127-32	18
1074	A preliminary evaluation of the discriminative power of the monoethylglycinexylidide formation test after intravenous and oral administration of lidocaine. <b>2001</b> , 33, 2557-62	2
1073	[Radiofrequency in the treatment of hepatocellular carcinoma]. <b>2001</b> , 24, 303-11	3
1072	The cost of palliative care for hepatocellular carcinoma in Hong Kong. <b>2001</b> , 19, 947-53	21
1071	Gastroesophageal variceal hemorrhage. <b>2001</b> , 345, 669-81	297

1070	Early administration of vapreotide for variceal bleeding in patients with cirrhosis. <b>2001</b> , 344, 23-8	173
1069	The effect of liver transplantation on circulating levels of estradiol and progesterone in male patients: parallelism with hepatopulmonary syndrome and systemic hyperdynamic circulation improvement. <b>2001</b> , 24, 503-9	23
1068	[Thyroid function tests in viral chronic hepatitis]. <b>2001</b> , 38, 254-60	2
1067	PREDICTING SURVIVAL IN END-STAGE LIVER DISEASE. <b>2001</b> , 2, 94-95	
1066	Elevation of CA-125 level is due to abdominal distension in liver transplantation candidates. <b>2001</b> , 72, 1519-22	12
1065	Primary prophylaxis of variceal bleeding in cirrhosis. <b>2001</b> , 13, 349-58	12
1064	Anesthetic Concerns for the Patient with Renal or Hepatic Disease. <b>2001</b> , 29, 213-228	4
1063	Cirrhosis and Laparoscopic Cholecystectomy. <b>2001</b> , 11, 165-169	19
1062	Sequential changes in the metabolic response to orthotopic liver transplantation during the first year after surgery. <b>2001</b> , 234, 245-55	80
1061	Correlations between colonic wall thickening in patients with virally induced cirrhosis on CT and clinical status. <b>2001</b> , 25, 786-91	5
1060	Fatal bleeding from a residual vein at the esophageal ulcer base after successful endoscopic variceal ligation. <b>2001</b> , 32, 158-60	12
1059	Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. <b>2001</b> , 233, 139-45	37
1058	Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis?. <b>2001</b> , 13, 1217-24	10
1057	Models predicting the natural history of cirrhosis and need for liver transplantation. <b>2001</b> , 6, 107-113	3
1056	Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. <b>2001</b> , 41, 628-35	30
1055	Perioperative Care for the Patient with Renal or Hepatic Disease. <b>2001</b> , 99-103	1
1054	Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. <b>2001</b> , 119, 1489-97	136
1053	[Pharmacological study and clinical effect of HIV protease inhibitor amprenavir]. <b>2001</b> , 117, 59-64	

1052	Basal and post-methionine serum homocysteine and lipoprotein abnormalities in patients with chronic liver disease. <b>2001</b> , 49, 325-9	11
1051	Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. <b>2001</b> , 234, 71-8	265
1050	Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. <b>2001</b> , 71, 402-5	195
1049	No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. <b>2001</b> , 13, 171-5	30
1048	Role of Helicobacter pylori in cirrhotic patients with dyspepsia: a 13C-urea breath test study. <b>2001</b> , 18, 140-50	10
1047	Binding rate constant of Tc-99m DTPA galactosyl human serum albumin measured by quantitative dynamic SPECT--clinical evaluation as a total and regional liver function test. <b>2001</b> , 15, 191-8	4
1046	Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. <b>2001</b> , 68, 83-6	106
1045	Le carcinome h�pato-cellulaire, pr�vention et diagnostic pr�coce: o�en sommes-nous?. <b>2001</b> , 31, 515-520	1
1044	Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler. <b>2001</b> , 27, 901-7	55
1043	Review article: current endoscopic therapeutic options in the management of variceal bleeding. <b>2001</b> , 15, 575-94	48
1042	Bolus somatostatin but not octreotide reduces hepatic sinusoidal pressure by a NO-independent mechanism in chronic liver disease. <b>2001</b> , 15, 857-64	14
1041	Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection. <b>2001</b> , 15, 1967-73	11
1040	Hepatic phenylalanine metabolism measured by the [13C]phenylalanine breath test. <b>2001</b> , 31, 356-61	22
1039	Cerebral vascular resistance assessed by transcranial color Doppler ultrasonography in patients with chronic liver diseases. <b>2001</b> , 16, 890-7	14
1038	Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. <b>2001</b> , 16, 660-5	88
1037	High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. <b>2001</b> , 16, 1274-81	36
1036	Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease. <b>2001</b> , 16, 1409-14	17
1035	Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. <b>2001</b> , 16, 1378-83	116

1034	The clinical importance of the trimethadione tolerance test as a method for quantitative assessment of hepatic functional reserve in patients with biliary atresia. <b>2001</b> , 26, 417-24	4
1033	Circulating levels of insulin-like growth factors and their binding proteins in patients with chronic liver disease: lack of correlation with bone mineral density. <b>2001</b> , 21, 123-8	21
1032	Quantitative testing of liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity. <b>2001</b> , 21, 26-30	32
1031	The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis. <b>2001</b> , 21, 350-6	8
1030	Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. <b>2001</b> , 91, 957-963	46
1029	Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. <b>2001</b> , 91, 1342-8	80
1028	Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. <b>2001</b> , 92, 126-35	69
1027	Characteristics and course of small hepatocellular carcinomas in patients with hepatitis C virus types 1 and 2. <b>2001</b> , 63, 120-127	5
1026	Association between duplex Doppler sonographic flow pattern in right hepatic vein and various liver diseases. <b>2001</b> , 29, 25-30	48
1025	Leukocyte arylsulfatase A activity in patients with alcohol-related cirrhosis. <b>2001</b> , 13, 297-300	5
1024	Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis. <b>2001</b> , 46, 1313-20	16
1023	Congestion of superior mesenteric veins and small bowel mucosal injury after endoscopic treatment of esophageal varices in patients with portal hypertension. <b>2001</b> , 46, 2353-9	2
1022	Relationship of blood trace elements to liver damage, nutritional status, and oxidative stress in chronic nonalcoholic liver disease. <b>2001</b> , 81, 245-54	35
1021	Influence of cirrhosis on lamotrigine pharmacokinetics. <b>2001</b> , 51, 410-4	36
1020	Prevalence of liver disease in patients with Streptococcus bovis bacteraemia. <b>2001</b> , 42, 116-9	54
1019	Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease. <b>2001</b> , 7, 948-53	225
1018	Decreased splanchnic oxygen uptake and increased systemic oxygen uptake in cirrhosis are normalized after liver transplantation. <b>2001</b> , 7, 1015-22	12
1017	Hemostatic profiles in 39 dogs with congenital portosystemic shunts. <b>2001</b> , 30, 97-104	40



1016	Increased Circulating Leptin Levels in Chronic Alcoholism. <b>2001</b> , 25, 83-88	97
1015	A Variant of Des- $\beta$ -Carboxy Prothrombin Was Increased in Alcoholic Liver Disease Without Hepatocellular Carcinoma. <b>2001</b> , 25, 46S-50S	5
1014	Influence of previous interferon therapy on recurrence after resection of hepatitis c virus-related hepatocellular carcinoma. <b>2001</b> , 92, 59-66	23
1013	Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. <b>2001</b> , 52, 199-207	37
1012	Nutrition and survival in patients with liver cirrhosis. <b>2001</b> , 17, 445-50	369
1011	Feature subset selection by genetic algorithms and estimation of distribution algorithms. A case study in the survival of cirrhotic patients treated with TIPS. <b>2001</b> , 23, 187-205	38
1010	Ziprasidone, a new atypical antipsychotic drug. <b>2001</b> , 21, 717-30	36
1009	Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. <b>2001</b> , 48, 110-5	68
1008	Improving prognosis following a first variceal haemorrhage over four decades. <b>2001</b> , 49, 682-5	153
1007	Hyperhomocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fibrosis. <b>2001</b> , 38, 1217-21	82
1006	Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. <b>2001</b> , 48, 390-6	102
1005	Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. <b>2001</b> , 39, 961-5	35
1004	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. <b>2001</b> , 48, 251-9	477
1003	Health-related quality of life in chronic liver disease: the impact of type and severity of disease. <b>2001</b> , 96, 2199-205	226
1002	Small Intestinal Bacterial Overgrowth versus Antimicrobial Capacity in Patients with Spontaneous Bacterial Peritonitis. <b>2001</b> , 36, 92-96	25
1001	Serum xanthine oxidase in human liver disease. <b>2001</b> , 96, 1194-9	40
1000	Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. <b>2001</b> , 96, 2442-7	73
999	Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients. <b>2001</b> , 96, 1575-80	32

998	Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. <b>2001</b> , 96, 1877-80	114
997	Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity?. <b>2001</b> , 96, 515-8	67
996	Prognostic value of hepatocyte proliferative activity after transjugular intrahepatic portosystemic shunt. <b>2001</b> , 96, 1866-71	3
995	Hemodynamic effects of a combination of prazosin and terlipressin in patients with viral cirrhosis. <b>2001</b> , 96, 1210-6	11
994	Assessment of utilities and health-related quality of life in patients with chronic liver disease. <b>2001</b> , 96, 579-83	116
993	Influence of esophageal varices and spontaneous portal-systemic shunts on postprandial splanchnic hemodynamics. <b>2001</b> , 96, 550-6	13
992	Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis. <b>2001</b> , 49, 106-11	15
991	Evidence for altered hepatic gluconeogenesis in patients with cirrhosis using in vivo 31-phosphorus magnetic resonance spectroscopy. <b>2001</b> , 49, 557-64	54
990	Expression of a novel protein by regenerating hepatocytes and peripheral blood lymphocytes. <b>2001</b> , 8, 1292-4	0
989	Renovascular impedance and esophageal varices in patients with Child-Pugh class A cirrhosis. <b>2001</b> , 219, 712-5	14
988	Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism. <b>2001</b> , 55, 980-8	34
987	Dendroaspis natriuretic peptide in hepatic cirrhosis. <b>2001</b> , 96, 2724-9	4
986	Portal venous stent placement in patients with pancreatic and biliary neoplasms invading portal veins and causing portal hypertension: initial experience. <b>2001</b> , 220, 150-6	54
985	Lack of prognostic usefulness of hepatic venous pressures and hemodynamic values in a select group of patients with severe alcoholic cirrhosis. <b>2002</b> , 97, 1187-90	12
984	Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. <b>2002</b> , 97, 2063-70	47
983	Spontaneous <i>Listeria monocytogenes</i> peritonitis: a population-based study of 13 cases collected in Spain. <b>2002</b> , 97, 1507-11	28
982	Prospective validation of the Rockall risk scoring system for upper GI hemorrhage in subgroups of patients with varices and peptic ulcers. <b>2002</b> , 97, 630-5	76
981	Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). <b>2002</b> , 97, 734-44	255

980	Xanthine oxidoreductase activity in human liver disease. <b>2002</b> , 97, 2079-85	50
979	Video-assisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic hepatic hydrothorax. <b>2002</b> , 97, 3172-5	53
978	Systemic nitric oxide production and renal function in nonazotemic human cirrhosis: a reappraisal. <b>2002</b> , 97, 2383-90	9
977	Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). <b>2002</b> , 97, 142-8	80
976	Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. <b>2002</b> , 97, 978-81	38
975	Impairment of psychomotor responses after conscious sedation in cirrhotic patients undergoing therapeutic upper GI endoscopy. <b>2002</b> , 97, 1717-21	37
974	Under pressure to prognosticate. <b>2002</b> , 97, 1088-90	
973	Renal tubular events following passage from the supine to the standing position in patients with compensated liver cirrhosis: loss of tubuloglomerular feedback. <b>2002</b> , 51, 736-41	11
972	Cirrhosis: modified caudate-right lobe ratio. <b>2002</b> , 224, 769-74	153
971	Portal vein pulsatility and spectral width changes in patients with portal hypertension: relation to the severity of liver disease. <b>2002</b> , 75, 417-21	20
970	Gadolinium-enhanced MR imaging of the liver: optimizing imaging delay for hepatic arterial and portal venous phases--a prospective randomized study in patients with chronic liver damage. <b>2002</b> , 225, 407-15	59
969	Impairment of albumin and whole body postprandial protein synthesis in compensated liver cirrhosis. <b>2002</b> , 282, E304-11	29
968	HCC: what's the score. <b>2002</b> , 50, 749-50	4
967	Rocuronium plasma concentrations during three phases of liver transplantation: relationship with early postoperative graft liver function. <b>2002</b> , 88, 764-70	18
966	Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. <b>2002</b> , 35, 1-10	158
965	Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. <b>2002</b> , 51, 853-9	228
964	Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. <b>2002</b> , 20, 4459-65	97
963	Remission and survival following monthly intraarterial cisplatin in nonresectable hepatoma. <b>2002</b> , 20, 613-25	38

962	Enhanced monocyte tissue factor expression in hepatosplenic schistosomiasis. <b>2002</b> , 13, 43-7	4
961	Detection of hypervascular hepatocellular carcinoma: comparison of SPIO-enhanced MRI with dynamic helical CT. <b>2002</b> , 26, 701-10	19
960	Helicobacter pylori, gastric juice, and arterial ammonia levels in patients with cirrhosis. <b>2002</b> , 34, 578-81	19
959	Increased rate of bone loss at the femoral neck in patients with chronic liver disease. <b>2002</b> , 14, 43-8	24
958	Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. <b>2002</b> , 14, 159-65	110
957	Surgery and ablative therapy for hepatocellular carcinoma. <b>2002</b> , 35, S130-7	56
956	Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. <b>2002</b> , 14, 377-81	19
955	Pharmacokinetic study of esomeprazole in patients with hepatic impairment. <b>2002</b> , 14, 491-6	23
954	Prediction of esophageal varices in patients with cirrhosis. <b>2002</b> , 34, 81-5	150
953	Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression: predictive factors of response to antirejection therapy. <b>2002</b> , 73, 1936-43	21
952	Prothrombin index is an indirect marker of severe liver fibrosis. <b>2002</b> , 14, 1133-41	57
951	Hepatic iron deposition on magnetic resonance imaging: correlation with inflammatory activity. <b>2002</b> , 26, 988-93	16
950	Preoperative predictors of survival after resection of small hepatocellular carcinomas. <b>2002</b> , 235, 722-30; discussion 730-1	146
949	Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified?. <b>2002</b> , 236, 602-11	146
948	Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. <b>2002</b> , 30, 1-6	327
947	Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function. <b>2002</b> , 37, 299-308	24
946	Serum biotinidase activity in children with chronic liver disease and its clinical significance. <b>2002</b> , 34, 59-62	13
945	Pharmacokinetics and Safety of Galantamine in Subjects with Hepatic Impairment and Healthy Volunteers. <b>2002</b> , 42, 428-436	8

944	Interferon for hepatocellular carcinoma. <b>2002,</b>	1
943	Small hepatocellular carcinoma: therapeutic effectiveness of percutaneous radio frequency ablation therapy with a LeVeen needle electrode. <b>2002, 21, 67-76</b>	9
942	Extrahepatic conditions and hepatic encephalopathy in elderly patients. <b>2002, 324, 1-4</b>	11
941	Prognostic assessment and evaluation of the benefits of treatment. <b>2002, 35, S138-42</b>	26
940	The use of quantitative Doppler ultrasonography to predict posthepatectomy complications on the basis of hepatic hemodynamic parameters. <b>2002, 132, 431-40</b>	7
939	Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. <b>2002, 30, 2205-11</b>	506
938	Chronic hepatic disease: usefulness of serial CT examinations. <b>2002, 26, 418-21</b>	4
937	Implications of estradiol and progesterone in pulmonary vasodilatation in cirrhotic patients. <b>2002, 25, 4-10</b>	13
936	The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. <b>2002, 97, 2855-60</b>	47
935	Extent of resection for hepatocellular carcinoma 2 cm or less in greatest diameter. <b>2002, 184, 437-40</b>	4
934	Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. <b>2002, 36, 66-71</b>	82
933	Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. <b>2002, 36, 356-61</b>	35
932	MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. <b>2002, 36, 494-500</b>	212
931	Surgical versus medical treatment of refractory ascites. <b>2002,</b>	
930	Vascular reserve in the lower limbs of cirrhotic patients: a duplex Doppler ultrasound study. <b>2002, 34, 717-22</b>	1
929	Hepatitis C virus RNA quantitation in hepatic veins and peripheral blood in patients with liver cirrhosis: evidence for low level intrahepatic hepatitis C virus replication in advanced liver disease. <b>2002, 34, 802-7</b>	3
928	Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial. <b>2002, 122, 916-22</b>	32
927	Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. <b>2002, 123, 134-40</b>	1170

926	Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. <b>2002</b> , 123, 728-34	135
925	Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. <b>2002</b> , 123, 719-27	220
924	Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. <b>2002</b> , 41, 999-1004	17
923	Cancer antigen 125 in patients with chronic liver disease. <b>2002</b> , 77, 538-41	30
922	Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. <b>2002</b> , 50, 881-5	185
921	Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. <b>2002</b> , 97, 1223-7	61
920	Impaired tuftsin activity in cirrhosis: relationship with splenic function and clinical outcome. <b>2002</b> , 50, 707-12	35
919	Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. <b>2002</b> , 359, 1734-9	2679
918	TIPS: a therapy to prevent variceal rebleeding in patients listed for liver transplantation. <b>2002</b> , 34, 635-7	6
917	Liver transplantation: who and when?. <b>2002</b> , 34, 2465-7	2
916	Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease. <b>2002</b> , 36, 793-8	87
915	Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. <b>2002</b> , 36, 751-8	44
914	Effects of long-term oral misoprostol administration on hepatic amino acid-nitrogen metabolism in patients with cirrhosis. <b>2002</b> , 37, 15-21	1
913	Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. <b>2002</b> , 37, 548-55	88
912	Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. <b>2002</b> , 37, 767-72	87
911	Hepatic venous pressure gradients measured by duplex ultrasound. <b>2002</b> , 57, 746-52	17
910	Computed tomographic features of hepatocellular carcinoma predict long-term survival after hepatic resection. <b>2002</b> , 28, 235-42	7
909	Portal venous velocity in the follow-up of patients with biliary atresia after Kasai portoenterostomy. <b>2002</b> , 37, 873-6	6

908	Abnormal brain energy metabolism shown by in vivo phosphorus magnetic resonance spectroscopy in patients with chronic liver disease. <b>2002</b> , 59, 75-82	16
907	Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. <b>2002</b> , 13, 995-9	25
906	Application of preoperative portal vein embolization before major hepatic resection in patients with normal or abnormal liver parenchyma. <b>2002</b> , 131, 26-33	83
905	Chemoembolization of hepatocellular carcinoma. <b>2002</b> , 13, S211-21	179
904	Diagnostic Value of Plasma Cystatin C as a Glomerular Filtration Marker in Decompensated Liver Cirrhosis. <b>2002</b> , 48, 850-858	123
903	[Hepatopulmonary syndrome in liver transplantation candidates]. <b>2002</b> , 39, 11-6	7
902	Hepatocellular carcinoma: therapeutic experience with percutaneous ethanol injection under real-time contrast-enhanced color Doppler sonography with the contrast agent Levovist. <b>2002</b> , 21, 1015-22	3
901	Outcome of peritoneal dialysis in cirrhotic patients with chronic renal failure. <b>2002</b> , 40, 161-8	45
900	Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. <b>2002</b> , 194, 592-602	313
899	Prognostic value of energy metabolism in patients with viral liver cirrhosis. <b>2002</b> , 18, 229-34	173
898	Malnutrition is a risk factor in cirrhotic patients undergoing surgery. <b>2002</b> , 18, 978-86	96
897	Texture analysis of human liver. <b>2002</b> , 15, 68-74	90
896	Quantitative Doppler evaluation of the splenoportal venous system in various stages of cirrhosis: differences between right and left portal veins. <b>2002</b> , 30, 537-43	11
895	Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. <b>2002</b> , 80, 143-8	54
894	Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy. <b>2002</b> , 95, 2353-60	130
893	Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. <b>2002</b> , 95, 2539-45	81
892	Quantitative lung perfusion scintigraphy and detection of intrapulmonary shunt in liver cirrhosis. <b>2002</b> , 16, 577-81	13
891	Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B. <b>2002</b> , 26, 555-60	25

890	Predictors of successful hepatic resection: prognostic usefulness of hepatic asialoglycoprotein receptor analysis. <b>2002</b> , 26, 1342-7		71
889	Plasma amino acids in cirrhosis and after liver transplantation: influence of liver function, hepatic hemodynamics and circulating hormones. <b>2002</b> , 16, 9-17		21
888	The pathophysiological basis of acute-on-chronic liver failure. <b>2002</b> , 22 Suppl 2, 5-13		138
887	Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. <i>British Journal of Surgery</i> , <b>2002</b> , 89, 418-22 <sup>53</sup>		138
886	Diagnostic des hpatopathies et de leur svfit. <b>2002</b> , 23, 41-48		2
885	Longitudinal bone loss in postmenopausal women with primary biliary cirrhosis and well-preserved liver function. <b>2002</b> , 252, 537-41		7
884	Liver transplant recipients' ability to cope during the first 12 months after transplantation--a prospective study. <b>2002</b> , 16, 345-52		16
883	Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. <b>2002</b> , 16, 361-72		73
882	13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. <b>2002</b> , 16, 717-25		45
881	Evaluation of Helicobacter pylori diagnostic methods in patients with liver cirrhosis. <b>2002</b> , 16, 1283-9		21
880	Review article: breath testing for human liver function assessment. <b>2002</b> , 16, 1977-96		86
879	Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice. <b>2002</b> , 54, 120-4		42
878	Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. <i>British Journal of Surgery</i> , <b>2000</b> , 87, 1182-7	5.3	80
877	Improving operative safety for cirrhotic liver resection. <i>British Journal of Surgery</i> , <b>2001</b> , 88, 210-5	5.3	47
876	Increased serum leptin concentrations correlate with soluble tumour necrosis factor receptor levels in patients with cirrhosis. <b>2002</b> , 57, 805-11		25
875	131I lipiodol therapy for unresectable hepatocellular carcinoma. <b>2002</b> , 72, 210-4		11
874	Hepatocellular carcinoma: current approaches to diagnosis and management. <b>2002</b> , 32, 394-400		16
873	Liver transplantation. <b>2002</b> , 17 Suppl 3, S294-7		1



872	Scoring severity of chronic liver disease. <b>2002</b> , 17 Suppl 3, S298-9	2
871	Pathophysiology of portal hypertension. <b>2002</b> , 17 Suppl, S482-7	7
870	Effect of anaemia on haemodynamics in patients with cirrhosis. <b>1999</b> , 14, 370-5	11
869	Effects of splenectomy on liver volume and prognosis of cirrhosis in patients with esophageal varices. <b>2002</b> , 17, 77-80	30
868	Mediation of transcatheter arterial chemoembolization induced gastric slow-wave dysrhythmia by endogenous prostaglandin. <b>2002</b> , 17, 46-51	2
867	Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study. <b>2002</b> , 17, 973-9	61
866	Hepatorenal syndrome in patients with cirrhosis. <b>2002</b> , 17, 739-47	42
865	Prognostic factors in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection. <b>2002</b> , 17, 1205-10	13
864	Delayed gastrointestinal transit in patients with hepatocellular carcinoma. <b>2002</b> , 17, 1254-9	8
863	Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. <b>2002</b> , 15, 34-38	15
862	Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: a study on neuroradiological and blood manganese changes. <b>2002</b> , 15, 188-195	28
861	Coagulation profiles and intraoperative substitution requirements during elective piggyback liver transplantation with prophylactic antifibrinolytic therapy. <b>2002</b> , 15, 310-316	2
860	Alterations in serum leptin in chronic liver disease. <b>2002</b> , 47, 183-9	16
859	Dopaminergic control of renal tubular function in patients with compensated cirrhosis. <b>2002</b> , 47, 392-400	4
858	Quantification of the electroencephalographic theta/alpha ratio for the assessment of portal-systemic encephalopathy following implantation of transjugular intrahepatic portosystemic stent shunt (TIPSS). <b>2002</b> , 17, 19-28	13
857	Clinical predictors of large esophagogastric varices in patients with hepatocellular carcinoma. <b>2002</b> , 47, 723-9	7
856	Child comes of age. <b>2002</b> , 35, 244-5	20
855	Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. <b>2002</b> , 35, 616-21	60

854	Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. <b>2002</b> , 35, 1282-4	84
853	Cardiovascular effects of canrenone in patients with preascitic cirrhosis. <b>2002</b> , 35, 1441-8	13
852	Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. <b>2002</b> , 36, 403-9	252
851	Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. <b>2002</b> , 36, 410-7	130
850	Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. <b>2002</b> , 36, 949-58	303
849	Influence of endothelin-1 on hemodynamics during liver transplantation with and without temporary portocaval shunt: results of a clinical randomized study. <b>2002</b> , 8, 27-33	3
848	Rapid improvement of autonomic and peripheral neuropathy after liver transplantation: a single case report. <b>2002</b> , 8, 164-6	6
847	Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. <b>2002</b> , 8, 278-84	164
846	Is MELD really the definitive score for liver allocation?. <b>2002</b> , 8, 795-8	27
845	Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. <b>2002</b> , 8, 765-74	322
844	Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. <b>2002</b> , 8, 873-83	311
843	An examination of factors predicting prioritization for liver transplantation. <b>2002</b> , 8, 957-61	3
842	Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. <b>2002</b> , 8, 1165-74	131
841	The impact of liver metastasis on mortality in patients initially diagnosed with locally advanced or resectable pancreatic cancer. <b>2003</b> , 33, 155-64	9
840	Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study. <b>2003</b> , 48, 877-81	11
839	Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. <b>2003</b> , 38, 230-7	101
838	Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. <b>2003</b> , 38, 599-612	596
837	Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. <b>2003</b> , 38, 1210-8	329

836	Validity of the <sup>13</sup> C-caffeine breath test as a noninvasive, quantitative test of liver function. <b>2003</b> , 38, 1227-36	41
835	Longitudinal assessment of mortality risk among candidates for liver transplantation. <b>2003</b> , 9, 12-8	151
834	Predictive models of short- and long-term survival in patients with nonbiliary cirrhosis. <b>2003</b> , 9, 260-7	21
833	Psychological outcome and quality of life following liver transplantation: a prospective, national, single-center study. <b>2003</b> , 9, 712-20	89
832	A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. <b>2003</b> , 9, 684-92	201
831	Impact of right-lobe live donor liver transplantation on patients waiting for liver transplantation. <b>2003</b> , 9, 863-9	40
830	Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. <b>2003</b> , 9, 961-9	49
829	Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. <b>2003</b> , 48, 179-86	34
828	TIPS for management of refractory ascites: response and survival are both unpredictable. <b>2003</b> , 48, 542-50	28
827	Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients. <b>2003</b> , 48, 556-60	57
826	Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. <b>2003</b> , 48, 802-8	18
825	Partial splenic embolization: long-term outcome. <b>2003</b> , 387, 421-6	59
824	Risk factors for nonhepatic surgery in patients with cirrhosis. <b>2003</b> , 27, 647-52	101
823	Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. <b>2003</b> , 58, 669-75	44
822	Evaluation of nutritional practice in hospitalized cirrhotic patients: results of a prospective study. <b>2003</b> , 19, 515-21	127
821	Thoracoabdominal approach for right-sided hepatic resection for hepatocellular carcinoma. <b>2003</b> , 196, 418-27	32
820	Colorectal adenocarcinoma in cirrhotic patients. <b>2003</b> , 196, 874-9	59
819	Prediction of GFR in liver transplant candidates. <b>2003</b> , 42, 1169-76	103

818	Management of variceal hemorrhage. <b>2003</b> , 40, 263-343	10
817	Malnutrition is not related to alterations in energy balance in patients with stable liver cirrhosis. <b>2003</b> , 22, 553-9	48
816	Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. <b>2003</b> , 97, 1253-62	271
815	The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. <b>2003</b> , 98, 2671-7	36
814	Autonomic deficit in early cirrhosis. <b>2001</b> , 33, 482-3	
813	Magnetic resonance imaging of the liver with ultrashort TE (UTE) pulse sequences. <b>2003</b> , 18, 709-13	38
812	Autonomic and peripheral neuropathy in endstage liver disease and following liver transplantation. <b>2003</b> , 28, 595-600	20
811	Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. <b>2000</b> , 6, 277-86	110
810	Around the world with the model for end-stage liver disease. <b>2003</b> , 9, 1118-1119	4
809	Autologous blood storage before hepatectomy for hepatocellular carcinoma with underlying liver disease. <i>British Journal of Surgery</i> , <b>2003</b> , 90, 23-8	53 33
808	Separate analysis of asialoglycoprotein receptors in the right and left hepatic lobes using Tc-GSA SPECT. <b>2003</b> , 38, 1401-9	15
807	Effect of Levovist on splanchnic hemodynamics in cirrhotic patients. <b>2003</b> , 29, 643-8	3
806	Hepatocellular carcinoma: surgical indications and results. <b>2003</b> , 47, 13-27	59
805	Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. <b>2003</b> , 23, 243-8	120
804	Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. <b>2003</b> , 23, 45-53	170
803	Hypoglycaemia in patients with liver diseases administered levothyroxine. <b>2003</b> , 28, 355-61	
802	Oxidative breakdown of octanoic acid is maintained in patients with cirrhosis despite advanced disease. <b>2003</b> , 15, 113-20	32
801	Emergency embolization of spontaneous ruptured hepatocellular carcinoma: correlation between survival and Child-Pugh classification. <b>2003</b> , 47, 231-5	18

800	Evaluation of the albumin-gamma-glutamyltransferase isoenzyme as a diagnostic marker of hepatocellular carcinoma-complicating liver cirrhosis. <b>2003</b> , 18, 288-95	9
799	Peripheral neuropathy in liver cirrhosis. <b>2003</b> , 18, 922-6	16
798	Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension. <b>2003</b> , 18, 934-42	85
797	Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function. <b>2003</b> , 18, 1156-61	11
796	Endoscopic sclerotherapy compared with no specific treatment for the primary prevention of bleeding from esophageal varices. A randomized controlled multicentre trial [ISRCTN03215899]. <b>2003</b> , 3, 22	25
795	Results of resections for hepatocellular carcinoma in a new hepatobiliary unit. <b>2003</b> , 73, 8-13	12
794	Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. <b>2003</b> , 17 Suppl 2, 98-102	19
793	Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma. <b>2013</b> , 19, 78-85	12
792	Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. <b>2013</b> , 19, 3207-16	12
791	Impact of cirrhosis on surgical outcome after pancreaticoduodenectomy. <b>2013</b> , 19, 7129-37	34
790	Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival. <b>2014</b> , 20, 8158-65	16
789	Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. <b>2014</b> , 20, 786-94	19
788	Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. <b>2014</b> , 20, 10960-8	4
787	Cardiac surgery in patients with liver cirrhosis: risk factors for predicting mortality. <b>2014</b> , 20, 12608-14	26
786	Recent advances in the surgical treatment of hepatocellular carcinoma. <b>2014</b> , 20, 14381-92	64
785	Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome. <b>2014</b> , 20, 14934-41	55
784	Covert hepatic encephalopathy: agreement and predictive validity of different indices. <b>2014</b> , 20, 15756-62	39
783	Therapy for alcoholic liver disease. <b>2014</b> , 20, 2143-58	45

782	Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis. <b>2015</b> , 21, 246-53	31
781	Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. <b>2015</b> , 21, 3013-9	10
780	High neutrophil-lymphocyte ratio indicates poor prognosis for acute-on-chronic liver failure after liver transplantation. <b>2015</b> , 21, 3317-24	15
779	Prognostic roles of preoperative $\alpha$ -fetoprotein and des- $\beta$ -carboxy prothrombin in hepatocellular carcinoma patients. <b>2015</b> , 21, 4933-45	36
778	Proportions of acetyl-histone-positive hepatocytes indicate the functional status and prognosis of cirrhotic patients. <b>2015</b> , 21, 6665-74	6
777	Impact of muscle wasting on survival in patients with liver cirrhosis. <b>2015</b> , 21, 7357-61	41
776	Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. <b>2015</b> , 21, 7637-47	60
775	Serum proinflammatory cytokines and nutritional status in pediatric chronic liver disease. <b>2015</b> , 21, 8927-34	14
774	Allocation of patients with liver cirrhosis and organ failure to intensive care: Systematic review and a proposal for clinical practice. <b>2015</b> , 21, 8964-73	12
773	Endozepine-4 levels are increased in hepatic coma. <b>2015</b> , 21, 9103-10	10
772	Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis. <b>2015</b> , 21, 9466-75	10
771	Platelet count combined with right liver volume and spleen volume measured by magnetic resonance imaging for identifying cirrhosis and esophageal varices. <b>2015</b> , 21, 10184-91	11
770	Hepatosplanchnic circulation in cirrhosis and sepsis. <b>2015</b> , 21, 2582-92	19
769	Advances in liver transplantation allocation systems. <b>2016</b> , 22, 2922-30	25
768	Pharmacokinetic drug interactions in liver disease: An update. <b>2016</b> , 22, 1260-78	43
767	Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. <b>2016</b> , 22, 10219-10225	11
766	Liver surgery in cirrhosis and portal hypertension. <b>2016</b> , 22, 2725-35	52
765	Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis. <b>2017</b> , 23, 3122-3132	18

764	Prognostic factors associated with mortality in patients with gastric fundal variceal bleeding. <b>2017</b> , 23, 496-504	9
763	Presence of columnar-lined esophagus is negatively associated with the presence of esophageal varices in Japanese alcoholic men. <b>2017</b> , 23, 7150-7159	2
762	Validation of prognostic indices in Egyptian Budd-Chiari syndrome patients: A single-center study. <b>2017</b> , 23, 629-637	6
761	Laparoscopic resection laparoscopic radiofrequency ablation for the treatment of small hepatocellular carcinomas: A single-center analysis. <b>2017</b> , 23, 653-660	11
760	Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review. <b>2020</b> , 26, 5022-5049	6
759	Nutritional status in non-alcoholic sub-clinical porto-systemic encephalopathy. <b>1998</b> , 4, 380-384	2
758	Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension. <b>1999</b> , 5, 296-300	31
757	Increased prevalence of intestinal inflammation in patients with liver cirrhosis. <b>1999</b> , 5, 391-396	41
756	Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital. <b>2000</b> , 6, 339-343	39
755	Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. <b>2002</b> , 8, 237-42	54
754	Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. <b>2003</b> , 9, 2666-70	45
753	Safety Profile and Efficacy of Chemoembolization with Doxorubicin - Loaded Polyethylene Glycol Microspheres in Patients with Hepatocellular Carcinoma. <b>2019</b> , 7, 742-746	3
752	Retrospective analysis of transcatheter arterial chemoembolization treatment for spontaneously ruptured hepatocellular carcinoma. <b>2019</b> , 18, 6423-6430	6
751	Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma. <b>2020</b> , 19, 691-699	9
750	A new method of endoscopic variceal ligation-injection sclerotherapy (EVLIS) for gastric varices. <b>1995</b> , 10, 108-19	12
749	Liver cirrhosis leads to poorer survival in patients with end-stage renal disease. <b>2016</b> , 31, 730-8	7
748	Vitamin D Receptor Gene Polymorphisms as a Predictive Risk Factor for Hepatocellular Carcinoma Development and Severity in Chronic Hepatitis B. <b>2016</b> , 13, 26-35	3
747	Patient selection for hepatic resection for metastatic colorectal cancer. <b>2012</b> , 3, 3-10	9

746	Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction. <b>2015</b> , 6, 259-67	23
745	Quantitative Platelet Abnormalities in Patients With Hepatitis B Virus-Related Liver Disease. <b>2009</b> , 2, 344-349	4
744	Modelflow method versus continuous thermodilution technique for cardiac output measurement in liver transplant patients. <b>2008</b> , 55, 57	1
743	The procedure outcome of laparoscopic resection for 'small' hepatocellular carcinoma is comparable to vlaparoscopic radiofrequency ablation. <b>2015</b> , 11, 231-5	4
742	Noninvasive predictors of large esophageal varices: is there an emerging role of aspartate aminotransferase-to-platelet ratio index in hepatocellular carcinoma?. <b>2015</b> , 27, 139-146	2
741	Effectiveness of intravenous infusion of N-acetylcysteine in cirrhotic patients undergoing major abdominal surgeries. <b>2015</b> , 9, 272-8	7
740	Delayed-onset chest infections in liver transplant recipients: a prospective study. <b>2016</b> , 10, 147-154	1
739	The Role of Hepatitis C virus and Possible Risk factors in development of Hepatocellular carcinoma: 400 Patients based study. <b>2019</b> , 31, 64-72	3
738	Impact of Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients. <b>2017</b> , 6, 151-157	2
737	Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. <b>2019</b> , 51, 1347-1356	4
736	Hepatocellular Carcinoma: Risk Factors, Diagnosis, Staging and Treatment in a Referral Centre. <b>2013</b> , 04, 384-393	2
735	Role of Tyro3, Axl, and Mer Receptors and Their Ligands (Gas6, and Protein S) in Patients with Hepatocellular Carcinoma. <b>2017</b> , 08, 112-130	7
734	Predictors of Intra-Hospital Mortality in Patients with Cirrhosis. <b>2014</b> , 04, 141-148	6
733	Liver Transient Elastography Combined to Platelet Count (Baveno VI) Predict High Esophageal Varices in Black African Patient with Compensated Hepatitis B Related Cirrhosis. <b>2018</b> , 08, 192-200	3
732	The Effect of Loop Diuretics on Sarcopenia and Long-Term Prognosis in Patients with Refractory Hepatic Ascites Treated with Tolvaptan. <b>2018</b> , 08, 201-208	1
731	Gastric cancer surgery for patients with liver cirrhosis. <b>2009</b> , 1, 49-55	18
730	Effect of Daikenchuto (TJ-100) on abdominal bloating in hepatectomized patients. <b>2013</b> , 5, 115-22	5
729	Predictors of long term survival after hepatic resection for hilar cholangiocarcinoma: A retrospective study of 5-year survivors. <b>2016</b> , 8, 436-43	10



728	N-butyl-2-cyanoacrylate, iso-amyl-2-cyanoacrylate and hypertonic glucose with 72% chromated glycerin in gastric varices. <b>2015</b> , 7, 411-6	1
727	Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. <b>2018</b> , 10, 51-61	3
726	Hepatectomy for gallbladder-cancer with unclassified anomaly of right-sided ligamentum teres: A case report and review of the literature. <b>2018</b> , 10, 523-529	1
725	Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function. <b>2020</b> , 12, 1031-1045	4
724	Soluble membrane attack complex in ascites in patients with liver cirrhosis without infections. <b>2010</b> , 2, 221-5	2
723	Surgical management of hepatocellular carcinoma. <b>2015</b> , 7, 245-52	52
722	Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion. <b>2016</b> , 8, 345-54	31
721	Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. <b>2017</b> , 9, 544-550	7
720	Association between Severity of Liver Disease, Frequency of Infection, and Degree of Gastric Lesion in Egyptian Patients with Hepatitis B Virus Infection. <b>2018</b> , 98, 221-226	3
719	'Les liaisons dangereuses': Hepatitis C, Rituximab and B-cell non-Hodgkin's lymphomas. <b>2012</b> , 3, 21-8	2
718	Liver transplantation in adults: Choosing the appropriate timing. <b>2012</b> , 3, 49-61	7
717	Locoregional treatment for hepatocellular carcinoma: The best is yet to come. <b>2015</b> , 7, 306-18	18
716	Evaluation of Treatment Response after Endoscopic Variceal Obturation with Abdominal Computed Tomography. <b>2020</b> , 14, 117-124	3
715	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <b>2019</b> , 13, 227-299	151
714	Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis?. <b>2019</b> , 30, 964-975	6
713	Prevalence of Insomnia and Sleep Patterns among Liver Cirrhosis Patients. <b>2014</b> , 12,	5
712	Gene regulations in HBV-related liver cirrhosis closely correlate with disease severity. <b>2007</b> , 40, 814-24	7
711	A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma. <b>2015</b> , 14, 869-80	12

710	The management of acutely bleeding varices by injection sclerotherapy. <b>1986</b> , 145, 130-3	8
709	Serum thrombopoietin levels and its relationship with thrombocytopenia in patients with cirrhosis. <b>2014</b> , 14, e18556	14
708	Heme Oxygenase-1 mRNA Expression in Egyptian Patients With Chronic Liver Disease. <b>2012</b> , 12, 278-285	2
707	Impact of Severity of Chronic Liver Disease on Health-Related Economics. <b>2020</b> , 20,	2
706	Acute-on-chronic liver failure syndrome - clinical results from an intensive care unit in a liver transplant center. <b>2020</b> , 32, 49-57	1
705	Prognostic Value of a New Marker of Ventricular Repolarization in Cirrhotic Patients. <b>2016</b> , 107, 523-531	5
704	Case Series of 10 Patients with Cirrhosis Undergoing Emergent Repair of Ruptured Umbilical Hernias: Natural History and Predictors of Outcomes. <b>2019</b> , 17, 210-213	5
703	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <b>2021</b> , 19, 541-565	74
702	Is Model for End-Stage Liver Disease score associated with quality of life after liver transplantation?. <b>2011</b> , 21, 207-14	9
701	Comparison of viral hepatitis-associated hepatocellular carcinoma due to HBV and HCV - cohort from liver clinics in Pakistan. <b>2014</b> , 15, 7563-7	15
700	Assessing the prognostic scores for the prediction of the mortality of patients with acute-on-chronic liver failure: a retrospective study. <b>2020</b> , 8, e9857	2
699	Hepatic Venous Waveform, Splenoportal and Damping Index in Liver Cirrhosis: Correlation with Child Pugh's Score and Oesophageal Varices. <b>2016</b> , 10, TC01-5	0
698	Child-Turcotte-Pugh Score as a Predictive Factor for Long-Term Survival After Repeat Hepatectomy for Recurrent Liver Metastases of Colorectal Cancer. <b>2021</b> , 105, 611-618	
697	Sarcomatoid hepatocellular carcinoma in a young African female. <b>2021</b> , 9, 2050313X211052452	
696	DOSE EXTRAPOLATION ACROSS POPULATIONS. <b>2021</b> , 417-428	
695	Gastrointestinal Cancers and Liver Cirrhosis: Implications on Treatments and Prognosis. <b>2021</b> , 11, 766069	0
694	Determination of the segmental hepatic clearance rate of Tc-mebrofenin and its application in the functional assessment of future liver remnant after liver resection. <b>2021</b> , 40, 385-396	0
693	Risk factors for community-onset pneumonia caused by drug-resistant pathogens: A prospective cohort study. <b>2021</b> ,	1

692	Factors Related to Sleeping Disorder Due to Pruritus in Patients with Chronic Liver Disease. <b>2021</b> , 60, 3195-3203	0
691	Transient elastography and platelet count as noninvasive predictors of gastroesophageal varices in patients with compensated hepatitis C virus-related liver cirrhosis. <b>2021</b> ,	
690	Endoscopic injection sclerotherapy improves liver function compared with endoscopic variceal ligation. <b>2021</b> , 11, 20479	
689	Assessing the prognosis of cirrhotic patients in the intensive care unit: What we know and what we need to know better. <b>2021</b> , 13, 1341-1350	0
688	Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. <b>2021</b> , 21, 386	0
687	Distinguishing between the complications of Wilson disease-related cirrhosis and HBV-related cirrhosis. <b>2021</b> , 1-7	
686	Determinaci3n de la tasa de aclaramiento hep3tico segmentario de 99mTc-mebrofenina y su aplicaci3n en la evaluaci3n funcional del remanente hep3tico futuro tras resecci3n hep3tica. <b>2021</b> , 40, 385-396	
685	TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. <b>2021</b> , 11,	12
684	Liver Transplantation for Biliary Atresia in Adulthood: Single-Centre Surgical Experience. <b>2021</b> , 10,	1
683	Amino Acid Profile in Malnourished Patients with Liver Cirrhosis and Its Modification with Oral Nutritional Supplements: Implications on Minimal Hepatic Encephalopathy. <b>2021</b> , 13,	1
682	Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis. <b>2021</b> , 11, 20506	0
681	Prevalence, risk factors, and short-term outcomes of postparacentesis acute kidney injury using revised criteria of the international club of ascites. <b>2021</b> , 100, e27431	
680	Predictors of Short-Term Mortality Following First Episode of Spontaneous Bacterial Peritonitis in Hospitalized Cirrhotic Patients. <b>2021</b> , 13, e18999	
679	Clinical characteristics and risk factors for mortality upon admission in patients with heart failure hospitalized due to COVID-19 in Spain. <b>2021</b> ,	1
678	Prediction and Risk Factors for Prognosis of Cirrhotic Patients with Hepatic Encephalopathy. <b>2021</b> , 2021, 5623601	0
677	Identifying early indicators of secondary peritonitis in critically ill patients with cirrhosis. <b>2021</b> , 11, 21076	1
676	Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. <b>2021</b> , 13,	2
675	Leberzirrhose und ihre Komplikationen. <b>2000</b> , 489-518	

- 674 Feature Subset Selection Using Probabilistic Tree Structures. A Case Study in the Survival of Cirrhotic Patients Treated with TIPS. **2000**, 97-110 2
- 673 Liver. **2000**, 183-194
- 672 Utilizaço das hepatectomias centrais nas cirurgias hepatobiliares. **2000**, 27, 413-421 1
- 671 Trans-thoracic microwave coagulo-necrotic therapy for hepatic tumors without chest tube insertion. **2001**, 19, 67-70
- 670 A variant of des-gamma-carboxy prothrombin was increased in alcoholic liver disease without hepatocellular carcinoma. **2001**, 25, 46S-50S 4
- 669 Portale Hypertension. **2002**, 745-797
- 668 Cancers of the large bowel and hepatobiliary tract. **2003**, 21, 509-34
- 667 Hepatobiliary Cancer, Pancreatic Cancer, and Neuroendocrine Cancers of the Gastrointestinal Tract. **2003**, 461-487
- 666 Management of Portal Hypertension. **2003**,
- 665 Alcohol and Nutrition. **2003**, 3-17
- 664 Alcohol-induced Liver Disease. **2004**, 205-217
- 663 Assessing the Effect of Disease State on the Pharmacokinetics of the Drug. **2004**, 345-372
- 662 Staging system for hepatocellular carcinoma. **2005**, 46, 53-63 1
- 661 Health Status Assessment and Economic Analyses in Cirrhosis and Portal Hypertension. **2005**, 469-484
- 660 Evaluation of Hepatic Function. **2005**, 129-137
- 659 Gastrointestinal Pharmacology. **2006**, 1258-1271
- 658 Hepatocellular Carcinoma. **2006**, 1109-1131
- 657 Pretransplant Evaluation and Care. **2006**, 933-945 2

656 Clinical Studies □ Typical Designs. **2006**, 659-720

655 Pharmacokinetics □ Pharmacodynamics in New Drug Development. **2006**, 335-375

654 Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. **2006**, 060928002456001-???

653 The Erythrocyte 2,3-diphosphoglycerate Concentration and Its Related Factors in Patients with End-stage Liver Disease. **2007**, 52, 430

652 Chemotherapy of Liver Tumors. **2007**, 1298-1311

651 C. **2007**, 223-305

650 De patiënt met een leverfunctiestoornis. **2007**, 259-267

649 Assessment of Liver Function in the Surgical Patient. **2007**, 30-36

648 Hepatocellular Carcinoma. **2007**, 1152-1158

647 [Role of capsule endoscopy in patients with portal hypertension and obscure gastrointestinal bleeding]. **2007**, 148, 1491-7

646 Liver Transplantation. **2008**, 99-137

1

645 The role and perspective of transplant hepatologists in Japan. **2008**, 49, 28-38

3

644 Laboratory aspects of important organic disorders with psychiatric sequelae. **2008**, 233-274

643 Living Donor Liver Transplantation in Japan. **2009**, 5, 13-21

642 Acute-on-Chronic Liver Failure in Cirrhosis: Defining and Managing Organ Dysfunction. **2009**, 658-671

2

641 Severity of illness and likely outcome from critical illness. **2009**, 17-29

0

640 Supraumbilical skin rash after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: Two case report. **2009**, 50, 390-396

639 5 Onderzoeksmethoden in de hepatologie. **2009**, 35-47

0

638 Infections in Cirrhosis in Critical Care. **2009**, 341-349

637 Infections in Cirrhosis in Critical Care. **2009**, 341-349

636 Scoring systems to evaluate severity-of-illness and organ dysfunction in patients admitted to the intensive care unit and emergency room. **2010**, 21, 327-342

635 Critères d'admission d'un malade cirrhotique en réanimation. **2010**, 117-126

634 Principles of anti-infective therapy. **2010**, 1275-1287

633 Anesthesia and the Hepatobiliary System. **2010**, 2135-2153

3

632 Clinical Scoring Systems. **2010**, 289-293

631 Chronic Liver Failure. **2010**, 371-380

630 Special Population Studies (Healthy Patient Studies). 1

629 Disorders of the Liver, Biliary System and Exocrine Pancreas in Pregnancy. 223-255

628 Liver Resection for Hepatocellular Carcinoma. **2011**, 109-134

627 Chronic Liver Disease in the Intensive Care. **2011**, 541-559

626 Hepatic Fibrosis and Cirrhosis. **2011**, 449-466

625 A case of untreated poorly differentiated hepatocellular carcinoma of 1.9 cm in diameter. **2011**, 52, 184-192

1

624 Portale Hypertension. **2011**, 749-782

623 Long-term results of small-diameter proximal splenorenal venous shunt: a retrospective study. **2011**, 17, 3453-8

622 Hepatologische Labordiagnostik. **2011**, 91-132

621 Postoperative Surveillance and Perioperative Prophylaxis. 161-234

- 620 Experimental study of scoring model for liver cirrhosis diseases. **2011**, 31, 485-489
- 619 Nonradiological Treatment for Liver Tumors. **2012**, 89-94
- 618 Patient Selection according to General Condition and Associated Disease. **2012**, 77-85
- 617 Advances in systemic therapy for hepatocellular carcinoma. **2012**, 1444-1452.e3
- 616 Portal Hypertension and Esophageal Varices. **2012**, 2065-2073
- 615 Features of Hormonal Disturbances in Cirrhotic Patients with Hepatic Encephalopathy. **2012**, 2, 84-89 ○
- 614 Impact of infection in hospitalized cirrhotic patients in a university hospital. **2012**, 02, 124-130 1
- 613 Pallidal Signal Intensities on T1-weighted MRI are Highly Observed in Advanced Liver Cirrhosis. **2012**, 38, 380-385
- 612 Perioperative Management. **2013**, 221-232
- 611 Hepatobiliäre Tumoren und Lebermetastasen. **2013**, 639-662
- 610 Diagnostic Operations of the Liver and Techniques of Hepatic Resection. **2013**, 1491-1506
- 609 Anesthesia for Patients with Hilar Cholangiocarcinoma. **2013**, 155-166
- 608 The Proper Scan Delay of the Hepatobiliary Phase of Gadoteric Acid-Enhanced Magnetic Resonance Imaging to Evaluate Small-Sized (≤ 1 cm) Hepatocellular Carcinoma in Cirrhotic Liver. **2013**, 68, 319
- 607 Multidisciplinary Approach to the Management of Portal Hypertension. **2013**, 1593-1609
- 606 Assessment of Liver Function. **2013**, 75-89
- 605 De patiënt met een leverfunctiestoornis. **2013**, 345-353
- 604 Transjugulair intrahepatischer portosystemischer Stentshunt. **2013**, 405-430
- 603 Diagnosis and Staging of Premalignant and Malignant Diseases of the Liver. 229-241

602 Non-Alcoholic Fatty Liver Disease, Hepatocellular Cancer, and Other Cancers. 192-205

601 Treatment of the Liver Cirrhosis: Modern Principles, Considering Syntropic Co- and Multimorbid Lesions of Other Organs and Systems of Organs. **2013**, 2, 37-45 2

600 Le carcinome h patocellulaire, de la surveillance au traitement. **2013**, 58, 35-37

599 Hepatic clearance measured with (99m)Tc-GSA single-photon emission computed tomography to estimate liver fibrosis. **2014**, 20, 16714-20 5

598 Liver and Bile Duct Cancer. **2014**, 1373-1396.e8 1

597 Considerations in Organ Failure. **2014**, 225-246

596 Assessment of the Nutritional Status of the Egyptian Patient with End Stage Liver Disease Prior to Liver Transplantation. **2014**, 04, 159-169 1

595 Severity of illness and likely outcome from critical illness. **2014**, 16-26.e3 1

594 Liver Transplantation for Primary Biliary Cirrhosis. **2014**, 287-300 0

593 Risikofaktoren und pr operative Ma nahmen aus internistischer Sicht. **1981**, 113-121

592 Hepatologie. **1981**, 877-958

591 Postersession VI. **1984**, 1804-1834

590 Symposium B. **1984**, 269-295

589 Child and Turcotte's classification of hepatic functional reserve and its modifications by Campbell and by Pugh in predicting blood loss during liver transplantation. **1985**, 208-220

588 Prevention of Recurrent Variceal Bleeding: Non-surgical Procedures. **1985**, 14, 209-232 6

587 The Value of Quantitation of Liver Function. **1987**, 187-188

586 Prophylactic Treatment of First Variceal Bleeding in Cirrhotics with Nadolol or Ranitidine: A Prospective Randomized Study. **1987**, 417-421

585 Scoring systems and computer-aided prognosis in patients with bleeding oesophageal or gastric varices. **1988**, 175-181



584 Assessment of Liver Function. **1988**, 378-382

583 Selective and total shunts in portal hypertension: facts and myths. **1988**, 333-347

582 The Present Day Usage of Nonselective Shunts. **1991**, 519-531

581 Risk factors in adult liver transplant recipients. **1991**, 289-294

580 Prevention of Recurrent Bleeding: Nonshunt Surgery. **1991**, 533-547

579 Varizensklerosierung. **1991**, 277-296

578 Ösophagusvarizenblutung. **1992**, 141-154

577 A Pugh score of 8 adequately selects patients with parenchymal cirrhosis for liver transplantation. **1992**, 5 Suppl 1, S175-8

576 Surgical Treatment of Malignant Liver Lesions. **1993**, 44-61

575 Sklerosierungstherapie von Ösophagusvarizen bei der Behandlung der Ösophagusvarizenblutung. **1993**, 345-351

574 Overview of Endoscopic Injection Sclerotherapy in 1200 Patients with Esophageal Varices. **1993**, 262-266

573 Donor Rating and Assessment of Pretransplant Prognosis by Use of the MEGX Test. **1993**, 19-24

572 Effect of Liver Disease on Drug Metabolism and Pharmacokinetics. **1996**, 367-394

0

571 Costs of transplantation. **1997**, 233-240

2

570 The liver in kidney disease. **1998**, 941-947

569 Wertigkeit biologischer Marker bei Hepatopathien aus internistischer Sicht. **1999**, 110-117

568 Use of Interferon- $\alpha$  For Prevention of Hepatocellular Carcinoma in Patients with Chronic Active Hepatitis C with Cirrhosis. **1999**, 93-102

567 Varizensklerosierung von Ösophagus- und Fundusvarizen und Gummibandligatur. **1999**, 240-255

566 Oral Cephalosporins. 222-268

565 Medication prescribing in liver dysfunction. **2014**, 4, 131-137

0

564 25-Hydroxyvitamin D3 Level in Patients with Chronic Viral Hepatitis B. **2014**, 14, 192-200

1

563 Hepatocellular Carcinoma. **2015**, 335-352

562 Acute and Chronic Liver Disease. **2015**, 523-550

561 Hepatocellular Carcinoma.

560 Pain Management in Patients with Hepatic Impairment. **2015**, 227-234

0

559 Visceral Fat Accumulation Is Associated with Increased Mortality Rate after Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma. **2015**, 06, 1124-1136

1

558 Role of Serum Zinc Level and P300 Event Related Potential in Detection of Minimal Hepatic Encephalopathy. **2015**, 05, 58-65

557 Preventive measures for recurrent hepatic encephalopathy in a hemodialysis patient. **2015**, 48, 199-205

1

556 Clinical Use of Indocyanine Green (ICG) Kinetics in Liver Anaesthesia and ICU. **2015**, 177-199

555 Gelatinase activities and TIMP-2 serum level in alcohol cirrhosis and chronic pancreatitis. **2015**, 26, 57-60

554 Diverse Utility of Endogenous Thrombin Potential and Thromboelastometry in the Assessment of Patients with Alcoholic Cirrhosis. **2015**, 1,

553 Liver. 241-262

552 Hepatic Fibrosis and Cirrhosis. 2070-2086

551 Liver Transplantation. 2129-2145

550 Sclerotherapy Using Aluminum Potassium Sulfate and Tannic Acid (ALTA) for Haemorrhoids in Patients With Liver Cirrhosis. **2015**, 3,

549 Better Management of Adverse Events Favors Sorafenib Treatment of HCC Patients and Impact on Survival. **2016**, 07, 275-284

1

548 Management of Choledocholithiasis in the Cirrhotic Patient. **2016**, 151-159

547 Which Is the Better Predictor of Hepatic Reserve Prior to Liver Resection: MELD or the Child-Pugh Score?. **2016**, 189-199

546 What Is the Best Way to Assess Hepatic Reserve Prior to Liver Resection in the Cirrhotic Patient?. **2016**, 165-177

545 Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC. **2016**, 3, 162-178

544 Changes in Serum Lipid Profile among Patients Suffering from Chronic Liver Disease Secondary to Hepatitis C. **2016**, 06, 333-342 1

543 Model for End-Stage Liver Disease (MELD) Score as a Biomarker. **2016**, 1-24

542 Liver Tumors. **2017**, 453-476

541 Is the Model for End-Stage Liver Disease (MELD) Score the Best Way to Evaluate Liver Transplant Patients Preoperatively?. **2017**, 229-231

540 Liver Resection. **2017**, 583-597

539 Arterial blood pressure circadian rhythm in normotensive decompensated cirrhotic patients before and after single paracentesis. **2016**, 70, 265-273

538 General Care of the Liver Patient. **2017**, 17-25

537 Colorectal Surgery in Cirrhotics. **2017**, 201-214

536 Primary Liver Cancer: Background and Clinical Evidence. **2017**, 103-117

535 Microbiological study of spontaneous bacterial peritonitis in Tanta University Hospitals. **2017**, 7, 5-8 1

534 Child-Turcotte-Pugh-Score. **2017**, 1-1

533 Complications of Chronic Alcoholism That Affect Critical Illness. **2017**, 249-266

532 Resection of Large Hepatocellular Carcinoma: Hanging Technique. **2017**, 3-16

531 Model for End-Stage Liver Disease (MELD) Score as a Biomarker. **2017**, 47-70

- 530 Performance of Disease-Specific Scoring Models in Intensive Care Patients with Severe Liver Diseases. **2017**, 11, OC12-OC16 2
- 529 The Impact of Liver Disease on Drug Metabolism. **2017**, 29-39
- 528 Liver. 241-262
- 527 EARLY DETECTION OF RENAL BLOOD FLOW IMPEDANCE BY COLOUR DOPPLER IN CHRONIC LIVER DISEASE WITH NORMAL RENAL PARAMETERS. **2017**, 6, 1924-1927
- 526 Preoperative Phenacetin Metabolism Test in the Prediction of Postoperative Liver Dysfunction of Patients with Hepatocellular Carcinoma. **2017**, 23, 2607-2611 4
- 525 Early-Onset Pneumonia After Liver Transplant: Microbial Causes, Risk Factors, and Outcomes, Mansoura University, Egypt, Experience. **2017**, 15, 547-553 1
- 524 Annual Change in FIB-4, but not in APRI, was a Strong Predictor for Liver Disease Progression in Chinese Patients with Chronic Hepatitis C. **2017**, 18,
- 523 Transplantation of the Liver. **2018**, 753-768.e3
- 522 The Evaluation of Tolvaptan Therapy and Long-Term Prognosis in Hepatocellular Carcinoma with Refractory Ascites. **2018**, 08, 39-44
- 521 Hepatocellular Carcinoma. **2018**, 27-51
- 520 Does Rifaximin Improve EEG and VEP in Egyptian Cirrhotic Patients with Minimal Hepatic Encephalopathy?. **2018**, 08, 362-376
- 519 Role of Nerve Growth Factor (NGF) and Its Receptor Tyrosine Kinase A (TrK A) in Egyptian Cirrhotic Patients with Pruritus. **2018**, 08, 317-326
- 518 Ultrasonoscopic description of the structure and function of the heart in patients with syntropic cirrhotic cardiomyopathy and their features depending on the main liver disease severity. **2018**, 24, 24-36
- 517 Hepatocellular Carcinoma. **2018**, 217-220
- 516 Prise en charge des complications de la cirrhose. **2018**, 263-279.e1
- 515 Medical Therapy Options for Advanced Disease in Hepatocellular Carcinoma. **2018**, 91-97
- 514 Approach to Jaundice and Abnormal Liver Function Test Results. **2018**, 99-116.e6
- 513 Patient Selection and Technical Considerations. **2018**, 3-13

512	ANTIVIRAL AND ANTICOAGULANT THERAPY IN A POLYMORBID PATIENT WITH CHRONIC VIRAL HEPATITIS C. TACTICS OF MANAGEMENT, FEATURES OF DRUG-DRUG INTERACTIONS. <b>2018</b> , 9-16	
511	Sofosbuvir/simeprevir versus sofosbuvir/ribavirin regimen in Egyptian patients with hepatitis C virus. <b>2018</b> , 8, 6-11	
510	Partial Splenic Artery Embolization in Cirrhosis Is a Safe and Useful Procedure. <b>2018</b> , 08, 327-336	0
509	Drug Metabolism in Liver Failure. <b>2018</b> , 69-78	
508	Cholecystectomy in Cirrhosis. <b>2018</b> , 279-289	1
507	Hepatic Encephalopathy in Patients in Lviv (Ukraine). <b>2018</b> , 6, 146-151	4
506	Anesth�sie pour endoscopie digestive interventionnelle. <b>2018</b> , 31, 24-28	
505	Preoperative Preparations for Patients with Hepatocellular Carcinoma. <b>2019</b> , 7-26	
504	Severity Degrees of Syntropic Stable Arterial Hypotension in the Cirrhotic Patients and Their Dependence on the Daily Blood Pressure Monitoring and Liver Damage Class by C.G Child - R.N. Pugh. <b>2018</b> , 3, 43-51	1
503	Types of Segment-Oriented Hepatic Resection by the Glissonean Pedicle Approach. <b>2019</b> , 49-260	
502	Evaluation of pharmaceutical intervention in patients with hepatic insufficiency in a hospital setting. <b>2018</b> , 9,	1
501	The role of red cell distribution width as a noninvasive index for predicting liver cell failure and portal hypertension in cirrhotic patients. <b>2018</b> , 30, 255-263	
500	Rate and Predictive Factors for Sustained Complete Response after Selective Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma. <b>2018</b> , 19, 3545-3550	8
499	Impact of sepsis and non-communicable diseases on prognostic models to predict the outcome of hospitalized chronic liver disease patients. <b>2018</b> , 10, 944-955	
498	Coagulopathy in Cirrhotic Patients: Evaluation and Management. <b>2019</b> , 229-244	
497	Correla�o entre a am�nia e o potencial evocado relacionado a eventos (P300) em pacientes cirr�ticos. <b>2009</b> , 17, 122-127	3
496	Early Phase Metabolic Research with Reference to Special Populations. <b>2019</b> , 517-538	
495	Prediction of Liver Function Based on DCE-CT. <b>2019</b> , 8-13	

- 494 Correlation between nutritional assessment and oxidative stress in candidates for liver transplant. **2020**, 18, eAO4039 2
- 493 Child-Turcotte-Pugh-Score. **2019**, 564-564
- 492 Regional gray matter abnormality in hepatic myelopathy patients after transjugular intrahepatic portosystemic shunt: a voxel-based morphometry study. **2019**, 14, 850-857 1
- 491 Relationship between Lp-PLA2 and Child-Pugh classification in patients with hepatitis B cirrhosis. **2019**, 27, 160-166
- 490 Scoring criteria for determining the safety of liver resection for malignant liver tumors. **2019**, 7, 234-248 1
- 489 Child-Pugh Classification using Magnetic Resonance Imaging using Gadoteric Acid-based Contrast Agent Compared with Indocyanine Green and 99mTc-galactosyl-human Serum Albumin Liver Scintigraphy. **2019**, 69, 183-189
- 488 Acute on Chronic Liver Failure. **2020**, 193-217
- 487 Prevalence of prolonged QT interval in patients with HCV-related chronic liver disease. **2019**, 71, 15 1
- 486 TO EVALUATE PROGNOSTIC VALUE OF MELD AND CHILD-TURCOTTE PUGH SCORES IN PATIENTS WITH LIVER CIRRHOSIS AND VARICEAL BLEEDING. **2019**, 6, 2586-2590
- 485 Dual Effects of Large Spleen Volume After Splenectomy for the Patients With Chronic Liver Disease. **2019**, 104, 412-422
- 484 Prescription Selection and Dosing. **2020**, 169-175
- 483 Is rectus abdominis thickness associated with survival among patients with liver cirrhosis? A prospective cohort study. **2019**, 137, 401-406 1
- 482 Prognostic Assessment of Budd-Chiari Syndrome. **2020**, 189-205
- 481 Liver Disease and Perioperative Risk. **2020**, 143-150
- 480 Should Frailty Include Multidimensional and Dynamic Factors?. **2020**, 233-246
- 479 Surgery for Budd-Chiari Syndrome. **2020**, 171-179
- 478 Acute-on-chronic liver failure. **2019**, 161-178
- 477 A population-based cohort study of mortality of intensive care unit patients with liver cirrhosis.

- 476 Application of acoustic radiation force impulse elastography combined with serum markers in Child-Pugh grading. **2020**, 75, e1670 0
- 475 OPTIMUM DURATION OF PERCUTANEOUS TRANSHEPATIC CHOLANGIODRAINAGE IN COMMON BILE DUCT DISEASES COMPLICATED BY OBSTRUCTIVE JAUNDICE. **2020**, 73, 1915-1925 1
- 474 Practical issues in measuring the anticoagulant effect of direct oral anticoagulants. **2020**, 70, 297-309
- 473 Serum Urea Predicts Long-term Mortality in Hospitalized Patients with Decompensated Cirrhosis. **2020**, 20,
- 472 The Relationship between Trace Elements and Depression among Older Patients with Chronic Liver Disease. **2020**, 17, em224
- 471 Efficacy and Pattern of Antibiotic Usage Among Patients with Cirrhosis and/or Chronic Liver Disease in Telangana, India. **2020**, 000, 1-6
- 470 PREDICTING DEATH IN PATIENTS WITH END-STAGE LIVER DISEASE: A NEW MODEL FOR ASSESSING DISEASE SEVERITY. **2020**, 21-27
- 469 Complex treatment of hepatocellular carcinoma at early (BCLC-A) and intermediate (BCLC-B) stages. **2020**, 25, 55-66
- 468 Pharmacokinetic Analysis, Analgesic Effects, and Adverse Effects of Tapentadol in Cancer Patients with Pain. **2020**, 43, 1000-1006 1
- 467 LIV-4: A novel model for predicting transplant-free survival in critically ill cirrhotics. **2020**, 12, 298-311 1
- 466 Elevated neopterin levels are associated with acute-on-chronic liver failure and mortality in patients with liver cirrhosis. **2020**, 52, 753-760
- 465 Correlation of serum betatrophin levels with disease severity and the emergence of insulin resistance in cirrhotic patients. **2020**, 10,
- 464 Long-term survival prediction for transjugular intrahepatic portosystemic shunt in severe cirrhotic ascites: assessment of ten prognostic models. **2021**, 33, 1547-1555 2
- 463 Multivariate predictive model for asymptomatic spontaneous bacterial peritonitis in patients with liver cirrhosis. **2020**, 26, 4316-4326 1
- 462 Peritoneal Dialysis in a Patient with Acute Kidney Injury, Thrombocytopenia, Urosepsis, and Liver Cirrhosis: A Case Report. **2020**, 21, e926226
- 461 Adult liver transplantation using pediatric donor livers after cardiac or brain death: A report of three cases. **2020**, 20, 27 0
- 460 The Profile and Role of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: An Immunohistochemical Study. **2021**, 29, 188-200 1
- 459 Genome-wide association study of TP53 R249S mutation in hepatocellular carcinoma with aflatoxin B1 exposure and hepatitis B virus infection in Guangxi.

458	The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis. <b>2020</b> , 47,	0
457	Histologic Changes in Core-Needle Liver Biopsies From Patients With Acute-on-Chronic Liver Failure and Independent Histologic Predictors of 28-Day Mortality. <b>2021</b> ,	1
456	A History of the Assessment of Liver Performance. <b>2021</b> , 18, 28-48	1
455	Bioelectrical impedance vector analysis in patients on the waiting list for liver transplant: Associated factors and prognostic effects. <b>2021</b> , 94, 111528	0
454	A Prospective Multicenter Study of the Chinese Scoring System for Hepatitis B Liver Failure. <b>2021</b> , 8, 751807	0
453	The effect of branched-chain amino acids on body protein breakdown and synthesis in patients with chronic liver disease. <b>1983</b> , 103-109	
452	The Epidemiological, Clinical, Biological and Morphological Characteristics of Primitive Liver Cancers in Bangui. <b>2020</b> , 10, 97-105	
451	Clinical and laboratory parameters as predictors of long-term outcome according to the etiology of underlying chronic liver disease in patients who underwent liver transplantation for hepatocellular carcinoma treatment. <b>2020</b> , 75, e1529	
450	Prognostic Models in Acute and Acute on Chronic Liver Failure. <b>2020</b> , 91-107	
449	MALNUTRITION IN CIRRHOSIS: ASSOCIATION WITH ETIOLOGY AND HEPATOCELLULAR DYSFUNCTION. <b>2020</b> , 57, 375-380	1
448	Neutrophil-to-Lymphocyte Ratio and Albumin: New Serum Biomarkers to Predict the Prognosis of Male Alcoholic Cirrhosis Patients. <b>2020</b> , 2020, 7268459	3
447	Bleeding After Elective Interventional Endoscopic Procedures in a Large Cohort of Patients With Cirrhosis. <b>2020</b> , 11, e00288	4
446	Effect of liver disease on pharmacokinetics. <b>2022</b> , 91-112	
445	The significance of C-reactive protein to albumin ratio in patients with decompensated cirrhosis. <b>2020</b> , 33, 667-674	1
444	Pharmacokinetic Considerations for Organ Dysfunction Clinical Trials in Early Drug Development. <b>2020</b> , 313-342	
443	Differential Impact of Serum 25-Hydroxyvitamin D3 Levels on the Prognosis of Patients with Liver Cirrhosis According to MELD and Child-Pugh Scores. <b>2020</b> , 35, e129	2
442	Systematic review and meta-analysis of risk scores in prediction for the clinical outcomes in patients with acute variceal bleeding. <b>2021</b> , 53, 1806-1815	1
441	ERKRANKUNGEN DER VERDAUUNGSORGANE. <b>2020</b> , pA-1-pA7.8-14	



- 440 Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease. **2020**, 12, 89-98 6
- 439 Serum cystatin C unmask renal dysfunction in cirrhosis and performs better in estimation of glomerular filtration rate. **2020**, 31, 1320-1330 0
- 438 Leberzirrhose und deren Komplikationen. **2020**, 345-375
- 437 Special Considerations in Organ Failure. **2020**, 285-313
- 436 Perioperative Risk Models. **2020**, 11-30
- 435 Hepatocellular Carcinoma (HCC), Where do we stand? Current situation. **2020**, 36, 344-348 3
- 434 Muscle depletion in cirrhotic patients assessed using computed tomography: a cross-sectional study. **2020**, 138, 152-157
- 433 Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis. **2020**, 12, 99-107 2
- 432 Hyaluronic Acid, Spleen Size and Prothrombin Time Predict the Existence of High-Risk Esophageal Varices in Non-Viral Cirrhosis in Real Life. **2020**, 17, 7-19
- 431 Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib. **2020**, 66, 275-283
- 430 Hepatitis B. **2020**, 26, 39-45
- 429 ACUTE-ON-CHRONIC LIVER FAILURE IS INDEPENDENTLY ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS. **2021**, 58, 344-352 0
- 428 Observational study of the relative efficacy of insulin-glucose treatment for hyperkalaemia in patients with liver cirrhosis. **2021**, 11, e051201
- 427 Presence of ascites at presentation is associated with absence of long term response amongst patients with Budd-Chiari syndrome when treated with medical therapy alone: A single centre real life experience. **2021**, 0
- 426 Clinical significance of the latency period of abnormal ammonia metabolism in chronic liver disease: Proposal of a new concept. **2021**,
- 425 Differential diagnosis of human hepatitis. **2008**, 21-46
- 424 Clinical characteristics of portal hemodynamics in alcoholic liver cirrhosis. **2004**, 28, 148S-152S 4
- 423 Hepatic Disease. **2004**, 463-490

422 Hepatocellular Cancer. **2003**, 314-321

421 The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions. **2008**, 6, 243-8

4

420 Hepatologische Labordiagnostik. **2006**, 85-125

419 CrossRef Listing of Deleted DOIs.

418 Immunomodulation Therapy for Alcoholic Hepatitis. **2007**, 323-336

417 Operative Therapie der portalen Hypertension. **2006**, 654-661

416 Liver Tumors. **2007**, 311-330

415 Hepatobiliäre Tumoren und Lebermetastasen. **2006**, 537-551

414 Association between vitamin D status and depression in children with chronic liver disease. **2020**, 10,

413 Liver fibrosis assessment by transient elastography in patients with liver cirrhosis after hepatitis C virus eradication. **2020**, 11, 26-37

412 The miR-21 potential of serving as a biomarker for liver diseases in clinical practice. **2020**, 48, 2295-2305

5

411 Right ventricular dysfunction in cirrhosis: A speckle-tracking echocardiography study. **2020**, 4, 1036-1040

0

410 Transjugulärer intrahepatischer portosystemischer Stentshunt. **2021**, 607-633

409 Prognostic Assessment of Variceal Bleeding in Liver Cirrhosis. **2021**, 161-169

408 Inpatient Anaesthesia. **1986**, 4, 445-457

407 The Patient with Liver Disease. **1986**, 4, 747-760

406 Surgical management of portal hypertension. **1995**, 162, 527-35

17

405 Medical evaluation before operation. **1982**, 137, 351-8

6

404	Anesthesia in 1984: how safe is it?. <b>1984</b> , 131, 437-41	6
403	Liver disease and anaesthesia. <b>1978</b> , 1, 1374-5	
402	Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature. <b>2005</b> , 7, 7	13
401	Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. <b>1999</b> , 45 Suppl 6, VI1-VI22	12
400	Cross reactivity due to positive canrenone interference. <b>2004</b> , 53, 772-3	1
399	Anaesthesia for injection of bleeding oesophageal varices. <b>1976</b> , 58, 315-7	2
398	Oesophageal varices: evaluation of injection sclerotherapy without general anesthesia using the flexible fiberoptic gastroscop. <b>1982</b> , 64, 401-5	9
397	Prospective study of a planned approach to the surgical management of bleeding oesophageal varices. <b>1986</b> , 68, 256-9	
396	Upper gastrointestinal bleeding in patients with liver cirrhosis. <b>2002</b> , 94, 712-5	13
395	Current management of advanced hepatocellular carcinoma. <b>2008</b> , 2, 64-70	18
394	Treatment of hepatocellular carcinoma: considerations regarding etiology and molecular biology. <b>2007</b> , 1, S85-9	
393	Spontaneous bacterial peritonitis: a review of treatment options. <b>2009</b> , 34, 204-10	22
392	Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. <b>2011</b> , 4, 40-4	38
391	Platelet count/bipolar spleen diameter ratio for the prediction of esophageal varices: The special Egyptian situation: Noninvasive prediction of esophageal varices. <b>2011</b> , 11, 278-84	13
390	Use of artificial neural network to predict esophageal varices in patients with HBV related cirrhosis. <b>2011</b> , 11, 544-7	8
389	Radio frequency ablation for primary liver cancer: an evidence-based analysis. <b>2004</b> , 4, 1-50	28
388	Unresectable hepatocellular carcinoma treated with transarterial chemoembolization: clinical data from a single teaching hospital. <b>2013</b> , 6, 367-71	2
387	The evolution in the prioritization for liver transplantation. <b>2012</b> , 25, 6-13	25

386	Significance of the C-caffeine breath test for patients with cirrhosis. <b>2014</b> , 27, 53-59	3
385	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <b>2013</b> , 9, 1-24	5
384	Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy. <b>2014</b> , 19, 703-8	15
383	Effects of cirrhosis on bone mineral density and bone metabolism. <b>2008</b> , 40, 18-24	3
382	The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. <b>2015</b> , 28, 109-117	14
381	Child-Pugh versus MELD score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis. <b>2015</b> , 8, 751-7	47
380	Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China. <b>2015</b> , 8, 1205-12	13
379	Perineural invasion: a potential reason of hepatocellular carcinoma bone metastasis. <b>2015</b> , 8, 5839-46	4
378	Predictive accuracy comparison of MELD and Child-Turcotte-Pugh scores for survival in patients underwent TIPS placement: a systematic meta-analytic review. <b>2015</b> , 8, 13464-72	17
377	FRZB up-regulated in hepatocellular carcinoma bone metastasis. <b>2015</b> , 8, 13353-9	4
376	Medical Care of the Patient With Compensated Cirrhosis. <b>2006</b> , 2, 124-133	1
375	Falsely Elevated Serum Vitamin B Levels Were Associated with the Severity and Prognosis of Chronic Viral Liver Disease. <b>2017</b> , 60, 31-39	8
374	Bleeding oesophageal varices: referral bias and survival. <b>1985</b> , 19, 189-91	2
373	Simplified fibre endoscopic sclerotherapy for oesophageal varices. <b>1982</b> , 16, 236-8	6
372	The effect of intravenous infusion of N-acetyl cysteine in cirrhotic patients undergoing liver resection: A randomized controlled trial. <b>2017</b> , 33, 450-456	3
371	Genetic heterogeneity in hepatocellular carcinoma and paired bone metastasis revealed by next-generation sequencing. <b>2017</b> , 10, 10495-10504	1
370	Magnetization transfer contrast of various regions of the brain in liver cirrhosis. <b>1999</b> , 20, 652-4	33
369	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <b>2021</b> , 21, 30	

368	A Single-Center Report on Liver Transplantation: First Experiences from Shahid Beheshti University of Medical Sciences. <b>2020</b> , 12, 252-256	1
367	1H-MR spectroscopy, magnetization transfer, and diffusion-weighted imaging in alcoholic and nonalcoholic patients with cirrhosis with hepatic encephalopathy. <b>2006</b> , 27, 1019-26	74
366	MR imaging of CNS involvement in children affected by chronic liver disease. <b>2000</b> , 21, 845-51	12
365	MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. <b>2006</b> , 27, 1373-8	88
364	Different combinations of the GLIM criteria for patients awaiting a liver transplant: Poor performance for malnutrition diagnosis but a potentially useful prognostic tool. <b>2021</b> , 41, 97-104	0
363	A validation study of combined resection and ablation therapy for multiple hepatocellular carcinoma. <b>2021</b> ,	0
362	Predictive potential of the MELD and Child-Turcotte-Pugh II scores for SBP in patients with cirrhosis and ascites. <b>2021</b> , 13, 101-109	0
361	Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis.. <b>2022</b> , 15, 747-757	0
360	The 2020 CCS atrial fibrillation guidelines for pharmacists: Top 10 takeaways.. <b>2022</b> , 155, 107-118	1
359	Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease.. <b>2021</b> , 13, 599-607	1
358	BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. <b>2021</b> ,	127
357	Impacts of body composition parameters and liver cirrhosis on the severity of alcoholic acute pancreatitis. <b>2021</b> , 16, e0260309	0
356	The Outcome after Hospital Discharge in Cirrhosis is Not Worsened with COVID-19 Infection: A Propensity Score-matched Analysis. <b>2021</b> ,	0
355	The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West. <b>2021</b> , 1	
354	Role of early transjugular intrahepatic portosystemic stent-shunt in acute variceal bleeding: An update of the evidence and future directions.. <b>2021</b> , 27, 7612-7624	0
353	Circulating MicroRNA-21 As A Novel Noninvasive Biomarker for Hepatocellular Carcinoma Compared with Alpha Fetoprotein Gold Test.	
352	Albumin for people with liver cirrhosis and bacterial infections. <b>2021</b> , 2021,	
351	Potential of PALBI-T score as a prognostic model for hepatocellular carcinoma in alcoholic liver disease.. <b>2022</b> , 6, 36-43	

350	Assessment of Plasma Vitronectin as Diagnostic and Prognostic Marker of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Cirrhosis. <b>2022</b> , 13, 9-19	2
349	Diagnostic potential of T1 and T2 relaxations in assessing the severity of liver fibrosis and necro-inflammation.. <b>2022</b> , 87, 104-112	0
348	Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment.. <b>2022</b> ,	4
347	Effect of delta Fetoprotein on the detection of liver cancer recurrence.. <b>2020</b> , 9, 6263-6274	2
346	QN-S3VM Method for Evaluation of Liver Functional Reserve. <b>2020</b> ,	
345	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <b>2020</b> , 21, 1-1	
344	Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma. <b>2021</b> ,	
343	Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients.. <b>2022</b> , 14,	0
342	Cognitive impairment in recipients of liver transplantation and relation to hepatic encephalopathy. <b>2022</b> , 29,	
341	Development of a Widely Applicable and Simple Prognostic Score for Patients with Acute-on-chronic Liver Failure. <b>2022</b> , 000, 000-000	
340	Practical Treatment Guidance for Cancer-Associated Thrombosis - Managing the Challenging Patient: A Consensus Statement.. <b>2022</b> , 103599	2
339	Relationship between the Level of Serum Golgi Protein 73 and the Risk of Short-term Death in Patients with ALD-ACLF. <b>2022</b> , 000, 000-000	1
338	Preoperative MELD score predicts adverse outcomes following gastrectomy: An ACS NSQIP analysis.. <b>2022</b> ,	1
337	Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis.. <b>2022</b> ,	0
336	Mortality Following Appendicectomy in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis.. <b>2022</b> , 46, 531	1
335	Tumour Staging for Hepatocellular Carcinoma. <b>2022</b> , 145-153	
334	Liver transplant allocation policies and outcomes in United States: A comprehensive review.. <b>2022</b> , 12, 32-42	5
333	Risk Factors for Esophageal Collateral Veins in Cirrhosis with and without Previous Endoscopic Esophageal Variceal Therapy.. <b>2022</b> , 2022, 6666791	0

332	Early prediction of decompensation (EPOD) Score - non-invasive determination of liver cirrhosis decompensation risk.. <b>2022,</b>	1
331	Evaluation of staging systems to predict prognosis in hepatocellular carcinoma patients treated with radioembolization.. <b>2022,</b> 8, e08770	
330	Machine learning to predict waitlist dropout among liver transplant candidates with hepatocellular carcinoma.. <b>2022,</b>	1
329	Prognostic impact of albumin-bilirubin score on the prediction of in-hospital mortality in patients with heart failure: a retrospective cohort study.. <b>2022,</b> 12, e049325	1
328	From LI-RADS Classification to HCC Pathology: A Retrospective Single-Institution Analysis of Clinico-Pathological Features Affecting Oncological Outcomes after Curative Surgery.. <b>2022,</b> 12,	3
327	Liver volume based prediction model for patients with hepatitis B virus-related acute-on-chronic liver failure.. <b>2022,</b>	1
326	Plasma angiopoietin 2 as a novel prognostic biomarker in alcohol-related cirrhosis and hepatitis. <b>2022,</b>	
325	Poor tolerability of lenvatinib in elderly patients 80 years old with hepatocellular carcinoma: A multicenter observational study.. <b>2022,</b> 10781552221077039	
324	Feeding Vessel Ablation: A Novel Subsegmental Devascularization Technique for the Treatment of Hepatocellular Carcinoma Located at the Liver Marginal Angle.. <b>2021,</b>	
323	Effect of Ayurveda Management on Liver Cirrhosis with Ascites-A Retrospective Cohort Study.. <b>2022,</b> 13, 100508	2
322	Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. <b>2022,</b> 45, 25-39	
321	Are seizures associated with neuroschistosomiasis mansoni? An exploratory survey in an endemic area of Brazil.. <b>2022,</b>	
320	Value of Bile Acids in Diagnosing Hepatitis C Virus-Induced Liver Cirrhosis and Hepatocellular Carcinoma. 79,	
319	QT Interval Prolongation Among Patients with Chronic Liver Disease Attending Jimma Medical Center Gastroenterology Clinic, Southwest Ethiopia. Volume 13, 9-18	
318	Food Intake Visual Scale-A practical tool for assessing the dietary intake of hospitalized patients with decompensated cirrhosis.. <b>2022,</b>	0
317	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.. <b>2022,</b>	4
316	Survival Analysis Using ALBI Grade for Patients Treated with DEE-TACE for Hepatocellular Carcinoma.. <b>2022,</b>	1
315	Hip Fractures in Patients with Liver Cirrhosis: Worsening Liver Function Is Associated with Increased Mortality.. <b>2021,</b>	0

- 314 Prediction of Survival After Partial Hepatectomy Using a Physiologically Based Pharmacokinetic Model of Indocyanine Green Liver Function Tests. **2021**, 12, 730418 3
- 313 Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: a retrospective cohort study.. **2022**, 10, 411 0
- 312 The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma.. **2022**, 36, 865-873 0
- 311 Management of the Patient on the Waiting List, Scoring Systems, and Priority. **2022**, 121-132
- 310 Prediction of Posthepatectomy Liver Failure with a Combination of Albumin-Bilirubin Score and Liver Resection Percentage.. **2022**, 234, 155-165
- 309 Nuclear Medicine Therapy in primary liver cancers. **2022**,
- 308 Severe Vitamin D Deficiency Is Strongly Associated with Liver Dysfunction and Disease Severity in Hepatitis B Virus Related Cirrhosis and Liver Failure Patients.. **2022**, 68, 16-22 1
- 307 Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems.. **2022**, 12, 850454 0
- 306 Patient stratification in hepatocellular carcinoma: impact on choice of therapy.. **2022**, 1
- 305 Profoundly Disturbed Lipoproteins in Cirrhotic Patients: Role of Lipoprotein-Z, a Hepatotoxic LDL-like Lipoprotein.. **2022**, 11, 1
- 304 Significance of promoter methylation of multiple tumor suppressor genes in hepatocellular carcinoma. **2022**, 23, 2
- 303 Palliative Care, Patient-Reported Measures, and Outcomes in Hospitalized Patients with Cirrhosis.. **2022**,
- 302 Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.. **2022**, 1 2
- 301 Risk factors of unplanned intraoperative conversion to hand-assisted laparoscopic surgery or open surgery in laparoscopic liver resection.. **2022**, 1 0
- 300 The useful predictors of zinc deficiency for the management of chronic liver disease.. **2022**, 57, 322 0
- 299 Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.. **2022**, JCO2102373 1
- 298 The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK-954).. **2022**,
- 297 Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts.. **2022**, 17, e0265668 0



296	Predicting Complications following Surgical Resection of Hepatocellular Carcinoma Using Newly Developed Neo-Glasgow Prognostic Score with ALBI Grade: Comparison of Open and Laparoscopic Surgery Cases.. <b>2022</b> , 14,	0
295	Portal Hypertensive Gastropathy in Liver Cirrhosis: Prevalence, Natural History, and Risk Factors.. <b>2022</b> , 61, 605-613	1
294	Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of early Progressive Disease Following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.. <b>2022</b> ,	1
293	COVID-19 in Cirrhotic Patients: Is Portal Vein Thrombosis a Potential Complication?. <b>2022</b> , 2022, 5900468	0
292	Serum serotonin as a non-invasive marker of portal hypertensive gastropathy in Egyptian patients with HCV-related liver cirrhosis.. <b>2022</b> , 85, 73-79	0
291	Differences in the intestinal microbiome associated with diarrhea during lenvatinib treatment for hepatocellular carcinoma.. <b>2022</b> ,	0
290	Prognostic Role of Albumin-Bilirubin Grade in Hepatocellular Carcinoma After Ultrasound-guided Percutaneous Radiofrequency Ablation: A Single-center Experience Over a Decade.. <b>2022</b> ,	0
289	T1 reduction rate with Gd-EOB-DTPA determines liver function on both 1.5 T and 3 T MRI.. <b>2022</b> , 12, 4716	1
288	Utility of prognostic scores in predicting short-term mortality in patients with acute-on-chronic liver failure. <b>2022</b> , 12,	
287	Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation.. <b>2022</b> ,	2
286	Noninvasive assessment of liver function reserve with fluorescent dosimetry of indocyanine green.. <b>2022</b> , 13, 1995-2005	0
285	Role of albumin in the treatment of decompensated liver cirrhosis.. <b>2022</b> ,	0
284	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma.. <b>2022</b> ,	
283	Serum Folate deficiency in HCV related Hepatocellular Carcinoma.. <b>2022</b> , 12, 5025	1
282	Assessment of Liver Function With MRI: Where Do We Stand?. <b>2022</b> , 9, 839919	1
281	Effect of Liver Cirrhosis on Theophylline Trough Concentrations: A Comparative Analysis of Organ Impairment Using Child-Pugh and MELD Scores.. <b>2022</b> ,	
280	Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV.. <b>2022</b> , 89, 396-404	0
279	Anticoagulation Considerations in Liver Disease.. <b>2022</b> , 45, 156-166	

278	Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy.. <b>2022</b> , 11,	1
277	Comparison of Liver Fibrosis and Function Indices with Extracellular Volume using Dual-Energy CT: A Retrospective Study.. <b>2022</b> ,	0
276	The exaggerated inflammatory response to bacterial products in decompensated cirrhotic patients is orchestrated by interferons, IL-6 and IL-8.. <b>2022</b> ,	1
275	Platelet-albumin (PAL) score as a predictor of perioperative outcomes and survival in patients with hepatocellular carcinoma undergoing liver resection in a Western center.. <b>2022</b> , 42, 101752	1
274	Inflammatory Biomarkers in Addictive Disorders.. <b>2021</b> , 11,	3
273	Hepatic impairment as a risk factor of adverse drug reactions. <b>2021</b> , 23, 939-948	
272	Preoperative nutritional score predicts underlying liver status and surgical risk of hepatocellular carcinoma.. <b>2021</b> , 14574969211061953	0
271	Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.. <b>2022</b> , 6, 29-35	0
270	Nomograms including the controlling nutritional status (CONUT) score in patients with hepatocellular carcinoma undergoing transarterial chemoembolization for prediction survival: A retrospective analysis. <b>2021</b> , 1-28	0
269	Red cell distribution width as a predictor of outcome in hospitalized cirrhotic patients.. <b>2021</b> , 33, e978-e985	0
268	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis. <b>2021</b> ,	4
267	Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial. <b>2021</b> , 326, 2161-2171	21
266	[Nutritional support for critically ill patients with COVID-19]. <b>2020</b> , 49, 347-355	1
265	The effect of intravenous infusion of N-acetyl cysteine in cirrhotic patients undergoing liver resection: A randomized controlled trial. <b>2017</b> , 33, 450	4
264	The Pharmacogenetics of Opiates and Its Impact on Delirium in Mechanically Ventilated Adults: A Pilot Study. 875512252210851	
263	Development and external validation of the Munich Sorafenib Evaluation Score for hepatocellular carcinoma.. <b>2022</b> ,	
262	Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 Gh Drug-Eluting Bead Transcatheter Arterial Chemoembolization.. <b>2022</b> , 14, e24047	0
261	Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan.. <b>2022</b> , 12, 6479	1

- 260 Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.. **2022**, 1
- 259 Development of a risk score model for 1-year graft loss after adult deceased donor liver transplantation in Japan based on a 20-year nationwide cohort. 0
- 258 Presentation\_1.pdf. **2018**,
- 257 Table\_1.XLS. **2018**,
- 256 Table\_2.XLSX. **2018**,
- 255 Table\_3.xls. **2018**,
- 254 Table\_4.xlsx. **2018**,
- 253 Data\_Sheet\_1.docx. **2019**,
- 252 Table\_1.docx. **2020**,
- 251 Table\_1.DOCX. **2018**,
- 250 Table\_1.DOCX. **2020**,
- 249 Table\_2.DOCX. **2020**,
- 248 Image\_1.PDF. **2018**,
- 247 Image\_2.PDF. **2018**,
- 246 Image\_3.PDF. **2018**,
- 245 Image\_4.PDF. **2018**,
- 244 Image\_5.PDF. **2018**,
- 243 Image\_6.PDF. **2018**,

242 Image\_7.PDF. 2018,

241 Table\_1.DOCX. 2018,

240 Table\_2.DOCX. 2018,

239 Table\_3.DOCX. 2018,

238 Table\_4.DOCX. 2018,

237 Table\_5.DOCX. 2018,

236 Table\_6.xls. 2018,

235 Hyperintense lesions of the globus pallidus on MRI in children with chronic liver disease. 1994, 153, 802-806 1

234 [Prediction model of mid-term fatality risk after radical resection in patients with hepatocellular carcinoma based on ALBI-grade]. 2020, 49, 375-382

233 Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data.. 2022, 8, 7-13

232 Prophylactic cyanoacrylate injection for gastric extension of esophageal varices: a randomized controlled trial.. 2022, 8, 84-91

231 Prevalence and correlates of poor sleep quality in chronic liver disease patients.. 2021, 14, 266-272

230 Decreased diversity of salivary microbiome in patients with stable decompensated cirrhosis.. 2020, 24, 157-165

229 Comparison of the New Neo-Glasgow Prognostic Score Based on the Albumin-Bilirubin Grade with Currently Used Nutritional Indices for Prognostic Prediction following Surgical Resection of Hepatocellular Carcinoma: A Multicenter Retrospective Study in Japan.. 2022, 14, 0

228 Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver Cirrhosis. 2022, 12, 1069

227 Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis.. 2022, 11, 0

226 Child-Pugh Score and -rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib.. 2022, 11, 0

225 Survival benefit of L-carnitine supplementation in patients with cirrhosis.. 2022, 0

- 224 Chronic liver disease questionnaire to manage patients with chronic liver diseases.. **2022,**
- 223 . **2022,** 0
- 222 Natural History of Compensated and Decompensated HCV-Related Cirrhosis in HIV-Infected Patients: A Prospective Multicentre Study. **2007,** 12, 899-908 19
- 221 Organ Allocation in Pediatric Abdominal Transplant. **2022,** 151180
- 220 "Beyond MELD" - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation.. **2022,** 76, 1318-1329 0
- 219 C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.. **2022,** 12, 8421 0
- 218 Diagnosis and predicted outcomes of patients with cystic fibrosis related liver disease considered for lung transplantation.. **2022,** e14713
- 217 Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel.. **2022,**
- 216 High Plasma Levels of Betaine, a Trimethylamine N-Oxide Related Metabolite, are Associated with Severity of Cirrhosis.. **2022,**
- 215 Splenic vein embolization as a feasible treatment for patients with hepatic encephalopathy related to large spontaneous splenorenal shunts. **2022,** 100725 1
- 214 Are MELD and MELDNa Still Reliable Tools to Predict Mortality on the Liver Transplant Waiting List?. **16,** Publish Ahead of Print,
- 213 Necrotizing Soft-Tissue Infections: A Retrospective Review of Predictive Factors for Limb Loss. **2022,** 14, 297 0
- 212 Increased Serum Levels of sCD206 Are Associated with Adverse Prognosis in Patients with HBV-Related Decompensated Cirrhosis. **2022,** 2022, 1-10
- 211 Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. 2
- 210 CLINICAL PROFILE, PATTERNS OF CARE & ADHERENCE TO GUIDELINES IN PATIENTS WITH HEPATOCELLULAR CANCER: PROSPECTIVE MULTI-CENTER STUDY. **2022,**
- 209 Tomoelastography based on multifrequency MR elastography predicts liver function reserve in patients with hepatocellular carcinoma: a prospective study. **2022,** 13, 0
- 208 Randomized Clinical Trial: Effects of β-Hydroxy-β-Methylbutyrate (HMB)-Enriched vs. HMB-Free Oral Nutritional Supplementation in Malnourished Cirrhotic Patients. **2022,** 14, 2344 1
- 207 Does first-line treatment have prognostic impact for unresectable HCC ? Atezolizumab plus bevacizumab versus lenvatinib. 1

- 206 Epidemiology, clinical features, and mortality rate of Wilson disease in Moroccan children: A pediatric case series. **2022,** ○
- 205 Correlation between dynamic changes in free triiodothyronine levels and 90-day prognosis in patients with HBV-related acute-on-chronic liver failure. **2022, 27,**
- 204 Suitability of Laparoscopic Liver Resection of Segment VII: a Retrospective Two-Center Study.
- 203 DNA and RNA oxidative damage in hepatocellular carcinoma patients and mortality during the first year of liver transplantation. **2022, 14, 1182-1189** ○
- 202 An mALBI-Child-Pugh-based nomogram for predicting post-hepatectomy liver failure grade B/C in patients with huge hepatocellular carcinoma: a multi-institutional study. **2022, 20,** ○
- 201 Minimally invasive ways to treat and prevent gastroesophageal portal bleeding. **2022, 27, 48-57**
- 200 The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer. ○
- 199 Analysis of the albumin-bilirubin score as an indicator of improved liver function among hepatitis C virus patients with sustained viral response after direct-acting antiviral therapy. ○
- 198 Sclerostin in Excessive Drinkers: Relationships with Liver Function and Body Composition. **2022, 14, 2574** ○
- 197 EASL International Recognition Award Recipient 2022: Prof. Patrick S. Kamath. **2022,**
- 196 Porto-pulmonary arterial hypertension: Translation of pathophysiological concepts to the bedside. **2022, 145, 107022** ○
- 195 Tools and scores for perioperative pulmonary, renal, hepatobiliary, hematological, and surgical site infection risk assessment: an update. 49,
- 194 Ferramentas e escores para avaliação de risco perioperatório pulmonar, renal, hepatobiliar, hematológico e de infecção do sítio cirúrgico: uma atualização. 49,
- 193 Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade). ○
- 192 Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. **2022, 34, 857-864** ○
- 191 Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to *Enterococcus faecalis* and *Enterococcus faecium*: a Multicenter Cohort Study from the PROBAC Project. 1
- 190 Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases. **2022, 97, 1380-1395**
- 189 Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. **2022, 11, 898** 1

- 188 Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). ○
- 187 Measurement of Mid-Arm Circumference as a Starting Point for Nutritional Assessment of Patients with Decompensated Cirrhosis: A Prospective Cohort Study.
- 186 Noninvasively Assessed Portal Hypertension Grade Predicts Post-Hepatectomy Liver Failure in Patients With Hepatocellular Carcinoma: A Multicenter Study. 12,
- 185 ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization. 2,
- 184 Usefulness of the GLIM criteria to predict sarcopenia and mortality in patients with chronic liver disease. ○
- 183 Short-term prognostic factors for hepatitis B virus-related acute-on-chronic liver failure. **2022**, 10, 8186-8195
- 182 Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. **2022**, ○
- 181 A Novel Nomogram for Prediction of Post-Hepatectomy Liver Failure in Patients with Resectable Hepatocellular Carcinoma: A Multicenter Study. Volume 9, 901-912 ○
- 180 Use of endoscopic band ligation alone and in combination with nonselective beta blockers for prevention of variceal bleeding in ascites patients on the liver transplant waiting list. **2022**, 24, 42-50 1
- 179 At the heart of the problem: congestive cardiac failure as a cause of ascites: A narrative review. **2022**, 101, e29951
- 178 Cirrhotic Cardiomyopathy: The Interplay Between Liver and Heart. **2022**,
- 177 Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians. **2022**, 14, 1562-1575 ○
- 176 Development and validation of a nomogram for predicting overall survival in cirrhotic patients with acute kidney injury. **2022**, 28, 4133-4151 ○
- 175 Handgrip strength: A simple and effective tool to predict mortality after liver transplantation. **2022**, ○
- 174 Volumetric imaging reveals VEGF-C-dependent formation of hepatic lymph vessels in mice. 10, ○
- 173 Machine learning predicts portal vein thrombosis after splenectomy in patients with portal hypertension: Comparative analysis of three practical models. **2022**, 28, 4681-4697 1
- 172 Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review. **2022**, ○
- 171 Development and validation of the Cirrhotic Ascites Severity model, a patient-reported outcome-based model to predict 1-year mortality.

- 170 Risk factors for acute kidney injury after liver transplantation in intensive care unit: a retrospective cohort study.
- 169 The Effect of Diet and Exercise Interventions on Body Composition in Liver Cirrhosis: A Systematic Review. **2022**, 14, 3365 2
- 168 Percutaneous transluminal angioplasty for symptomatic hepatic vein-type Budd-Chiari syndrome: feasibility and long-term outcomes. **2022**, 12,
- 167 Liver Transplant Recipient Characteristics Associated With Worse Post-Transplant Outcomes in Using Elderly Donors. 35,
- 166 Radiological and pathological assessment with EOB-MRI after Y90 radiation lobectomy prior to liver resection for hepatocellular carcinoma. **2022**, 0
- 165 Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma. 1
- 164 The gut microbiota as a vehicle for the prevention and treatment of hepatocellular carcinoma. **2022**, 115225 0
- 163 Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria. 0
- 162 The Indications and Implications of Liver Transplantation. **1999**, 29, 144-152 0
- 161 Indications for open hepatectomy in the era of laparoscopic liver resection: a high volume single institutional study. 0
- 160 Development and validation of a prognostic nomogram for decompensated liver cirrhosis. 10, 10467-10477 0
- 159 Total Joint Arthroplasty Should Not Be Delayed in Hepatitis C Patients After Successful Treatment Achieving a Sustained Viral Load. **2022**, 17, 107-113 0
- 158 Association of Sat-a and Alu methylation status with HCV-induced chronic liver disease and hepatocellular carcinoma. **2022**, 321, 198928 0
- 157 Development of the AAST Disease Severity Stratification System. **2022**, 29-41 0
- 156 Surgical Approach to Cirrhotic Patients. **2022**, 487-504 0
- 155 Clinical observation and risk assessment after splenectomy in hepatocellular degeneration patients associated with hypersplenism. 9, 0
- 154 Clinical features of patients with chronic liver disease in Japan related to alcohol use: Nationwide examination using alcohol use disorders identification test. 0
- 153 Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients. **2022**, 26, 1



- 152 Establishment and validation of a prediction model for the first recurrence of Budd-Chiari syndrome after endovascular treatment: A large sample size, single-center retrospective study. ○
- 151 Comparison of survival prediction values of different scoring models for patients undergoing transjugular intrahepatic portal shunt: A multicenter retrospective study. **2022**, 1, 107-115 ○
- 150 The Effect of Stereotactic Body Radiation Therapy for Hepatocellular Cancer on Regional Hepatic Liver Function. **2022**, ○
- 149 Systemic exposure to propranolol in patients with chronic liver disease and its correlation with portal blood flow. 9, ○
- 148 Design and conduct considerations for studies in patients with hepatic impairment. ○
- 147 Shortness of breath due to portopulmonary hypertension and hepatopulmonary syndrome: diagnostic challenges and complex management approach in frail patients. **2022**, 22, 485-489 ○
- 146 Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials. ○
- 145 Measurement of skeletal muscle volume is useful for predicting prognosis in patients with liver cirrhosis. **2022**, 34, 1151-1157 ○
- 144 A comprehensive review of prognostic scoring systems to predict survival after transjugular intrahepatic portosystemic shunt placement. **2022**, 1, 133-144 1
- 143 Liver resection of hepatocellular carcinoma in HIV-HCV co-infected patients: a retrospective case series. **2022**, 12, ○
- 142 Retrospective Study of the Efficacy and Safety of Chemoembolization with Drug-Eluting Microspheres Combined with Intra-Arterial Infusion of Bevacizumab for Unresectable Hepatocellular Carcinoma. Volume 9, 973-985 ○
- 141 AIMS65 and PALBI Scores as Predictors of Six Months Mortality in Cirrhotic Patients with Acute Variceal Bleeding. **2022**, 12, ○
- 140 Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort. **2022**, 101, e30097 ○
- 139 A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis. ○
- 138 Human stem cells for decompensated cirrhosis in adults. **2022**, 2022, ○
- 137 The Liver Maximum Capacity Test (LiMAX) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment. **2022**, 14, 5323 ○
- 136 Efficacy predictors of third-generation cephalosporins in treating spontaneous bacterial peritonitis. **2022**, 101, e30164 ○
- 135 The Elevated De Ritis Ratio on Admission Is Independently Associated with Mortality in COVID-19 Patients. **2022**, 14, 2360 ○

- 134 Branched-chain amino acids supplementation has beneficial effects on the progression of liver cirrhosis: A meta-analysis. *10*, 10984-10996 ○
- 133 Sustained high expression of BTLA on CD4+ T cell contributes to high rate of bacterial infection and mortality in patients with HBV-related acute-on-chronic liver failure via CD4+ T cell exhaustion. ○
- 132 Clinical significance of neutrophil extracellular traps biomarkers in thrombosis. **2022**, *20*, 1 ○
- 131 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. **2022**, *28*, 583-705 3
- 130 Platelet-to-lymphocyte ratio in patients with metastatic breast cancer treated with eribulin. ○
- 129 Modified Albumin-Bilirubin Grade and Alpha-Fetoprotein Score (mALF Score) for Predicting the Prognosis of Hepatocellular Carcinoma after Hepatectomy. **2022**, *14*, 5292 ○
- 128 Near-zero open conversion rate of laparoscopic liver resection: a high-volume single-center experience of the past 5 years. ○
- 127 The effect of sarcopenia and serum myokines on prognosis and survival in cirrhotic patients: a multicenter cross-sectional study. **2022**, *34*, 1261-1268 ○
- 126 Mac-2-binding protein glycosylation isomer is useful to predict muscle cramps in patients with chronic liver disease. **2022**, *101*, e31145 ○
- 125 Polyarthritis presented in a patient with untreated chronic hepatitis B infection. ○
- 124 New indexes derived from routine blood tests and their clinical application in hepatocellular carcinoma. **2022**, 102043 ○
- 123 Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study. **2022**, *101*, e30871 ○
- 122 Splenic Artery Ligation: An Ontable Bail-Out Strategy for Small-for-Size Remnants after Major Hepatectomy: A Retrospective Study. **2022**, *12*, 1687 ○
- 121 Interspecies differences in clinical characteristics and risk factors for third-generation cephalosporin resistance between *Escherichia coli* and *Klebsiella pneumoniae* bloodstream infection in patients with liver cirrhosis. **2022**, *41*, 1459-1465 ○
- 120 Spontaneous portosystemic shunt as a potential marker for severe liver damage and high risk of complications associated with portal hypertension in patients with hepatitis B-related cirrhosis: a multicenter study from China. ○
- 119 Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma. **2022**, *61*, 3157-3164 ○
- 118 Treatment patterns for hepatocellular carcinoma in patients with Child-Pugh class B and their impact on survival: A Korean nationwide registry study. 2
- 117 Analysis of ESPEN and GLIM algorithms reveals specific drivers for the diagnosis of malnutrition in patients with chronic gastrointestinal diseases. **2022**, 111887 ○

116	A Pilot Study of High-Definition Transcranial Direct Current Stimulation in Refractory Status Epilepticus: The SURESTEP Trial.	0
115	The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study. <b>2022</b> , 85, 433-437	0
114	Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor. <b>2022</b> , 17, e0277266	0
113	Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment. <b>2022</b> , 14, 5524	0
112	High-risk liver patients are not associated with adverse events following pancreaticoduodenectomy. <b>2022</b> ,	0
111	Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. <b>2022</b> , 12,	0
110	Approach to Stereotactic Body Radiotherapy for the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh B-7 Cirrhosis.	0
109	Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis. <b>2022</b> , 100627	0
108	Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma.	0
107	Risk stratification system for skin and soft tissue infections after allogeneic hematopoietic stem cell transplantation: PAH risk score.	0
106	Impact of prothrombin and factor V Leiden mutations on the progression of fibrosis in patients with chronic hepatitis C. <b>2022</b> , 17, e0276592	0
105	Red blood cell transfusion is associated with an increased risk of splanchnic vein thrombosis in patients with cirrhosis.	0
104	Significance of elevated serum and hepatic NOD-like receptor pyrin domain containing 3 (NLRP3) in hepatitis C virus-related liver disease. <b>2022</b> , 12,	0
103	Different scores in assessing the severity and prognosis of HBV-related-a cute-on-chronic Liver Failure.	0
102	Detecting liver cirrhosis in computed tomography scans using clinically-inspired and radiomic features. <b>2023</b> , 152, 106378	2
101	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <b>2022</b> , 23, 1126	4
100	Covered Transjugular Intrahepatic Portosystemic Shunt in the Treatment of Portal Hypertension: Looking for the Right Patient and the Right Time. 2-11	0
99	Low high-density lipoprotein cholesterol levels predicting poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure. 9,	0

- 98 Impact of COVID-19 on endoscopic follow-up of gastroesophageal varices. **2022**, 12, ○
- 97 A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis. **2022**, 17, e0277829 ○
- 96 Therapeutic plasma-exchange improves short-term, but not long-term, outcomes in patients with acute-on-chronic liver failure: A propensity score-matched analysis. ○
- 95 Systematic review: the role of frailty in advanced chronic liver disease. ○
- 94 Elevated calprotectin levels are associated with mortality in patients with acute decompensation of liver cirrhosis. 14, 1964-1976 ○
- 93 Noninvasive Prediction of Ki-67 Expression in Hepatocellular Carcinoma Using Machine Learning-Based Ultrasomics. ○
- 92 Effect of albumin measurement methods on the albuminBilirubin grade. 000456322211436 ○
- 91 Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients. **2022**, 58, ○
- 90 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. ○
- 89 Preoperative Transient Elastography in Patients with Esophageal Cancer. **2022**, 12, 3194 ○
- 88 Effects of Short-Term Human Albumin Infusion for the Prevention and Treatment of Hyponatremia in Patients with Liver Cirrhosis. **2023**, 12, 107 ○
- 87 Survival prediction using the Freiburg index of post-TIPS survival (FIPS) in critically ill patients with acute- on chronic liver failure: A retrospective observational study. 9, ○
- 86 Does etiological investigation have an impact on the outcomes of community-acquired pneumonia? **IA** prospective cohort study. **2022**, ○
- 85 Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumabBevacizumab. 2
- 84 Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis. **2022**, 17, e0279416 ○
- 83 Easy to say, hard to do. To the anniversary of two fundamental discoveries. Part 2. **2022**, 14, 500-518 ○
- 82 Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes. ○
- 81 Effects of Rifaximin on Circulating Albumin Structures and Serum Ammonia Levels in Patients with Liver Cirrhosis: A Preliminary Study. **2022**, 11, 7318 ○

- 80 New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study. ○
- 79 Omega-3 polyunsaturated fatty acids are associated with sarcopenia in patients with liver cirrhosis and hepatocellular carcinoma. ○
- 78 External validation of Chronic Liver Failure-Consortium Acute Decompensation score in the risk stratification of cirrhotic patients hospitalized with acute variceal bleeding. Publish Ahead of Print, ○
- 77 Establishment and validation of a prediction model for the first recurrence of Budd-Chiari syndrome after endovascular treatment: a large sample size, single-center retrospective study. ○
- 76 Prognosis prediction performs better in patients with non-cirrhosis hepatitis B virus-related acute-on-chronic liver failure than those with cirrhosis. 13, ○
- 75 CLIF-SOFA and CLIF-C scores for the prognostication of acute-on-chronic liver failure and acute decompensation of cirrhosis: A systematic review. 14, 2025-2043 ○
- 74 Plasma human neutrophil peptides as biomarkers of disease severity and mortality in patients with decompensated cirrhosis. ○
- 73 Assessment and prediction of malnutrition and sarcopenia in liver cirrhosis patients. **2023**, 48, ○
- 72 Circadian rhythms and the liver. ○
- 71 Disease Severity Scoring System in Chronic Liver Disease. **2023**, 105-113 ○
- 70 A novel Chongqing index of post-TIPS survival for predicting survival in Chinese cirrhotic patients after transjugular intrahepatic portosystemic shunt: A multicenter, retrospective study. ○
- 69 Predicting dry weight in patients with cirrhotic ascites undergoing large-volume paracentesis. **2023**, ○
- 68 Seven centimeters as an optimal cutoff value for prognosis stratification in large monofocal hepatocellular carcinoma. **2024**, 408, ○
- 67 A novel prognostic model for predicting the risk of first variceal hemorrhage in patients with HBV-related cirrhosis. 13, ○
- 66 Surgical Strategies for Recurrent Hepatocellular Carcinoma after Resection: A Review of Current Evidence. **2023**, 15, 508 ○
- 65 Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia. **2023**, 59, 146 ○
- 64 Cirrhosis and non-hepatic surgery in 2022: a precision medicine approach. ○
- 63 Application of Quantitative Difference to Evaluate Artificial Liver Support Effect in Acute-on-chronic Liver Failure (Preprint). ○

- 62 U-shaped relationship between subcutaneous adipose tissue index and mortality in liver cirrhosis. ○
- 61 Clinical Usefulness of Surgical Resection Including the Complementary Use of Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma. **2023**, 15, 236 ○
- 60 Effectiveness of COVID-19 Vaccination with mRNA Vaccines for Patients with Cirrhosis in Hungary: Multicentre Matched Cohort Study. **2023**, 11, 50 ○
- 59 Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?. 9, ○
- 58 Mortality scoring systems for liver transplant recipients: before and after model for end-stage liver disease score. **2023**, 18, 21-28 ○
- 57 Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial. ○
- 56 Recipient Survival after Orthotopic Liver Transplantation: Interpretable Machine Learning Survival Tree Algorithm for Patient Specific Outcomes. Publish Ahead of Print, ○
- 55 Acute kidney injury development and impact on clinical and economic outcomes in patients with cirrhosis: an observational cohort study over a 10-year period. Publish Ahead of Print, ○
- 54 Improvement of sarcopenia is beneficial for prognosis in cirrhotic patients after TIPS placement. **2023**, ○
- 53 Satellite liver transplant centres significantly improve transplant assessment outcomes for patients with chronic liver disease but not hepatocellular carcinoma: a retrospective cohort study. [flgastro-2022-102366](#)<sup>o</sup> ○
- 52 A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. **2023**, 401, 347-356 3
- 51 Cirrhosis: Reviewing the Literature and Future Perspectives. 111-117 ○
- 50 Inadequate social support decreases survival in decompensated liver cirrhosis patients. **2023**, 46, 28-38 ○
- 49 Serum Myostatin among Excessive Drinkers. **2023**, 24, 2981 ○
- 48 Nonselective beta-blockers in primary prophylaxis of esophageal variceal bleeding in patients with ascites waitlisted for liver transplantation. **2023**, 25, 68-76 ○
- 47 Prognostic significance of sarcopenia and severe vitamin D deficiency in patients with cirrhosis. ○
- 46 Effect of Selenium Deficiency on the Development of Overt Hepatic Encephalopathy in Patients with Chronic Liver Disease. **2023**, 12, 2869 ○
- 45 Echinocandin use in an Australian tertiary hospital: implications for antifungal stewardship. ○

- 44 Liver Transplantation for Budd-Chiari Syndrome in the MELD Era. **2022**, 8, e1407 ○
- 43 Development and validation of the Adult cirrhosis Knowledge Questionnaire. **2023**, 35, 333-341 ○
- 42 Usefulness of the AlbuminBilirubin Score in Determining the Initial Dose of Voriconazole for Patients with Liver Cirrhosis. **2023**, 46, 230-236 ○
- 41 Immune checkpoint molecule Tim-3 promotes NKT cell apoptosis and predicts poorer prognosis in Sepsis. **2023**, 109249 ○
- 40 Liver and spleen stiffness for the diagnosis of oesophageal varices in adults with chronic liver disease. **2023**, 2023, ○
- 39 Effect of the transjugular intrahepatic portosystemic shunt on peptidomics composition of peripheral plasma. ○
- 38 Treatment of recurrent hepatocellular carcinoma following liver resection, ablation or liver transplantation. 11, 47-54 ○
- 37 Impact of COVID-19 on Patients with Decompensated Liver Cirrhosis. **2023**, 13, 600 ○
- 36 Microscopic vascular invasion may not be associated with survival of patients undergoing resection for solitary hepatoma of  $\geq$  2 cm. **2023**, 18, e0281154 ○
- 35 Nurse-assisted and multidisciplinary outpatient follow-up among patients with decompensated liver cirrhosis: A systematic review. **2023**, 18, e0278545 ○
- 34 Validation of the diagnostic accuracy of neutrophil to lymphocyte ratio (NLR) and mean platelet volume (MPV) in cirrhotic patients with spontaneous bacterial peritonitis. **2023**, 13, ○
- 33 Stationary Trend in Elevated Serum Alpha-Fetoprotein Level in Hepatocellular Carcinoma Patients. **2023**, 15, 1222 ○
- 32 Management of Hepatocellular Carcinoma. **2023**, 158, 410 ○
- 31 Evaluation of Pretreatment AlbuminBilirubin Grade as a Better Prognostic Factor Compared to ChildBugh Classification in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization Combined with Radiotherapy. **2023**, 13, 354 ○
- 30 Sclerostin, vascular risk factors, and brain atrophy in excessive drinkers. 17, ○
- 29 Machine learning-based model for predicting the esophagogastric variceal bleeding risk in liver cirrhosis patients. **2023**, 18, ○
- 28 Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy. 13, ○
- 27 The Association of Albumin-Bilirubin (ALBI) Grade with Mortality Risk in Trauma Patients with Liver Injuries. Volume 16, 279-286 ○

- 26 Factors predicting mortality in patients with alcoholic liver cirrhosis visiting the emergency department. **2023**, 102, e33074 ○
- 25 Conversion of Minimally Invasive Liver Resection for HCC in Advanced Cirrhosis: Clinical Impact and Role of Difficulty Scoring Systems. **2023**, 15, 1432 ○
- 24 Monitoring the hepatobiliary function using image techniques and labeled cholephilic compounds. 18-33 ○
- 23 Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series. **2023**, 46, 460-469 ○
- 22 Portal Hypertension. **2023**, 495-503 ○
- 21 Delimiting Low Level of Difficulty Scoring System Based on the Extent of Resection Difficulty Scoring System for Laparoscopic Liver Resection. ○
- 20 CHIBA score: a novel model for predicting 3-month mortality in a cohort of Decompensated Liver Disease (DCLD). **2023**, 13, ○
- 19 Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations. 11, 1753-1760 ○
- 18 Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX [REVOlUTION] trial. **2023**, 20, 100466 ○
- 17 Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure. **2023**, 95, ○
- 16 Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology. **2023**, 15, 1687 ○
- 15 Comparison of Child-Pugh, MELD, MELD-Na, and ALBI Scores in Predicting In-Hospital Mortality in Patients with HCC. **2023**, 14, 148-162 ○
- 14 Assessment of clinico-epidemiological profile of Hepatocellular carcinoma in the last two decades. **2023**, 35, ○
- 13 Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Multicenter Study. **2023**, Publish Ahead of Print, ○
- 12 Novel CABIN score outperforms other prognostic models in predicting in-hospital mortality after salvage transjugular intrahepatic portosystemic shunting. 14, 34-45 ○
- 11 Child-Pugh Class B or C Liver Disease Increases the Risk of Early Mortality in Patients With Hepatitis C Undergoing Elective Total Joint Arthroplasty Regardless of Treatment Status. **2023**, Publish Ahead of Print, ○
- 10 Evolution of risk prediction models for post-operative mortality in patients with cirrhosis. ○
- 9 Predicting Post-hepatectomy Liver Failure Preoperatively for Child-Pugh A5 Hepatocellular Carcinoma Patients by Liver Stiffness. ○



- 8 Prevalence of portal vein and splanchnic venous thrombosis in dogs with chronic hepatitis. ○
- 7 Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics. **2023**, 25, ○
- 6 Value of Some Scoring Systems for the Prognosis of Rebleeding and In-Hospital Mortality in Liver Cirrhosis with Acute Variceal Bleeding. **2023**, 14, 144-155 ○
- 5 Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations. **2023**, 15, 2001 ○
- 4 The Added Value of Sarcopenia on Existing Risk Scores to Predict Mortality after TIPS Placement: A Multicenter Study. **2023**, ○
- 3 A radiographic tumor burden score-based preoperative model to predict overall survival in patients with hepatocellular carcinoma undergoing resection. ○
- 2 Small Intestinal Bacterial Overgrowth Is Associated with Poor Prognosis in Cirrhosis. **2023**, 11, 1017 ○
- 1 Transforming Growth Factor  $\beta$ s as a Marker of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus Infection. **2023**, 11, 702-709 ○